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The individualization of drug therapy
“Doctors are men who prescribe medicines of which they know little, to cure 
diseases of they know less, in human beings of whom they know nothing” 
Voltaire
In the ideal world, a doctor knows everything about his patient to treat 
him or her according to their specific needs. Unfortunately, this is not 
the case and may never be the case. That doesn’t mean that for centuries 
we haven’t tried to individualize our treatment to the patient’s needs to 
the best of the knowledge known at the time. In ancient Egyptian times, 
attempts have been made to treat every patient according to their 
symptoms with hundreds of drugs being described in the literature. 
Similar practices can be found in ancient China in the 1st century BC, as well 
as ancient Greece in the 4th century BC. The struggle for the optimal 
therapy for every patient is clearly something that we have been dealing 
with for centuries and is still a cornerstone in clinical medicine. 
Throughout my doctoral research project in Toronto, I was introduced 
to the field of clinical pharmacology and quickly fell in love. Dr. Saskia 
de Wildt, my co-supervisor, showed me all the possibilities of clinical 
pharmacology and how important it is in every day care of patients. 
She has been an absolute mentor to me, introducing me to the world of 
research, conferences and networking. Every conference I’ve been able 
to attend has been a new experience and made me more convinced that 
clinical pharmacology can have a major role in the care of patients. Saskia 
was key for my decision to keep being involved in clinical pharmacology. 
The last couple of years have been an amazing and sometimes wild 
ride, but has resulted in this thesis. I hope you will read it with as much 
pleasure as I had in creating it. 
Violette
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General Introduction
Solid organ transplantation has dramatically increased the survival of 
both adult and children suffering from end-stage organ failure and 
improved the quality of life of these patients.1,2,3,4 With the introduction
of calcineurin-inhibitors (CNIs) the short-term survival of transplant 
recipients improved even further.5 Presently, more than 90% of the 
immunosuppressive protocols in organ transplantation have CNIs 
incorporated as the primary immunosuppressant, resulting in CNIs being 
the mainstay of immunosuppressive therapy.6,7 
In 1995, tacrolimus, a macrolide CNI originating from the fungus 
Streptomyces tsukubaensis, was introduced8,9 and became part of 
clinical practice in 1997.8 It is metabolized by the cytochrome P450 (CYP) 
enzymes CYP3A4 and CYP3A5, and is a substrate for the efflux pump 
ABCB1.10 CYP3A4, CYP3A5 and ABCB1 are all expressed in the liver, 
intestine and kidney, and are therefore expected to influence the oral 
bioavailability as well as the systemic clearance of tacrolimus. 
Tacrolimus has a narrow therapeutic window11 and there is a clear 
relationship between the tacrolimus trough concentrations and the 
outcome of the patient. Subtherapeutic levels have been associated with 
rejection and supra-therapeutic levels with tacrolimus toxicity.12 
Therefore, therapeutic drug monitoring (TDM) is recommended.12,13,14,15 
Yet, the monitoring of tacrolimus concentrations is relatively complicated 
 due to the pharmacokinetic properties of tacrolimus; the effect of a dose 
adjustments may only be evident after a couple of days.16 The predefined 
therapeutic range is dependent on the transplanted organ and the time 
after transplantation. Interestingly, only little evidence is available to 
support these therapeutic ranges.17 Nevertheless, balancing between 
under-dosing and over-dosing is a critical aspect of the care of trans-
plant patients, but is very complicated as many factors can influence 
tacrolimus trough concentrations.18
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Despite the better short-term outcomes, the use of tacrolimus brings 
with it serious adverse effects, such as renal dysfunction, neurotoxicity, 
hypertension, glucose intolerance and liver function abnormalities.19,20,21 
Especially, tacrolimus-induced nephrotoxicity is of particular concern as it 
can result in a second transplantation or re-transplantation of the kidney.
Two forms of tacrolimus-induced nephrotoxicity have been described 
before. Acute nephrotoxicity is reversible and usually occurs within a 
couple of days after starting tacrolimus treatment. It may be counteracted 
with a dosage reduction or complete tacrolimus withdrawal. This acute 
form is characterized by a reduced glomerular filtration rate (GFR) due to 
a constriction of the afferent glomerular arteriole resulting in a decreased 
renal plasma flow. These changes seem to be due to an imbalance in 
the secretion and metabolism of nitric oxide, prostaglandines (both 
vasodilatory), thromboxane and endothelin (both vasoconstrictive) 
together with increased activity of the sympathetic nervous system. 
Tacrolimus may interfere with the normal tubular function and may cause 
mesangial cell contracting, thus altering the glomerular permeability.22
Chronic nephrotoxicity occurs with prolonged use of tacrolimus. 
The main clinical sign is a slow decline in renal function, which may 
result in end-stage renal failure. Most patients have hypertension as well, 
and the absence of proteinuria in these patients may help to distinguish 
tacrolimus-induced nephrotoxicity from other causes. However, this has 
not been proven yet. Chronic nephrotoxicity may not always resolve by 
dosage reductions or tacrolimus withdrawal. Initially, it has been reported 
that chronic nephrotoxicity is characterized by arteriolar hyalinosis, 
tubular atrophy, glomerular sclerosis, thickening of the Bowman’s capsule 
and interstitial striped fibrosis.22
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However, over the last couple of years a debate has developed on the 
existence of tacrolimus-induced nephrotoxicity. As chronic renal failure 
has multiple causes (i.e. CNI use, diabetes, HCV-associated glomerulo-
nephritis, atherosclerosis), proving tacrolimus is the actual cause of the 
decline in renal function is challenging. Biopsies would be the preferred 
diagnostic tool; however, biopsies are not routinely taken. Additionally, 
the classical histological signs of tacrolimus-induced nephrotoxicity are 
currently under debate for its specificity.23,24 For these reasons, we will use 
the term “renal failure” in the context of renal dysfunction in transplant 
recipients taking tacrolimus, as specific tacrolimus-induced nephrotoxicity 
cannot be proven at this point in time. 
Renal failure is clinically diagnosed by an increase in the glomerular 
filtration rate (GFR), which is derived from the serum creatinine (SCr) 
levels. One of those formulas to estimate the GFR is the Schwartz formula. 
The Schwartz formula has been developed in 1987 especially for use in 
children and has been used ever since. It is especially adapted to take the 
gender and age of the children into account.25 Additionally, the National 
Kidney Foundation clinical guidelines on chronic renal failure containing 
a classification system of the severity of renal failure (KDOQI).26 
This classification system can aid in the management of the patient with 
renal failure, but also to standardize research outcomes. 
To identify a change in SCr concentrations and thus GFR, a decrease 
of 50% of renal function is needed and will not reflect accurate renal 
function unless steady state concentration have been reached.34,35 
Moreover, the SCr concentrations are influenced by factors such as muscle 
mass and meals.34,35 There is a need for new acute kidney injury (AKI) 
biomarkers, since the use of SCr has several well-recognized drawbacks.
As renal failure is an important side effect of CNI therapy, in 2003 Ojo 
et al conducted a large landmark study looking into the prevalence of 
renal failure after non-renal transplantation. Overall, 11,426 (16.5%) of 
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the 69,321 non-renal solid organ transplant recipients developed chronic 
renal failure.27 However, the majority of the patients were treated with 
cyclosporine (60%) rather than tacrolimus. No other study has been done 
since to determine the incidence of renal failure in patients treated with 
tacrolimus alone. 
Tacrolimus disposition
Adults
A wide inter- and intra-variability in tacrolimus disposition is present 
among adult transplant recipients.9 Several factors influencing this 
variation have been reported and include the patient’s age, gender, 
ethnicity, concomitant medication, hematocrit and albumin 
levels.12,19,28 In addition to these clinical factors, the polymorphically 
expressed CYP3A5 gene, involved in the metabolism of tacrolimus 
genes has been reported to influence the tacrolimus disposition in adult 
transplant recipients.19 In kidney, liver and heart transplant recipients it 
has been shown that CYP3A5-expressers (CYP3A5*1/*1 or CYP3A5*1/*3 
carriers) had higher tacrolimus dosing requirements and lower tacrolimus 
dose adjusted trough concentrations compared to CYP3A5 non-expressers 
(CYP3A5*3/*3 carriers). The influence of the efflux transporter ABCB1 
SNPs 3435C>T, 1236C>T and 2677G>T/A remains to be elucidated as 
results have been contradictory.19
As genetic variation in CYP3A is associated with the wide inter- and 
intra-variability in tacrolimus disposition, an impact of this variation on 
the risk of developing chronic renal failure may be present. In addition 
to polymorphisms in enzymes and transporters involved in tacrolimus 
disposition (i.e CYP3A and ABCB1), polymorphisms in genes involved in 
the pharmacodynamic effects (i.e. ACE gene, TGF-ß) of tacrolimus may 
play a role as well. 
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Children
Children have long been believed to be little version of adults and 
decisions on drug therapy have mainly been based on this hypothesis. 
Over the last decades, our knowledge on growth and development of 
children has largely expanded and we now recognize that the changes 
that children are undergoing will affect how the body handles drugs 
and their responses to these drugs.29 It is therefore key to study children 
separately from adults, both for the disposition and effects of drugs. 
Factors influencing tacrolimus disposition have not been as widely 
studied in children as in adults. A wide variability in tacrolimus disposi-
tion has been reported, yet, little is known about the impact of clinical 
factors (such as age, weight, hematocrit) or polymorphisms in metabolizing 
enzymes on tacrolimus disposition. 
In pediatric liver and kidney transplant recipients it was shown that age, 
body weight, hematocrite and CYP3A5 genotype are associated with 
altered tacrolimus disposition.30 Children younger than 5 years of age 
needed higher tacrolimus dosages to achieve similar tacrolimus trough 
concentrations.31,32 In addition, children with a hematocrite level of <33% 
had a higher tacrolimus clearance. This finding can be explained as 
tacrolimus is highly protein bound and accumulates in the erythrocytes. 
When patients experience low hematocrite and albumin concentrations 
this will results in a reduction of the whole-blood concentrations and 
higher tacrolimus clearance.32 As reviewed by Quteineh et al. in pediatric 
liver and kidney recipients pediatric CYP3A5-expressers required higher 
tacrolimus dosages compared to CYP3A5 non-expressers.31,32 In pediatric
liver transplant recipients, carriers of the ABCB1 T-T-T haplotype had 
higher tacrolimus dosing requirements (0.26 [0.15-0.32] versus 0.11 
[0.01-0.25] mg/kg/12h) compared to non-carriers.31 
To our knowledge, no studies have been done in pediatric heart, lung or 
small bowel transplant recipients. 
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The study by Ojo et al27 reporting the prevalence of renal failure in 
non-renal solid organ transplant recipients mainly focused on adult 
patients. During childhood the kidney is still growing and developing, 
resulting in a low GFR at birth and exceeding adult values at 3 to 6 years 
of life.33 For this reason, in addition to the age-related pharmacokinetics 
of tacrolimus, we cannot extrapolate the data from the study by Ojo et 
al.27 to pediatric solid organ transplant recipients. Unfortunately, data in 
children on the prevalence of renal failure in pediatric solid organ trans-
plant recipients treated with tacrolimus are scarce. 
In conclusion, despite tacrolimus being part of most pediatric solid 
organ transplant protocols, our knowledge on the disposition and its 
adverse effects in children is still very limited. This leaves pediatric trans-
plant recipients at an increased risk of therapy failure with subsequent 
graft loss but also of increased toxicity, with possible renal failure. 
Therefore, the overall aim of this thesis was to identify clinical and 
genetic factors associated with tacrolimus pharmacokinetic and pharma-
codynamic parameters in pediatric solid organ transplant recipients to 
ultimately optimize tacrolimus dosing.
In Chapter 2; the available data on the prevalence of renal failure following
solid organ transplantation in children is presented. In addition, in 
Chapter 3, we reviewed the available literature on genes related to renal 
failure in both adult and pediatric solid organ transplant recipients. 
In the second part of this thesis, we studied the impact of genetic 
polymorphisms in CYP3A and POR on the disposition and renal function
of tacrolimus in pediatric solid organ recipients. In Chapter 4 we 
determine the possible association between CYP3A5 genotype and 
age on tacrolimus trough concentrations and dosages in pediatric 
heart transplant patients. With the discovery of the new SNP 
CYP3A4*22 we reanalyzed our initial pediatric heart transplant cohort 
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and increased our sample size to determine if this new polymor-
phisms has an additional effect on tacrolimus disposition (Chapter 5). 
Since the variability in tacrolimus disposition can only partly be explained by 
differences in expression of CYP3A4 and CYP3A5, polymorphisms in the 
gene encoding the P450 oxidoreductase (POR) protein that enables the 
activity of CYP enzymes, may be of interest. In Chapter 6 we evaluated
the possible relationship between POR*28 genotype and tacrolimus 
disposition in pediatric kidney transplant recipients.
The third part of this thesis concerns the pharmacodynamic effects of 
tacrolimus, with a particular focus on renal failure in pediatric transplant 
recipients treated with tacrolimus. Chapters 7, 8 and 9 are all part of a 
multicenter cohort study aimed to determine the relationship of genetic 
(96 SNPs) and non-genetic factors with the risk to develop renal failure 
in pediatric solid organ transplant recipients. Chapter 10 of this thesis
presents a pilot study on a potential novel AKI biomarker neutrophil 
gelatinase-associated protein (NGAL) in the first two weeks post- 
transplant. The final part summarizes the results of all studies and discusses 
the challenges encountered along with suggestions for future research 
topics (Chapters 11). 
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List of abbreviations
ABCB1  ATP-binding cassette sub-family B member 1
ACE  Angiotensin-converting enzyme
AKI  Acute Kidney Injury
CNI(s)  Calcineurin-inhibitor(s)
CYP  Cytochrome P450 enzyme
CYP3A  Cytochrome P450, family 3, subfamily A
CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A5 Cytochrome P450, family 3, subfamily A, polypeptide 5
GFR  Glomerular Filtration Rate
HCV  Hepatitis C Virus
KDOQI  The National Kidney Foundation Disease Outcomes 
  Quality Initiative 
NGAL  Neutrophil gelatinase-associated protein
POR  P450 oxidoreductase
SCr  Serum Creatinine
SNP(s)  Single Nucleotide Polymorphism(s)
TDM   Therapeutic Drug Monitoring
TGF-ß  Transforming Growth Factor beta 
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Abstract
Background Renal dysfunction after non-renal transplantation in 
adult tacrolimus-treated transplant patients is well documented. Little 
is known about its prevalence in children. Age-related changes in both 
disposition and effect of tacrolimus as well as renal function may preclude 
extrapolation of adult data to children. 
Objectives To systematically review the literature on renal dysfunction in 
non-renal pediatric transplant recipients treated with tacrolimus. 
Methods PubMed/Medline, Embase and Google were searched from 
their inception till April 19th 2012 with the search terms “tacrolimus”, 
“renal function”, “transplantation” and “children”. 
Results Eighteen of 385 retrieved papers were considered relevant. 
Twelve dealt with liver, four with heart transplant, one with heart and 
lung transplant, and one with intestinal recipients. Reported prevalences 
of mild and severe chronic kidney disease ranged from 0%-39% and 
0%-71.4%, respectively, for liver, and from 22.7%-40% and 6.8%-46%, 
respectively for heart and/or lung transplant recipients. Ranges remained 
wide after adjusting for follow-up time and disease severity. Possible 
explanations are inclusion bias and definitions used for renal dysfunction.
Conclusions A considerable proportion of pediatric non-renal transplant 
patients who receive tacrolimus-based immunosuppression, appear 
to suffer from chronic kidney disease. This conclusion warrants further 
research into the real risk, its risk factors and individualization of immuno-
suppressant therapy. 
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Introduction
Renal dysfunction is a serious complication of non-renal solid organ 
transplantation that may ultimately result in the need for dialysis or 
renal transplantation. In a large registry study by Ojo et al 11,426 (16.5%) 
of the total of 69,321 mainly adult, non-renal solid organ transplant 
recipients developed chronic kidney disease (defined as an estimated 
glomerular filtration rate [eGFR] ≤29 ml/min/1.73m2) at a median of 35 
months after transplantation (mean 46±38 months). In that study, the 
5-year cumulative incidence of chronic kidney disease (CKD) ranged 
from 6.9% for heart and lung transplant recipients to 21.3% for intestinal 
transplant recipients. The majority of the patients included in this study used 
cyclosporine (60%) rather than tacrolimus as the primary immuno- 
suppressant.1 
Data on the prevalence of CKD after non-renal solid organ transplantation 
in children are sparse. During childhood the kidney is still growing with 
nephron recruitment being completed at approximately 18 to 24 months. 
During this time the renal parenchyma increases with the patient’s height 
and due to an increase of the filtration surface per body surface area.2,3,4 
Therefore, the GFR is low at birth, increases during the first year of life to 
exceed adult values at age 3 to 6 years.5 As the kidney has not completely
matured until after the age of 6 years, the impact of non-renal solid 
organ transplantation on kidney function may differ between children and 
adults. Furthermore, older age has been implicated as a risk factor for CKD, 
which could also result in a difference in the prevalence of CKD between 
adults and children.1 Chronic kidney disease in children can have multiple
causes. The chronic use of calcineurin-inhibitors, such as tacrolimus, might 
be more important in children as other possible causes (i.e. diabetes, 
HCV-associated glomerulonephritis, atherosclerosis) are less common in 
children compared to adults.
26 | Chapter 2
Tacrolimus, a macrolide calcineurin-inhibitor, was introduced in 1995 
into clinical practice and was included in treatment protocols from 1997 
onwards.6 Originating from a fungus (Streptomyces tsukubaensis), the 
drug is an effective immunosuppressant agent. However, a range of 
serious adverse effects in addition to renal dysfunction, including 
neurotoxicity, glucose intolerance, liver function abnormalities and 
hypertension, complicates its use.7,8 One of the most serious complica-
tions of chronic calcineurin inhibitor use is CKD.9 Although its importance 
has recently been debated10 there is compelling evidence that prolonged 
use of calcineurin inhibitors is indeed nephrotoxic.11,12,13
Although both cyclosporine and tacrolimus act by inhibiting calcineurin, 
the precise molecular mechanism causing CKD remains unclear and 
seems to differ between the two drugs.9,14,15,16 Recently, Lamoureux et 
al. showed that exposure to tacrolimus and cyclosporine in a human 
kidney cell line resulted in different proteomic profiles, suggesting different 
molecular mechanisms of toxicity.17 Similarly, in rats, proteins involved 
in the mechanism of kidney damage also showed different expression 
profiles for cyclosporine and tacrolimus.18 These findings point at the 
necessity to separately study the adverse renal effects of cyclosporine and 
tacrolimus. 
The prevalence of CKD in pediatric recipients of a non-renal organ 
treated with tacrolimus is unclear. Data from the adult population may 
not be extrapolated to children and the mechanisms underlying the 
nephrotoxicity of tacrolimus may be different from those of cyclosporine. 
Therefore, we aimed to determine the reported prevalences of CKD in 
children who had received a non-renal solid organ transplant and who 
received tacrolimus rather than cyclosporine as the primary immuno-
suppressant by systematically reviewing the literature. 
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Methods
Literature search
A literature search was conducted by reviewing Pubmed/Medline, 
Embase and Google from their inception till April 19th 2012 with the 
search terms “tacrolimus”, “renal function”, “transplantation” and “children”. 
Subsequently, references of retrieved papers were screened for more 
references. 
The inclusion criteria were: human studies, original research, tacrolimus, 
non-renal transplantation, renal function, and children. Only non-renal 
solid organ transplant papers were included as the cause for CKD in 
renal organ transplant recipients are multifactorial and therefore looking 
at non-renal solid organ transplantations might be a cleaner model. 
Case reports, case series and reviews were excluded. Conversion studies 
and studies with mixed patient groups (i.e. adults and children together, 
cyclosporine and tacrolimus together) were also excluded. 
Outcome
The primary outcome of our review was to determine the prevalence 
of CKD post-transplantation in non-renal solid organ transplant 
recipients. The study author’s definition of CKD was accepted. For a 
secondary analysis we defined CKD as mild (eGFR >60 and <90 ml/
min/1.73m2) and moderate-severe (eGFR <60 ml/min/1.73m2) CKD. 
The prevalence of CKD for the secondary analysis was determined in 
those papers that reported prevalence numbers at least one year post-
transplantation. 
Quality assessment
To test the quality of the papers included, we used the checklist 
Strengthening the Reporting of Observational studies in Epidemiology.19 
We scored the items either by “yes”, “partial” or “no” depending if the item 
in question could be found in the included paper. A partial response 
was given in case a question had multiple items and not every item was 
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reported. We would count the amounts of times we scored a “yes” or a 
“partial”. The minimal score possible is 0 and the maximal score 34. 
Data abstraction
Two researchers (VG, KC), not blinded to the papers’ title or authors, 
reviewed titles and abstracts of the retrieved papers for eligibility. 
Disagreements about eligibility were resolved by discussion and 
consensus. 
Results 
The initial search retrieved 385 papers. After removing all duplicates 
and papers not meeting the inclusion criteria, eighteen papers were 
considered relevant. Twelve papers20,21,22,23,24,25,26,27,28,29,30,31 reported on 
liver, one on combined heart and lung transplant,32 four on heart trans-
plant33,34,35,36 and one on intestinal transplant recipients (Figure 1).37
Liver transplant recipients
Twelve papers published between 1995 and 2008 reported the 
prevalence of CKD in liver transplant recipients (Table 1). Ages in 
these studies ranged from 3 months to 23.2 years; the follow-up time 
Potential relevant
articles
N = 385
Liver transplant
articles
N = 12
Heart transplant
articles
N = 4
Combines heart and lung 
transplant article
N = 1
Intestinal transplant 
article
N = 1
Articles excluded for 
nor meeting our 
inclusion criteria
N = 367
Fig. 1. Flow of process during the review process.
Figure 1. Flow of process during the review process.
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ranged from one month to 14 years post-transplantation. Eleven 
studies17,21,22,24,25,26,27,28,29,30,31 used clinical biomarkers, such as GFR or serum 
creatinine, to define CKD. One study did not mention the method used.23
More specifically, two studies estimated GFR by measuring the inulin clear-
ance28 or the plasma disappearance of 99mTc-DTPA. Others used serum 
creatinine and the Schwartz formula. All six studies using the Schwartz 
formula21,24,25,28,29,31 employed an age and gender specific formula. 
Even though these six studies used the same measurement, a meta- 
analysis could not be done as the study designs were different and only 
two of these papers reported prevalence numbers. One study used the 
Counahan-Barratt formula.26 Two studies22,30 used serum creatinine. 
Two studies used the KDOQI guidelines to grade the severity of chronic 
kidney disease and thus to determine the prevalence.20,31 The other 
studies used different cut-offs for GFR or serum creatinine to identify 
patients with and without CKD. 
Overall, only in 8 of the 12 papers a prevalence number could be 
extracted from the presented data; the reported prevalence of CKD 
ranged from 0%-88.5% in these papers. Four of the other studies 
reported a median decrease in CKD in the first year post-transplantation 
ranging from 8%-32%25,26,28,29 with a slight improvement in renal function
after the first year post-transplantation ranging from 1% till 29.6% 
compared to the first year post-transplantation.25,28 However, renal 
function did not return to baseline values in any of these four cohorts. 
The fifth study showed a median decrease in serum creatinine from 
0.87 ± 1.1 mg/dl (76.9 ± 97.2 umol/L) pre-transplant to 0.44 ± 0.16 mg/dl 
(38.9 ± 14.1 umol/L) on day 180 after transplantation.30
Further focusing on renal function one year post-transplantation and 
classifying CKD into mild (eGFR >60 and <90 ml/min/1.73m2) and 
moderate-severe (eGFR <60 ml/min/1.73m2), we identified six relevant 
studies: the reported prevalence ranged from 0%-39%20,24,31 for mild 
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and 0%-71.4%20,21,24,27,31 for moderate-severe CKD at least one year post-
transplantation. However, one study reporting no CKD did not define 
renal dysfunction at all. Renal function was not one of their main outcome 
measures and their sample size was quite small.24 Hence, the above find-
ings should be interpreted with care. The study that reported the highest 
prevalence had a different design than the other studies. By categorizing 
the patients into three groups with either a GFR <15 or GFR 16-25 or GFR 
>26 ml/min/1.73m2 it seems that only very sick patients were included.21 
Therefore, to correct for possible bias, we also analyzed the reported 
prevalence after excluding these two papers. This resulted in prevalences 
of 20%-39% and 1.67%-17% for mild and moderate-severe CKD, 
respectively. 
Heart and lung transplant recipients
We identified five papers32,33,34,35,36 reporting renal function after 
transplantation in either heart and lung transplant recipients32 or heart 
transplant recipients33,34,35,36 published between 1999 and 2011 (Table 2).
Ages ranged from 7 hours until 18 years. Four papers32,33,34,36 used the 
age and gender-adjusted Schwartz formula to calculate the GFR; one of 
these used a cut-off criterion to determine CKD.32 The prevalence of CKD 
in these papers ranged from 6.8% - 46% with a follow-up time ranging 
from 14 days post-transplantation till 7 years post-transplantation. 
One paper35 used serum creatinine as a biomarker to determine CKD, 
but did not mention a cut-off criterion to define CKD. Serum creatinine 
levels at 3 months post-transplantation were slightly higher compared to 
pre-transplant serum creatinine levels (0.9 ± 0.1 ng/dl versus 0.7 ± 0.1 ng/dl).35
The prevalence of mild CKD at least one year post-transplantation 
ranged from 22.7%-40%; that of severe CKD ranged from 6.8% to 46%.32,33,34 
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Intestinal transplant recipients
We identified one paper discussing the renal function after intestinal 
transplantation (Table 3).37 The age of the children ranged from 0.6 till 
15.6 years at the time of transplantation. The follow-up time ranged from 
pre-transplantation up to 9.8 years post-transplantation. Chronic kidney 
disease was defined as an eGFR <90 ml/min/1.73m2 calculated by using
the Schwartz formula. The pre-transplant eGFR was reported to be 
138 ± 42 ml/min/1.73m2 and decreased to 102 ± 35 ml/min/1.73m2  at 
two years post-transplantation. We were not able to extract a prevalence 
number of mild or moderate-severe CKD, as the numbers of patients 
experiencing CKD were not mentioned in the paper. 
Quality assessment
The quality of these studies varied between the papers, with scores 
ranging from 10 to 24. Separate scores can be found in Table 1. The study 
by Staatz et al8 had the highest reporting quality with a score of 24. 
All 18 papers provided an informative and balanced summary in the 
abstract, explained the scientific background and rationale for the 
investigation, gave characteristics of the study participants and 
summarized the key results in the discussion. The worst reported items 
all concerned the statistical methods and included an explanation how 
the missing data was addressed (none of the papers), a description of 
any sensitivity analysis (1 paper), an explanation how the loss to follow-
up was addressed (2 papers) and the description of any methods used to 
examine subgroups and interactions (4 papers). 
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Discussion
Chronic kidney disease (CKD) is a potential serious complication of 
non-renal solid organ transplantation in children and needs to be studied 
in detail to optimize the management and protect the kidney while 
ensuring the transplanted organ is optimally functioning. This review 
aimed to determine the reported prevalence of CKD in pediatric, 
non-renal, solid organ transplant recipients treated with tacrolimus 
and the methods used to quantify this adverse event. We found an 
extremely wide prevalence range from 0% to almost 90%. The range 
remained wide after narrowing down the scope to CKD at least one year 
post-transplantation: a prevalence of mild CKD ranging from 0% till 40%; 
that of severe CKD ranging from 0%-71.4%. After excluding a study with 
possible selection bias and one in which the criterion of CKD was not 
defined, the mean prevalence of mild CKD ranged from 20%-40% and 
severe CKD from 1.67%-46%. 
It would have been ideal to do a meta-analysis to have stronger evidence 
and a more definite answer to the question what the prevalence of CKD 
is after non-renal solid organ transplant recipients. Regrettably, we could 
not synthesize the studies into a meta-analysis in view of the widely 
ranging definitions and measurements. Additionally, the incidence 
of chronic kidney disease pre-transplantation, peri-operative and 
post-transplantation would be of more interest as it will reflect the 
new cases of CKD instead of an overall occurence. Yet, due to the cross- 
sectional nature of the available literature we were limited in reporting 
the prevalence instead. 
The variability in the prevalence of chronic kidney disease may be 
explained by by inter-study variation in the factors cumulatively affecting 
renal function such as gender, ethnicity, intraoperative factors, such as 
hypotension and need for dialysis, postoperative factors (i.e. acute renal 
failure) and long-term exposure to different calcineurin inhibitors.38,39
Importantly, differences in the methods used to diagnose CKD may have 
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significantly contributed to inter-study variation. Renal function was 
determined in many different ways. However, every method has its 
own inaccuracies. Even though inuline clearance is considered the gold 
standard for measuring GFR in children, it could overestimate GFR if 
steady state has not been achieved.40 The use of radioisotopes may 
introduce inaccuracies due to the different commercial products that are 
being used.41 The use of estimated GFR values to determine if a patient 
experiences CKD also has its challenges. Although most of the included 
papers used the Schwartz formula,42 the precision of the creatinine 
assay importantly determines its results.43 This is of particular concern 
with low serum creatinine levels in which enzymatic creatinine values 
can run lower compared to those determined by the Jaffe method.42,44 
This will result in an overestimation of the GFR if the same “k” is used, 
Therefore, the constant in the Schwartz formula may have to be validated 
for each method used in all different centers. 
As can be seen in the included papers, many different ways of determining 
the GFR have been used, each with their own limitation. However, to date 
no standardized method for determining the GFR exists. Furthermore, 
the use of cut-off values to determine (the severity of ) chronic kidney 
disease in the included papers was variable. Two papers used the KDOQI 
cut-offs and others used non-defined/arbitrarily cut-offs. All of these 
reasons could contribute to the differences found in the prevalence of CKD.
Our findings suggest that the prevalence of CKD post-transplantation 
in children is greater than that in adults, although the results may be 
biased to a certain extent by the limitations above. Younger children 
(<6 yrs of age) will need on average higher tacrolimus doses to achieve 
similar target levels36 and may consequently be exposed to higher 
levels of possibly nephrotoxic tacrolimus metabolites. Filler et al have 
shown that children metabolize sirolimus differently than adults, resulting 
in different metabolites.45 As tacrolimus and sirolimus are both 
metabolized by CYP3A and share their FK-binding protein 12 pathway, 
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children might metabolize tacrolimus differently, as well. We speculate 
that an age-related difference in tacrolimus disposition, with possibly 
different metabolite formation as well, may be involved in a different 
effect of tacrolimus on the developing kidney. The developing kidney in 
itself may also be more susceptible to the nephrotoxic effects of 
tacrolimus. 
Other methods to determine chronic kidney disease - Cystatin C, the CKiD 
formula and two different Schwartz formulas - were recently compared in 
pediatric heart transplant recipients. The conventional Schwartz formula 
tended to overestimate the GFR compared to Cystatin C, the CKid formula 
and one of the Schwartz formulas.46 Additionally, the four methods yielded
different classifications of patients according to the National Kidney 
Foundation’s KDOQI classification methods. The conventional Schwartz 
formula classified 78% of the patients as having a normal GFR; the other 
methods arrived at no more than 31%-51%.46 These results show that 
these newer methods might be a good alternative or addition to the 
methods used to date. 
We were limited in that we could not always extract prevalence numbers. 
In seven studies25,26,28,29,30,35,37 either no cut-off for defining CKD was 
given or the proportion of patients experiencing defined renal dysfunction 
was not specified. A further limitation is the wide range of the follow-up 
periods. This was a limitation when studies did not report the prevalence 
per time interval, distinguishing acute renal dysfunction from chronic 
kidney disease. Five of the included studies did not report the exact 
follow-up time, so it was not clear when the renal dysfunction occurred 
after transplantation. 
The relatively small sample sizes in the included studies limit the 
generalizability of the data. Overall a mean of 43 transplant recipients 
were included per study; the mean number was 39 for the studies in 
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liver transplant recipients and 46 for those in heart and lung transplant 
recipients. And then, selection bias may have contributed to the large 
variation in reported prevalence. Four studies excluded patients who 
did not survive the first year post-transplantation.20,26,27,33 Others exclud-
ed patients with a previous history of renal dysfunction22 or patients 
transplanted within the last 3 months or having died within the first 6 
months post-transplantation.25,34 This may mean a predominance of 
patients with less severe disease. 
Chronic kidney disease in children after solid organ transplantation can 
have multiple causes. The chronic use of calcineurin-inhibitors, such as 
tacrolimus, might be more important in children as other possible causes 
(i.e. diabetes, HCV-associated glomerulonephritis, atherosclerosis) are 
less common in children compared to adults. Nonetheless, proving 
that tacrolimus is the actual cause is difficult as renal biopsies are not 
regularly done in non-renal transplant recipients and there is no 
consensus on specific histological signs of renal failure caused by 
calcineurin-inhibitors. The classical histopathological signs of calcineurin-
inhibitor nephrotoxicity (i.e. tubular vacuolizations, (striped) interstitial 
fibrosis, and arteriolar hyalinosis) are under debate for their reliability to 
determine tacrolimus-induced nephrotoxicity.9,47 Yet, other causes than 
tacrolimus use can still be responsible for the post-tranpslant renal dys-
function (i.e. rejection) and need to be considered in differential diagnosis 
as a possible cause for the CKD.   
Finally, reporting quality of the studies considered was quite variable, 
which may have contributed to the wide prevalence range. The two 
studies22,47 with the best reporting quality are probably the most 
useful in estimating the real prevalence of CKD. They reported comparable 
prevalences of CKD in liver transplant recipients, i.e. 21.7% and 22.9%. 
However, only one study enabled to distinguish between mild and severe 
CKD; the respective prevalences were 21.7% and 1.67%.20
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Consensus should be reached on the preferred standard methods to 
determine CKD and identify patients. Measuring GFR and analysis of 
biopsies at routine intervals will help to accurately identify CKD and 
its severity as well as the underlying histological changes. This may 
enable an accurate estimation of the severity of the problem and identify 
timely interventions in patients at risk. Using a checklist such as the 
STROBE statement19 could improve reporting of studies and help to 
better understand the results. 
Conclusion
We aimed to gather evidence on the prevalence of CKD in tacrolimus-
treated, non-renal, pediatric solid organ transplant recipients. In the 18 
relevant papers the reported prevalence ranged from 0%-88.5%. 
Ranges remained wide after adjusting for follow-up time and severity 
of disease; 20%-40% for mild CKD and 1.67%-46% for severe CKD. 
Although the limitations of these studies demand cautious interpretation, 
it seems that CKD in transplant patients receiving tacrolimus is more 
frequent in children than in adults. This conclusion warrants further 
research into risk factors and individualization of therapy, taking the 
continuum of development into account. 
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Summary
Background Calcineurin inhibition (CNI) is the mainstay of immu-
nosuppressant therapy for most solid organ transplant patients. High 
tacrolimus levels are related with acute nephrotoxicity, but the relation-
ship with chronic toxicity is less clear. Variation in disposition of tacrolimus 
is associated with genetic variation in CYP3A5. Hence, could genetic 
variation in CYP3A5 or other genes involved in tacrolimus disposition and 
effect be associated with a risk for tacrolimus-induced nephrotoxicity? 
To perform a review of the literature and to identify if genetic variation 
in CYP3A5 or other genes involved in tacrolimus disposition or effect 
may be associated with tacrolimus-induced nephrotoxicity and/or renal 
dysfunction in solid organ transplant recipients.
Material/Methods Pubmed/Medline, Embase and Google were 
searched from their inception till November 8th 2010 with the search 
terms ‘tacrolimus’, ‘genetics’, and ‘nephrotoxicity’or ‘renal dysfunction’. 
References of relevant articles were screened as well.
Results We identified 13 relevant papers. In kidney recipients, 
associations between donor ABCB1, recipient CCR5 genotype and 
tacrolimus-induced nephrotoxicity were found. CYP3A5 genotype studies
 in kidney recipients yielded contradictory results. In liver recipients, a 
possible association between recipient ACE, CYP3A5, ABCB1 and CYP2C8 
genetic polymorphisms and tacrolimus-induced nephrotoxicity was 
suggested. In heart recipients, TGF-ß genetic polymorphisms were 
associated with tacrolimus-induced nephrotoxicity. The quality of the 
studies varied considerably.
Conclusions Limited evidence suggests that variation in genes involved 
in pharmacokinetics (ABCB1 and CYP3A5) and pharmacodynamics (TGF-ß, 
CYP2C8, ACE, CCR5) of tacrolimus may impact a transplant recipients’ risk 
to develop tacrolimus-induced nephrotoxicity across different transplant 
organ groups.
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Background
Calcineurin inhibition (CNI) is the mainstay of immunosuppressant 
therapy for most solid organ transplant patients. Having been 
introduced in 19951,2 the macrolide calcineurin inhibitor drug tacrolimus
was included in many treatment protocols from 1997 onwards1. 
Tacrolimus originates from a fungus (Streptomyces tsukubaensis) and 
it is an effective immunosuppressant agent. But its use brings with it 
serious adverse effects such as renal dysfunction, neurotoxicity, glucose 
intolerance, liver function abnormalities and hypertension.3,4,5,6
Tacrolimus has a narrow therapeutic window and as a serum concentration- 
response relationship exists between tacrolimus and acute nephrotoxicity, 
therapeutic drug monitoring is recommended to minimize tacrolimus- 
related acute renal dysfunction7. Tacrolimus-related acute and chronic 
nephrotoxicity is a well-recognized adverse effect7,8 and a serious 
concern, often leading to permanent renal damage or even kidney loss. 
In the 2003 landmark study by Ojo et al8, the five year cumulative 
incidence of chronic renal failure for a cohort of 70,000 adult non- 
renal transplant patients was 16.5% and end-stage renal disease (ESRD) 
developed in 28.9% of these patients. In that cohort, chronic renal failure 
was associated with an increased risk of death (relative risk: 4.55; 
CI95% 4.38–4.74). However, most of the patients in this study received 
cyclosporine. Meanwhile, tacrolimus has become the primary calcineurin 
inhibitor for immunosuppressant treatment in solid organ transplant 
recipients.9 Both cyclosporine and tacrolimus are associated with chronic 
nephrotoxicity, but the incidence and underlying mechanisms seem to 
differ.10,11,12 
Furthermore, the adverse event profiles of the two drugs are differ-
ent.11,12,13,14,15 Both cyclosporine and tacrolimus are mainly metabolized 
by CYP3A4, but there is a bigger role for CYP3A5 in the metabolism of 
tacrolimus.16 Although the risk of chronic renal failure in tacrolimus 
treated transplant patients is increased, not all patients develop renal 
failure. To identify patients at risk, more in depth knowledge of genetic 
and non-genetic risk factors is needed. 
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The genetically polymorphic cytochrome P450 3A5 (CYP3A5) is a phase 
I metabolizing enzyme involved in the metabolism of tacrolimus.17 Carrying 
the CYP3A5*3 allele results in a premature stop codon and the absence of 
the CYP3A5 protein (non-expressors).18 Genetic variation in the drug-
metabolizing enzyme cytochrome P450 3A5 (CYP3A5) is associated with 
interindividual differences in tacrolimus clearance in kidney, lung and 
heart transplant patients, not only in adults, but also in children.19,20 CYP3A5 
expressors need higher doses of tacrolimus to reach the same therapeutic 
levels. And as high tacrolimus levels are associated with acute renal failure, 
genetic variation in CYP3A5 may also impact the risk to develop chronic 
renal failure. The ABCB1 transporter actively transports substrates out 
of the cell.21,22 As tacrolimus is a substrate for ABCB1, variation in ABCB1 
expression rate is thought to influence the plasma and/orintracellular 
concentration of tacrolimus.23
The effect of tacrolimus on the kidney appears to be multi-factorial. Renal 
failure may occur due to an imbalance in the secretion and metabolism 
of nitric oxide, prostaglandines (both vasodilatory), thromboxane and 
endothelin (both vasoconstrictive) together with increased activity of the 
sympathetic nervous system. Consequently, variation in genes affecting 
these processes, such as ACE, TGF-ß and CYP2C8 may also impact on the 
risk to develop renal failure while using tacrolimus. Transforming growth 
factor-ß (TGF-ß) seems to play a role in the development of fibrosis in 
the kidney, which is a typical histological feature of tacrolimus-induced 
nephrotoxicity24,25 CYP2C8 is thought to counter the vasoconstrictive 
effect of tacrolimus, through a reduction of epoxyeicosatrienoic acids 
(EETs) formation by CYP2C8.26,27
The objective of the present study was to systematically review the current 
evidence for genetic associations with tacrolimus-induced nephrotoxicity 
and/or renal dysfunction in adult and pediatric renal and non-renal organ 
transplant recipients.
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Material and Methods
Literature search
The Pubmed/Medline, Embase and Google databases were searched from 
their inceptions till November 8, 2010. The search terms were: ‘tacrolimus’,
‘genetics’, ‘nephrotoxicity’ and ‘renal dysfunction’. Additionally, reference 
lists of articles were screened. 
We reviewed the titles and abstracts of the retrieved papers for eligibility. 
The inclusion criteria were: human studies, original genetic research, 
tacrolimus. For renal transplant patients, we only included papers that 
used biopsy-proven nephrotoxicity defined as such by the authors of the 
papers. For the non-renal transplant patients we only included papers 
that used renal function, as defined by the authors.
Quality assessment
Study quality, in terms of internal and external validity and power, was 
assessed with the Downs- Black scale (Supplementary Figure 1).28 
To our knowledge quality assessment scales for genomic association 
studies are lacking.  We looked for other scales that could be used alternatively. 
The Downs Black scale has been identified as a valuable tool to assess 
methodological quality of non-randomized studies. 29 
Two reviewers (VG, PM) applied the Downs-Black scale without blinding 
of authorship. Discrepancies were resolved by discussion and if necessary 
by a third reviewer (SW). The scale rated items with ‘1’ if the item was 
reported, ‘0’ if the item was not reported or ‘U’ if the reviewers were unable 
to make a determination. An exception is item number 5 (the distribution 
of the principal confounders): scored with ‘2’ if all the confounders were 
listed, ‘1’ if it was only partially reported, ‘0’ if not at all. Another exception 
is item number 27 (the power of the study): scored from 0–5. 
The maximum total score is 32. 
The reviewers used decision rules. For one, in the Downs-Black scale 
the term “intervention” was replaced with ‘tacrolimus regimen’ where 
applicable. As the scale can also be used for intervention studies, three 
items14,23,24 pertaining to blinding and randomization were scored as 
50 | Chapter 3
‘U’ and did not contribute to the total scores. The directions for use of the 
scale were otherwise followed. Study power was calculated using the data 
provided in the articles, if sufficient. We compared proportions yes/no renal 
dysfunction/nephrotoxicity for carriers with and without genetic 
polymorphism, using the power calculator for proportions from Sigmaplot 
(version 11.0, Systat software, 2008). We contacted authors of four 
papers to obtain more information needed to complete the power 
calculation. All studies were evaluated for a type-1 error rate with a=set 
to 0.05. Study power is scored as follows: A=<80% power  0, B=80% 
power  1, C=85% power  2, D=90% power  3, E=95% power  4 
and F=99% power  5.
Results
Our initial search yielded 51 articles, of which 9 met the inclusion criteria. 
The reference lists yielded 4 more papers, resulting in a total of 13 
papers (Figure 1). Table 1 shows detailed characteristics of the study 
populations, outcome measures and outcomes of all studies. Adult 
patients were studied in ten papers, pediatric patients in three papers.
Potentially relevant
Search terms: tacrolimus, genetics, nephrotoxicity
Yield: 51 articles
Articles meeting inclusion criteria
Yield: 9 articles
Remove all studies not
meeting inclusion criteria
(n=42)
Total studies included in the review
(n=13)
Adult studies
(n=11)
Children studies
(n=2)
Studies found through
references
(n=4)
Figuur 1: Flow diagram of selection process.
Figure 1. Flow diagram of selection process.
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Adults
Twenty-four polymorphisms in nine different genes (CYP3A4, CYP3A5, 
ABCB1, CYP2C8, ACE, TGF-ß, CYP2J2, AGT1, AT1) were investigated in adults. 
YP3A Seven articles studied the association between CYP3A polymor-
phisms and renal toxicity of tacrolimus.30, 31, 32, 33, 34, 35, 36
CYP3A
Kidney transplant
Kuypers et al.31 reported a higher incidence of biopsy-proven CNI-
nephrotoxicity in renal transplant recipients (n=95) carrying the 
CYP3A4*1/CYP3A5*1 or CYP3A4*1B/CYP3A5*1 expressor genotype 
compared to non-carriers of the alleles (37.5% vs. 11.2%, P=0.03 and 
42.8% vs. 11.2%, P=0.02). With a larger cohort (n=304), three years later, 
the same group confirmed previous results that carrying the CYP3A5*1 
genotype increases the risk for biopsy-proven tacrolimusinduced nephro-
toxicty (HR: 2.38 (1.15–4.92), P=0.01) at 3 months post-transplant.36 
In this second study, de novo arteriolar hyalinization was used as of the 
histological definition of calcineurin- inhibitor toxicity (CNIT). In contrast 
to the two previous studies, a third study in 67 kidney recipients 
from a Chinese population showed a higher incidence of nephrotox-
icity in the CYP3A5*3/*3 genotype group, using protocol biopsies at 
one month post-transplant.32 CNIT was graded based on histological
changes from 0 to 3, with 3 being most severe. In patients with the 
CYP3A5*3/*3 genotype, interstitial fibrosis (1.04±0.51 vs. 0.53±0.61, 
p<0.01) and vacuolization (0.89±0.63 vs. 0.40±0.63, p<0.05) were more 
severe than in patients with the CYP3A5*1/*3 genotype. Similarly, 136
renal transplant recipients with the CYP3A5*3/3 genotype presented with 
a non-significant trend towards a higher incidence of developing biopsy 
proven nephrotoxicity compared to CYP3A5*1/*3 and CYP3A5*1/*1 
genotypes (33% vs. 9% and 10%, P=0.1).33 Finally, Naesens et al.35 did not 
find an association between donor and recipient CYP3A5 genotype and 
histological signs of nephrotoxicity in 252 renal transplant recipients.
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Liver transplant
In 60 liver transplant recipients, CYP3A5 nonexpressors had a higher risk 
to develop dysfunction HR 3.16 (CI95% 1.01-6.16, p<0.05).
30
Heart transplant
In contrast, Klauke et al.34 found no association between the CYP3A5 
genotype and an increase in serum creatinine (SCr ≥1.8 mg/dl) in 53 heart 
transplant patients. 
ABCB1
Kidney transplant
In 252 renal transplant recipients, a significant association was found 
between ABCB1 genotype and histological signs of nephrotoxicity, as 
defined by interstitial fibrosis/tubular atrophy.35 When both donor and 
recipient are homozygous for the T variant of ABCB1 3435 there was an 
odds ratio of 3.9 (CI95% 2.0–7.6, P<0.001) for higher Interstitial Fibrosis/
Tubular Atrophy (IF/TA) grades compared to no homozygosity for the 
C3435T polymorphism.
Liver transplant
In liver transplant patients, Hebert et al.37 showed that 50% of patients with 
the ABCB1 11/22 haplotype (2677G,3435C/2677T,3435T) experienced renal 
dysfunction (serum creatinine ≥1.6 mg/dl) compared to 31% of patients 
with the ABCB1 11/11 haplotype (2677G,3435C/2677G,3435C) and 11.2% 
of patients with the ABCB1 22/22 haplotype (2677T,3435T/2677T,3435T). 
Three other studies did not identify a relation with ABCB1 genotype and 
nephrotoxicity.31,34,36 For both cohorts, it was not possible to determine 
the association for the tacrolimus patients separately, as this was not 
reported in the papers. 
CYP2C8 and CYP2J2.
Liver transplant
In 41 liver transplant recipients, carrying the CYP2C8*3 polymorphism was 
associated with a higher risk OR 16.67 (CI95% 2.8–99.6) to develop renal 
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dysfunction.39 In the same cohort, no association was found with CYP2J2 
genotype and renal dysfunction. 
ACE, AGT1 and AT1
Liver transplant
In 143 liver transplant recipients, (100 on tacrolimus), the ACE D/D 
genotype was significantly associated with a higher risk of renal dysfunc-
tion RR 4.3 (CI95%1.9–9.7, P=0.0001).
40 In the same cohort, no correlation 
was found between AGT1 or AT1 genetic variation and renal dysfunction.
Children
We identified only two studies in children. Grenda et al., studied twenty-
four polymorphisms in ten different genes (CYP3A5, ABCB1, TGF-ß, IL10, 
IL6, CCR5, TNF-alpha, IL2B, IL1RN, MCP-1, VEGF) in 207 (61 on tacrolimus) 
pediatric kidney transplant recipients.41 The rationale for studying these 
genotypes was not given by the authors of the paper. Except from CCR5, 
no relation between any of these genotypes and nephrotoxicity, defined 
by clinically indicated biopsy or deterioration of renal function, was found. 
We identified one other study in pediatric liver transplant recipients.42
ABCB1
Kidney transplant
In contrast to adults, in 207 (61 on tacrolimus) pediatric kidney transplant 
recipients no association between ABCB1 genotype and nephrotoxicity, 
as defined by biopsy or reduced renal function was found.41
Liver transplant
In 51 paediatric liver recipients, T-T-T haplotype (C1236T, G2677T, C3435T) 
was associated with an increased risk of a reduction in creatinine clear-
ance at 6 months post-transplant.42 At 6 months post-transplant, 52.9% 
of the patients with renal dysfunction were carriers of the T-T-T haplotype 
compared to 29.4% in the patients without renal dysfunction (P=0.029). 
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CCR5
Kidney transplant
In the Grenda et al study, all transplant recipients with nephrotoxicity 
(n=18) carried CCR5 wildtype compared to 79% of the no-nephrotoxicity 
group (n=28, P=0.041).41
Quality assessment
Overall, the quality of the studies was moderate: the mean score on the 
Downs-Black scale 28 was 17.8±4.1 (range 11–25). Separate scores are 
given in the Table 1. Appropriateness of the statistical tests used, the 
compliance of the intervention and whether patients were recruited from 
the same population were the best-reported items. These aspects were 
reported in all 13 studies. The worst reported items were on determining 
if the outcomes were blinded to genotype of the patients (only 3 
papers) and the population pool subjects were recruited from (5 papers) 
and whether losses to follow-up were taken into account (4 papers).
Statistical power
Four papers32,33,39,42 lacked sufficient data to recalculate the power. 
We were able to contact the authors of two of these papers39,42 however 
only one42 provided additional data. For those without sufficient data, 
the item was scored with a ‘U’ as in ‘unable to determine’. Only three 
studies36,38,40 had sufficient power, rated with 4 or 5 points. All studies con-
sidered a p<0.05 as statistically significant, and none made adjustment 
for multiple testing of genetic variants. 
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Discussion
This literature review shows that specific polymorphisms in six different 
genes have been implicated to be associated with the variation in the 
incidence of renal dysfunction in adults or children who have 
received tacrolimus for immunosuppression after solid organ transplant. 
The identified genes are CYP3A5, ABCB1, CYP2C8, ACE, TGF-ß and CCR5. 
Five studies suggest a role for the CYP3A5 gene (four kidney31,32,33,36 one 
liver30), whereas three studies (two kidney,35,41 one heart34) could not 
confirm such an association. For two papers, this lack of an association 
may be due to the small number of patients studied (n=61 and n=21, 
respectively). 
In two studies researching kidney recipients, patients who are 
CYP3A5 expressors had a higher risk of nephrotoxicity while the 
opposite was found in two other studies. The discrepancy between these 
studies may be explained by the outcome measure used. In the largest 
study to date, calcineurin inhibitor induced nephrotoxicity was defined 
as de novo arteriolar hyalinosis at 3 months after transplant and yearly 
thereafter. Hence, patients who received a donor kidney with arteriolar 
hyalinosis at transplant, would not be scored as CNIT, while this may 
have been the case in the other studies where any arteriolar hyalinosis 
was scored or other histological signs, according to Banff 2001, such as 
interstitial fibrosis/ tubular atrophy. The disparate results may further 
be explained by the timing of biopsies, e.g. early (at 1 month) versus 
late (over 3 months after transplant). When taking these differences and 
inherent limitations of the different studies into account, the strongest 
evidence points towards a positive association between CYP3A5 expressors 
and a higher risk for calcineurin induced nephrotoxicity in adult renal 
transplant patients. For liver transplant patients only one paper (n=60) 
was identified, with the opposite finding for recipient CYP3A5. This may 
be explained by the effect of genetic differences in renal CYP3A5 activity, 
versus the genetic differences in hepatic CYP3A5 in the renal transplant 
patients. 
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There is also a discrepancy with regard to ABCB1. Only 3 (one in 
kidney35 and two in liver37,42) of the 8 papers on the association of 
ABCB1 polymorphisms and tacrolimus-induced nephrotoxicity found a 
positive association. Again, similar reasons as for the CYP3A5 associa-
tions for these discrepancies apply: small patient populations, mixed 
tacrolimus/cyclosporine cohorts, follow-up time, different organs and 
different ABCB1 haplotypes. Taking these differences/ limitations into 
account, no conclusion can be drawn regarding the association between 
ABCB1 genotype and renal dysfunction in adult heart or liver transplant 
recipients. For pediatric liver transplant patients, an association for early 
(less than 1 year after transplant) renal dysfunction and ABCB1 genotype 
in patients on tacrolimus may be present. In adult and renal transplant 
patients, no association between recipient ABCB1 genotype and CNIT 
seems to be evident, although this is dependent on the definition. If IF/TA 
are also considered due to tacrolimus, such an association may exist. 
The discrepancies in the findings regarding CYP3A5 and ABCB1 could also 
be related to one another. A possible interaction between the CYP3A 
and ABCB1 expression has been proposed in the past, showing higher 
hepatic and intestinal CYP3A4 expression in ABCB1 2677TT carriers than 
homozygotes for ABCB1 2677G.43 A gender effect on this interaction 
has been suggested as well, with women carrying the ABCB1 2677TT-
3435TT haplotype showing significantly higher CYP3A4 mRNA expression 
levels in the native intestine than ABCB1 2677GG-3435CC carriers. This was 
not found in men.44 
Smith et al.39 reported a higher risk of developing renal dysfunction in adult 
liver recipients carrying the CYP2C8*3 polymorphism. The patient group 
was a mixed one, but the patients receiving tacrolimus were also analyzed 
separately. The odds ratio for these patients was much higher at 16.67 
(CI95% 2.8–99.6). In spite of the very wide confidence interval, the risk is 
considerate since the lower limit is almost.3 The results of this study 
strongly suggest a role for CYP2C8 in the risk of tacrolimus-related renal 
dysfunction in adult liver recipients. The ACE study40 was assigned the 
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highest overall quality score of 25 and the highest power (99%). The liver 
transplant recipients group was mixed (tacrolimus or cyclosporine), but 
tacrolimus treatment was predominant (100 of 142 patients). The results 
suggest an association between ACE and renal dysfunction in adult liver 
recipients who receive tacrolimus. 
The results for TGF-ß in adult heart transplant patients are interesting with 
an association between this genotype (Pro10 and Pro25 carriers) and an 
increased risk for end-stage renal failure. Only a small minority received 
tacrolimus (21 of 402), but considering the proposed mechanism of 
action in the kidney of both cyclosporine and tacrolimus, it is reasonable 
to assume that results may be similar if only patients on tacrolimus are 
studied. 
For the other genes not mentioned in detail that were studied by 
different groups, no correlation between genotype and renal dysfunction 
and/or nephrotoxicity in solid organ transplant recipients was reported. 
Considering the limitations of the differentstudies discussed above, it can, 
however not be ruled out that these genes do not play a role in the risk to 
develop renal dysfunction after tacrolimus exposure. 
However, the candidate-gene approach used in all of the included 
papers has a limitation in its design, as it only targets the genes thought 
to be important to the researcher are included in the design of the study. 
A Genome-Wide Association Study (GWAS) or a proteomic study might 
give a better understanding of the mechanisms involved in the patho-
physiology of transplant-related diseases. 
The first limitation of this review resides in the multifactorial background 
of renal dys-function after transplantation. Besides the use of calcineurin- 
inhibitors, such as tacrolimus, other possible causes (i.e. diabetes, athero-
sclerosis, HCV associated glomerulonephritis) might be the reason for the 
renal dysfunction experienced after transplantation.45 Furthermore, renal 
biopsies are not regularly done creating difficulties tracking the progress 
of the renal dysfunction. Yet, even if they were, controversy exists 
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on the specific histological signs for calcineurin-inhibitor induced 
nephrotoxicity.10,46 Secondly, the study design and reporting of the 
some of the studies that we identified are suboptimal. Reporting can be 
improved by using a recently published guideline on the reporting in 
genetic association studies (STREGA).47 As we have discovered in our 
review, reporting of the methods in particular is sub standard. The laboratory 
methods, the genotyping methods as well as the error rates and call rates 
should be reported. The laboratory where genotyping was done should be 
identified as well. Additionally, it should be specified whether genotypes 
were assigned using all of the data from the study simultaneously or in 
smaller batches, and whether or how the Hardy- Weinberg equilibrium 
was considered. Although the papers in this review lacked much of this 
information and often results were not adjusted for multiple testing, they 
did report on other aspects mentioned in the guideline, especially in the 
results section. For example, the proportions of successfully genotyped 
patients were reported in 9 of the 13 papers.
Conclusions
Despite the fact that the factors discussed may limit overall conclusions 
on pharmacogenomic variation in tacrolimus-induced nephrotoxicity, we 
believe that interesting candidate genes have been identified. 
The pharmacokinetic genes (e.g. CYP3A5, ABCB1) and some pharmacody-
namic genes (e.g. CYP2C8, TGF-ß) deserve further investigation – also in 
children. Critically, it will be important to include all the target genes in 
a single predictive analysis, and not isolated ones. An important finding 
of the present analysis is that most studies had little statistical power to 
detect any genotype-phenotype associations. Although we realize that 
obtaining a large enough sample size is difficult regarding (pediatric) 
transplant recipients, we feel that future studies should try and increase 
the number of subjects studied, by genetic meta-analysis and/or consor-
tia formation.
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Supplementary figure 1: Downs-Black scale28
Reporting
1. Is the hypothesis/aim/objective of the study clearly described?
 Yes 1  No 0
2. Are the main outcomes to be measured clearly described in the Introduction or Methods Section? 
 If the main outcomes are first mentioned in the Results section, the questions should be answered no. 
 Yes 1  No 0
3. Are the characteristics of the patients included in the study clearly described?
 In cohort studies and trials, inclusion and/or exclusion criteria should be given. 
 In case-control studies, a case-definition and the source for controls should be given
 Yes 1  No 0
4. Are the tacrolimus regimens clearly described?
 Treatments and placebo (where relevant) that are to be compared should be clearly described. 
 Yes 1  No 0
5. Are the distributions of principal confounders in each group of subjects to be compared clearly 
 described?
 A list of potential confounders is provided.
 Yes 2  Partially 1  No 0
6. Are the main findings of the study clearly described?
 Simple outcome data (including denominators and numerators) should be reported for all major 
 findings so that the reader can check the major analyses and conclusions. (This question does not 
 cover statistical tests which are considered below)
 Yes 1  No 0
7. Does the study provide estimates of the random variability in the data for the main outcomes?
 In non normally distributed data the inter-quartile range of results should be reported. In normally 
 distributed data the standard error, standard deviation or confidence intervals should be reported. 
 If the distribution of the data is not described, it must be assumed that the estimates used were ap 
 propriate and the question should be answered yes.
 Yes 1  No 0
8. Have all important adverse events that may be a consequence of the tacrolimus regimen been 
 reported?  This should be answered yes if the study demonstrates that there was a comprehensive 
 attempt to measure adverse events. (A list of possible adverse events is provided.)
 Yes 1  No 0
9. Have the characteristics of patients lost to follow-up been described?
 This should be answered yes where there were no losses to follow-up were so small that findings 
 would be unaffected by their inclusion. This should be answered no where a study does not report 
 the number of patients lost to follow-up.
 Yes 1  No 0
10. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main 
 outcomes except where the probability value is less than 0.001?
 Yes 1  No 0
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External validity
All the following criteria attempt to address the representativeness of the findings of the study and whether 
they may be generalised to the population from which the study subjects were derived.
11. Were the subjects asked to participate in the study representative of the entire population from 
 which they were recruited? The study must identify the source population for patients and 
 describe how the patients were selected. Patients would be representative if they comprised the 
 entire source population, an unselected sample of consecutive patients, or a random sample. 
 Random sampling is only feasible where a list of all members of the relevant population exists.   
 Where a study does not report the proportion of the source population from which the patients 
 are derived, the question should be answered as unable to determine.
 Yes 1  No 0  Unable to determine 0
12. Were those subjects who were prepared to participate representative of the entire population 
 from which they were recruited? The proportion of those asked who agreed should be stated. 
 Validation that the sample were representative would include demonstrating that the distribution 
 of the main confounding factors was the same in the study sample and the source population. 
 Yes 1  No 0  Unable to determine 0
13. Were the staff, places, and facilities where the patients were treated, representative of the 
 treatment the majority of patients receive? For the question to be answered yes, the study should 
 demonstrate that the intervention was representative of that in use in the source population. 
 The question should be answered no if, for example, the intervention was undertaken in a specialist 
 centre unrepresentative of the hospitals most of the source population would attend.
 Yes 1  No 0  Unable to determine 0
Internal validity - bias
14. Was an attempt made to blind study subjects to the tacrolimus regimen they have received?
 For studies where the patients would have no way of knowing which intervention they received, 
 this should be answered yes.
 Yes 1  No 0  Unable to determine 0
15. Was an attempt made to blind those measuring the main outcome of the tacrolimus regimen?
 Yes 1  No 0  Unable to determine 0
16. If any of the results of the study were based on “data dredging”, was this made clear?
 Any analyses that had not been planned at the outset of the study should be clearly indicated. 
 If no retrospective unplanned subgroup analyses were reported, then answer yes.
 Yes 1  No 0  Unable to determine 0
17. In trials and cohorts studies, do the analyses adjust for different lengths of follow-up of patients, 
 or in case-control studies, is the time period between the tacrolimus regiment and outcome the 
 same for cases and controls?
 Yes 1  No 0  Unable to determine 0
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18. Where the statistical tests used to assess the main outcomes appropriate?
 The statistical techniques used must be appropriate to the data. For example non-parametric 
 methods should be used for small samples sizes. Where little statistical analysis has been 
 undertaken but where there is no evidence of bias, the question should be answered yes. 
 If the distribution of the data (normal or not) is not described it must be assumed that the estimates 
 used were appropriate and the question should be answered yes. 
 Yes 1  No 0  Unable to determine 0
19. Was compliance with the tacrolimus regimen reliable?
 Where there was non compliance with the allocated treatment or where there was contamination 
 of one group, the question should be answered no. For studies where the effect of any mis- 
 classification was likely to bias any association to the null, the question should be answered yes.
 Yes 1  No 0  Unable to determine 0
20. Where the main outcome measures used accurate (valid and reliable)?
 For studies where the outcome measures are clearly described, the question should be answered 
 yes. For studies which refer to other work or that demonstrates the outcome measures are accurate, 
 the question should be answered yes. 
 Yes 1  No 0  Unable to determine 0
Internal validity – confounding (selection bias)
21. Were the cases and controls (case-control studies) recruited from the same population?
 For example, patients for all comparison groups should be selected from the same hospital. 
 The question should be answered unable to determine for cohort and case-control studies where 
 there is no information concerning the source of patients included in the study.
 Yes 1  No 0  Unable to determine 
22. Were the cases and controls (case-control studies) recruited over the same time period?
 For a study which does not specify the time period over which patients were recruited, the question 
 should be answered unable to determine.
 Yes 1  No 0  Unable to determine 0
23. Were study subjects randomised to intervention groups?
 Studies which state that subjects were randomised should be answered yes except where the 
 method of randomisation would not ensure random allocation. For example alternate allocation 
 would score no because it is predictable.
 Yes 1  No 0  Unable to determine 0
24. Was the randomised intervention assignment concealed from both patients and health care 
 staff until recruitment was complete and irrevocable? All non-randomised studies should be 
 answered no. If assignment was concealed from patients but not from staff, it should be answered no. 
 Yes 1  No 0  Unable to determine 0
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25. Was there adequate adjustment for confounding in the analyses from which the main findings 
 were drawn? This question should be answered no for trials if: the main conclusions of the study 
 were based on analyses of treatment rather than intention to treat; the distribution of known 
 confounders in the different treatment groups was not described; or the distribution of known 
 confounders differed between treatment groups but was not taken into account in the analyses. 
 In non randomised studies if the effect of the main confounders was not investigated or 
 confounding was demonstrated but no adjustment was made in the final analyses the question 
 should be answered as no.
 Yes 1  No 0  Unable to determine 0
26. Were losses of patients to follow-up taken into account?
 If the numbers of patients lost to follow-up are not reported, the question should be answered as 
 unable to determine. If the proportion lost to follow-up was too small to affect the main findings, 
 the question should be answered yes.
 Yes 1  No 0  Unable to determine 0
Power
27. Did the study have sufficient power to detect a clinically important effect where the probability 
 value for a difference being due to chance is less than 5%?
 
 Sample sizes have been calculated to detect a difference or x% and y%.
  Size of smallest group 
 A <n1 0
 B n1- n2 1
 C n3- n4 2
 D n5- n6 3
 E n7-n8 4
 F n8
+ 5
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Summary
Background Tacrolimus is one of the commonly used immuno-
suppressive drugs for pediatric heart transplants. Large variation exists in 
pharmacokinetics during the direct post-transplant period, resulting 
in an increased risk of adverse events. Limited data are available on the 
interaction of age, CYP3A5 and ABCB1 genotype, and disease severity on 
the variation in disposition and outcome in pediatric heart transplant 
recipients.
Method We studied the relationship between age and CYP3A5 and 
ABCB1 genotype and the Pediatric Risk of Mortality (PRISM) score on 
tacrolimus dose (mg/kg), steady-state trough concentrations, and 
concentration/dose ratio, as well as rejection and renal function for 14 
days after heart transplant in children.
Results Tacrolimus was administered to 39 children (median age, 6.0 
years) after transplant. A correlation was found between the age at the 
time of transplant and the tacrolimus dosing requirements (rs = –0.447, 
p = 0.004) and the concentration/dose ratio (rs = 0.351, p = 0.029). CYP3A5 
expressors required median (interquartile range) higher doses of 
tacrolimus (0.14 [0.09] vs 0.06 [0.04] mg/kg/12 hours, p 0.001), and had 
lower concentration/dose ratios (45.34 [44.54] vs 177.78 [145.38] ng/ml 
per mg/kg/12 hours, p = 0.0001). This relationship was not seen with the 
ABCB1 genotype. Age and CYP3A5 genotype predicted the tacrolimus 
dosing requirements as well as the concentration/dose ratio (R2 = 0.351, 
p = 0.001 and R2 = 0.521, p = 0.001). No relationship was found between 
any of the CYP3A5 or ABCB1 genotypes and the estimated glomerular 
filtration rate.
Conclusion Younger age and CYP3A5 expressor genotype were 
independently associated with higher dosing requirements and lower 
tacrolimus concentration/dose ratios.
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Introduction
After its introduction into clinical use in 1997, tacrolimus became one 
of the most commonly used drugs for immunosuppressive treatment 
of solid-organ transplant recipients. In heart transplant recipients, it is 
often preferred to cyclosporin1 for its lower incidence of hypertension, 
dyslipidemia, and fewer cosmetic adverse effects, such as hirsutism and 
gingival hypertrophy.1,2,3 A narrow therapeutic window complicates 
tacrolimus dosing, however. 
The first weeks after transplantation are generally marked by the highest 
risk for organ rejection. During this period, considerable variability in 
drug concentrations and pharmacokinetics can contribute to rejection 
risk with underdosing and drug toxicity (eg, nephrotoxicity, neurotox-
icity) with overdosing. Sub-therapeutic tacrolimus concentrations confer 
a risk for biopsy-proven rejection in adult and pediatric heart transplant 
recipients.4,5,6 Furthermore, in 112 adult cardiac transplant recipients, early 
renal insufficiency, defined as 10% rise in serum creatinine and a serum 
creatinine above 1.5 mg/dl on Day 3 after transplantation, was associated 
with tacrolimus levels.7 
The pharmacokinetics of tacrolimus have been extensively studied 
in adults.8,9 However, limited data exist on the sources of large inter-
individual and intraindividual variability of tacrolimus pharmacokinetics 
in children. Faster tacrolimus clearance rate in children aged younger 
than 6 years and higher tacrolimus doses per kilogram of body weight to 
achieve the target concentrations in this age group have been reported 
in liver, renal, and hematopoietic stem cell transplant recipients.10,11,12,13 
The causes for these differences are presently unknown but may be due 
to age-related changes in CYP3A activity and to the large size of the liver 
allograft relative to body size in children aged younger than 6 years.14 
The relationship between the CYP3A5 genotype and higher tacrolimus
clearance has been well established in adult cardiac transplant 
patients9,15 but only limited data are available in pediatric cardiac transplant 
recipients. A recent study16 reported a relationship in 65 pediatric 
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patients between CYP3A5 genotype and tacrolimus clearance at 3, 6 
and 12 months after transplantation. This study suggested that CYP3A5 
expressors (CYP3A5*1/*3) need higher drug doses to maintain the same 
blood concentration at 3, 6 and 12 months after transplant. However, 
the effects of mutations in ABCB1 genotypes on tacrolimus disposition in 
liver and kidney transplant recipients were inconsistent, with reports 
both supporting17,18,19,20 or refuting such an association.17,20,21 The study in 
pediatric heart transplant recipients demonstrated an association 
between ABCB1 C3435T and G2677T/A and tacrolimus dosing require-
ments at 6 and 12 months after transplantation.16 
These studies did not evaluate the influence of genotype in relation to 
other clinical factors, such as age and comorbidity, on dose requirements 
in the early period after transplantation. A large variation in tacrolimus 
pharmacokinetics may occur in the early post-transplantation period due 
to critical illness-related factors, such as mechanical ventilation, altered 
cardiac output and consequent altered liver and kidney blood flow, body 
fluid, and plasma protein changes. Hence, we speculated that in patients 
with a higher severity of illness, as defined by the risk of mortality at 
intensive care unit admission by the Pediatric Risk of Mortality (PRISM) 
score, lower tacrolimus requirements would be observed. Our objective 
was to determine the effects of age, recipient CYP3A5 and ABCB1 
genotypes, and PRISM score on tacrolimus disposition in the first 14 
days after transplant in pediatric heart allograft recipients. In addition, 
we wanted to investigate the association between recipient CYP3A5 and 
ABCB1 genotypes and tacrolimus levels on transplant outcomes such as 
rejection and renal function.
Patients and methods
This study was approved by the Institutional Research Ethics Board, and 
informed consent was obtained from parents and/or children during 
enrollment. Pediatric heart transplant recipients (aged 18 years at the 
time of transplant) who received oral tacrolimus during the first 14 days 
after transplant between 1995 and 2008 at the Hospital for Sick Children, 
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Toronto, Ontario, were eligible for study entry. 
DNA samples were derived from a cohort of patients prospectively 
enrolled in the Sickkids Heart Centre Biobank.
Immunosuppressive protocol
Induction therapy with anti-thymocyte globulin was started peri- 
operatively and given up to 2 to 5 days after transplantation in all patients. 
Tacrolimus was started at Day 2 to 3 after transplantation, with a starting 
dose of 0.2 mg/kg/day orally, divided twice daily. The treating physician 
used therapeutic drug monitoring to adjust the tacrolimus dose to a 
target level of 10 to 12 ng/ml. Additional immunosuppressive therapy 
consisted of a maintenance dose of mycophenolate mofetil and steroids.
Pharmacokinetic and pharmacodynamics outcome measures
As dependent variables, we collected tacrolimus dose (mg/kg/12 hours) 
and tacrolimus trough concentrations from patient health records. 
Dose-corrected tacrolimus concentrations were calculated by dividing 
the tacrolimus trough concentration by the weight-adjusted dose. 
Data were collected on the occurrence of rejection and renal function 
in our population. Rejection was graded according to the International 
Society of Heart and Lung Transplantation’s (ISHLT) grading system.22 
Rejection was defined as an ISHLT grade 2R or higher. Creatinine clear-
ance was estimated with the Schwartz formula, using the last available 
serum creatinine level during the study period.
Covariates
Patient sex, age, weight, the comedication received, CYP3A5 and ABCB1 
genotype, and PRISM score were collected as independent variables.
Tacrolimus concentrations
Tacrolimus blood trough concentrations were determined in ethylenedi-
aminetetraacetic acid (EDTA)-treated whole blood (0.25 ml) on the day 
of sampling, using liquid chromatography tandem mass spectrometry 
(LC-MS-MS) as previously described, as part of clinical care.23
74 | Chapter 4
Genotyping
Blood for genotyping was collected in EDTA-containing tubes, and 
DNA was extracted using a Magna-Pure LC (Roche Diangostics GmbH, 
Mannheim, Germany). Polymerase chain reaction (PCR)–restriction 
fragment length polymorphism for CYP3A5*3 and ABCB1 C3435T, G2677T, 
and C1236T were performed as described previously.24,25,26 Patients not 
carrying the CYP3A5*3 allele were assigned the CYP3A5*1/*1 genotype by 
default.
Statistical analyses
Data are presented as mean ± standard deviation or median and 
interquartile range (IQR) when the data were skewed. Differences were 
compared using the Mann-Whitney test or the Kruskal-Wallis test. 
The Spearman  test was used to test possible correlations. A linear multi-
variate analysis was performed to test the influence of thepredictors on 
all dependent variables. All data analyses were performed using SPSS 
16.0 software (SPSS, Chicago, IL). The Hardy-Weinberg equilibrium was 
calculated by using the method from Rodriguez et al.27
Results
Patient characteristics
The study comprised 39 eligible pediatric heart transplant recipients 
(25 boys, 14 girls) who were a median age of 6.0 (IQR: 13.75) years and 
a median weight of 13.1 (IQR: 25.5) kg. A detailed list of the patients’ 
demographics can be found in Table 1.
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Table 1: Demographics of the population
Variable All patients (n=39)
Age in years
< 1yrs
6.0 (13.75)
15/39 (38.5%)
Gender
Female 14
Male 25
Weight in kg 13.1 (25.5)
Ethnicity
Caucasian 28
African-American 2
Asian 4
Unkown 5
Diagnosis
Dilated cardiomyopathy 22
Congenital heart disease 15
Unknown 2
PRISM score† 9.50 (10)
Need for pre-transplant mechanical ventilation 17.9% (7/39)
Need for post-transplant mechanical ventilation
Days on mechanical ventilation
74.4 % (29/39)
2.56 (3.6)*
Tacrolimus oral dose (mg/kg/12h) 0.06 (0.06)
Tacrolimus trough level (ng/ml) 9.6 (2.08)
Concentration/Dose ratio (ng/ml per mg/kg/12h) 150.79 (173.3)
Tacrolimus disposition
During the 2-week post-transplant period, 258 tacrolimus concentrations 
were available for analysis. A median of 6 concentration measurements 
were available for each patient during the study period. The median 
tacrolimus trough concentration was 9.6 (IQR: 2.08) ng/ml, and the 
median dose requirement was 0.06 (IQR: 0.06) mg/kg/12 hours. The median 
concentration/weight-adjusted dose ratio (as a surrogate for estimated 
clearance) was 150.79 (IQR: 173.3) ng/ml/dose. Of all analyzed concen-
trations, 32.0% were above the target range and 53.7% were below the 
target range (Figure 1). On Day 7, 28% were above the target range and 
51.3% were below the target range.
Table 1: Results are reported in median (IQR) unless noted otherwise. * mean ± sd The tacrolimus dose, 
tacrolimus trough level and concentration/dose ratio are averages of all values obtained during the 14 day 
post-transplant period. † = The PRISM score is based on variables collected during the first 24 hours of ICU 
admission after transplantation.
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Outcome
None of the patients were diagnosed with a grade 2R or higher of 
rejection in the first 14 days after transplantation. The median estimated 
glomerular filtration rate (eGFR) at the last available creatinine level was 
130.29 (IQR: 66.27) ml/min/1.73 m2.
Relationship with genotype 
DNA for CYP3A5 genotyping was available for 37 of the 39 patients. Only 
1 patient carried the CYP3A5*1/*1 genotype, 7 carried the CYP3A5*1/*3 
genotype, and 29 carried the CYP3A5*3/*3 genotype. CYP3A5 genotypes 
did not deviate from the Hardy-Weinberg equilibrium (Χ2 0.49, p=0.5). 
CYP3A5 expressors (CYP3A5*1/*1 and CYP3A5*1/*3) required significantly 
higher doses of tacrolimus than the nonexpressors, at 0.14 (IQR, 0.09) vs 
0.06 (IQR: 0.04) mg/kg/12 hour (p=0.001; Figure 2). 
Figure 1: Histogram of tacrolimus concentrations
Figure 1: Vertical lines denote therapeutic range in first two weeks after heart transplant. % = percentage of 
samples outside of therapeutic window
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Figure 2: Relationship between CYP3A5 genotype and tacrolimus dosing requirements
Figure 2: * = p<0.05 expressors vs. non-expressors, • = Outliers
Expressors also had significantly lower tacrolimus trough concentrations, 
at 7.7 (IQR: 5.85) vs 9.8 (IQR: 3.05) ng/ml (p=0.032), and lower concentra-
tion/ dose ratios of 45.34 (IQR: 44.54) vs 177.78 (IQR: 145.38) ng/ml per 
mg/kg/12 hours (p=  0.0001; Table 2). 
Table 2: Relationship of CYP3A5 genotype with tacrolimus disposition
Tacrolimus trough levels 
(ng/ml)
Tacrolimus dosing requirements 
(mg/kg/12h)
Concentration/dose ratio 
(ng/ml per mg/kg/12h)
N Median (IQR) P-value N Median (IQR) P-value N Median (IQR) P-value
CYP3A5 37 0.032* 37 0.002* 37 <0.0001*
Expressors 8 7.70 (5.85) 8 0.139 (0.09) 8 45.34 (44.54)
Non-expressors 29 9.80 (3.05) 29 0.055 (0.04) 29 177.78 (145.38)
* = p<0.05 expressors vs non-expressors
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Table 3: ABCB1 genotype frequencies
Genotype Frequency (percentage) Hardy-Weinberg equilibrium
Chi-square p-value
ABCB1 χ2=1.29 P=0.2
3435 CC 12 (32%)
3435 CT 15 (41%)
3435 TT 10 (27%)
ABCB1 χ2=0.02 P=0.9
2677 GG 11 (30%)
2677 GA 1 (3%)
2677 GT 17 (46%)
2677 TT 8 (21%)
ABCB1 χ2= 0.29 P=0.5
1236 CC 10 (27%)
1236 CT 20 (54%)
1236 TT 7 (19%)
DNA for ABCB1 C3435T, ABCB1 G2677T/A, and ABCB1 C1236T genotyping
was available for 37 of the 39 patients. The frequencies of each of the 
genotypes are described in Table 3. None of the ABCB1 genotypes 
deviated from the Hardy-Weinberg equilibrium. No relationship was 
found between tacrolimus dosing requirements, tacrolimus trough 
concentrations, or concentration/dose ratio and ABCB1 3435, 2677, and 
1236 genotypes (Table 4). 
Relationship with age and PRISM scores 
Tacrolimus dosing requirements were higher in younger than older 
children (rs=–0.447, p=0.004; Figure 3). Concentration/dose ratios were 
lower in younger children (rs=0.351, p=0.029); however, the tacrolimus 
trough concentrations were not significantly correlated with age (rs=0.052, 
p=0.752). No significant correlation was found between the PRISM score 
and tacrolimus dosing requirements (rs=–0.29, p=0.09), concentra-
tion/dose ratios (rs=0.20, p=0.25), or tacrolimus trough concentrations 
(rs =–0.150, p=0.38). 
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Table 4: Relationship of ABCB1 genotype with tacrolimus disposition
Tacrolimus trough level 
(ng/ml)
Tacrolimus dosing requirements 
(mg/kg/12h)
Concentration/Dose Ratio 
(ng/ml per mg/kg/12h)
N Median (IQR) P-value N Median (IQR) P-value N Median (IQR) P-value
ABCB1 3435 37 0.466 37 0.899 37 0.823
CC 12 9.85 (5.07) 12 0.062 (0.11) 12 150.16 (301.16)
CT 15 9.50 (2.75) 15 0.055 (0.08) 15 150.79 (175.33)
TT 10 10.03 (1.97) 10 0.073 (0.06) 10 145.10 (156.82)
ABCB1 2677 37 0.318 37 0.963 37 0.531
GG 11 9.80 (5.70) 11 0.067 (0.09) 11 154.55 (331.46)
GA/GT 18 9.50 (3.68) 18 0.073 (0.08) 18 139.54 (151.79)
TT 8 10.17 (1.88) 8 0.072 (0.05) 8 174.12 (138.62)
ABCB1 1236 37 0.413 37 0.835 37 0.776
CC 10 10.20 (5.40) 10 0.061 (0.06) 10 179.01 (283.16)
CT 20 9.50 (2.88) 20 0.074 (0.08) 20 139.54 (178.71)
TT 7 10.20 (2.30) 7 0.081 (0.04) 7 170.46 (144.19)
Figure 3: The relationship between mean tacrolimus dosing requirements and patient’s age at the time of transplant.
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Interplay of age and CYP3A5 genotype 
Age and CYP3A5 genotype both appeared to be associated with 
tacrolimus dosing requirements or the concentration/ dose ratio. 
The contribution of both parameters was assessed with multivariate 
linear regression. Age and CYP3A5 genotype were independently 
associated with the tacrolimus dosing requirements (R2=0.351, p=0.001) 
and with the concentration/dose ratio (R2=0.521, p=0.001). This was 
reflected by the observation that in CYP3A5 expressors younger than 6 
years, the dosing requirements were more than 1.5 times higher than 
in CYP3A5 expressors older than 6 years (0.15 [IQR: 0.08] vs 0.09 [IQR: 
0.04] mg/kg/12 hours). CYP3A5 non-expressors younger than 6 years 
also needed 1.5 times higher doses than CYP3A5 non-expressors older 
than 6 years (0.07 [IQR: 0.18] vs 0.047 [IQR: 0.25] mg/kg/12 hours). In ad-
dition, the dosing requirements of CYP3A5 expressors younger than 6 
years were 3 times higher than CYP3A5 non-expressors older than 6 years 
(0.15 [IQR: 0.08] vs 0.04 [IQR: 0.25] mg/kg/12 hours). When the analysis 
excluded 1 patient who received fluconazole and 2 patients who received 
amiodarone, which are CYP3A inhibitors, the results were similar for the 
relationship between CYP3A5 and ABCB1 genotype and age and tacrolimus 
disposition. 
Relationship between genetic variation, tacrolimus levels, and outcomes 
We did not find a relationship between eGFR at the last available creatinine 
level and median or highest tacrolimus trough level (rs=0.128, p=0.439; 
rs=–0.005, p=0.975). We also did not find a relationship between eGFR at 
the last available creatinine level and CYP3A5 genotype for expressors 
(median eGFR, 125.37 [IQR, 56.77] ml/min/1.73m2) vs non-expressors 
(130.43 [IQR: 72.65] ml/min/1.73m2, p=0.941).
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Discussion
Our data show that less than 15% of tacrolimus trough concentrations 
are within the (narrow) target range in the early post-transplant 
period in pediatric heart transplant recipients. Age and CYP3A5 genotype, 
independently, both contribute to the variation in the tacrolimus dosing 
requirements in this cohort. 
Limited data exist on pharmacogenetic influences in pediatric transplant 
recipients:
·  Zheng et al16 reported similar results at 3, 6, and 12 months after 
 transplantation in 65 pediatric heart transplant recipients. These 
 investigators showed a significant difference in the tacrolimus concen- 
 tration/dose ratio between CYP3A5 expressors and non-expressors, 
 with the expressors requiring higher doses to maintain the same 
 tacrolimus blood concentration.
·  A lower tacrolimus oral clearance was reported by Zhao et al28 for 
 pediatric kidney transplant recipients with the CYP3A5*3/*3 genotype 
 compared with those with the CYP3A5*1/*3 genotype less than 2 
 months after transplant. 
·  Two other studies of pediatric liver transplant recipients found no 
 relationship between recipient CYP3A5 genotype and tacrolimus 
 disposition; in contrast, the liver donor’s CYP3A5 genotype was a 
 significant predictor.18,29 
Our study showed a CYP3A5 recipient genotype-tacrolimus disposition
relationship in the first 2 weeks after transplantation, arguably one of 
the most vulnerable periods. We did not find associations between 
ABCB1 genotype and tacrolimus dosing requirements and disposition. 
This is consistent with a study in children done by Zheng et al,16 which 
also failed to find an association at 3 months after pediatric heart trans-
plant. In contrast, at 6 and 12 months after transplant, they found lower 
concentration/dose ratios in patients with the GG and CC haplotype 
(ABCB1 G2677T/A and C3435T, respectively). They explained this by higher 
cytokines concentrations in the early post-transplant period (ie, 3 months) 
that may have contributed to increased variability in P-glycoprotein 
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expression. Other studies also provide conflicting data about this 
association, with more studies showing positive associations late after 
transplant rather than the early period.17,29 
The effect of age on tacrolimus pharmacokinetics has been reported.30 
Studies of pediatric renal31 and liver12,13,32 transplant recipients have shown 
that pre-pubertal children need 2 to 3 times higher doses than adults. 
In pediatric bone marrow transplantation, a higher clearance rate, 
compared with adults, was reported.33 Within the pediatric population,
age-related differences between younger and older children in tac-
rolimus pharmacokinetics have been reported as well. Przepiorka et al10 
documented a decreased tacrolimus clearance in the first 2 weeks after 
hematopoietic stem cell transplantation only for children aged older than 
12 years. In addition, at steady state, the clearance rate was higher for 
those younger than 6 years than in older children. In pediatric renal trans-
plant recipients, Kim et al11 showed that the younger children (-5 years 
and 5–12 years) required 2.7 and 1.9 times higher dosages, respectively, 
than older children (12 years), and that a significant inverse correlation 
between dose/kg and age among all age groups was present. Naesens 
et al34 reported that younger pediatric renal transplant recipients need-
ed significantly higher doses to achieve comparable tacrolimus trough 
concentrations compared with older children. Our results show similar 
findings, with higher dose requirements and lower concentration/dose 
ratios (as surrogate marker for clearance) in younger pediatric heart trans-
plant recipients. 
Ontogeny in tacrolimus biotransformation may explain these findings. 
The hepatic metabolism of drugs is altered in younger children, with 
different ages for the different cytochromes to reach maturity, resulting 
in different metabolism rates14 and consequent clearance rates. For many 
CYP3A4/5 substrates, it is widely established that clearance is increased in 
the age group between 6 months and 3 years. This has been attributed to 
higher CYP3A4/5 activity compared with adults, but others have suggested 
this is due to a larger liver/body size ratio in children than in adults.14,35 
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No patient experienced rejection within the 14 days after transplanta-
tion. Therefore, we were unable to test a relationship of genetic variation 
with outcomes. However, the potential influence of the pharmacokinet-
ic variability in the first 14 days after transplantation on the long-term 
rejection risk still needs to be studied. In addition, we could not estab-
lish a relationship between genetic variability, tacrolimus levels, and renal 
function. Possible reasons could be the relatively small sample size as well 
as the limited 14-day interval. As an increase in serum creatinine is only 
apparent with a marked decrease in renal function, the 14-day interval 
may not have been big enough to see an effect of the high tacrolimus 
levels on causing a rise in serum creatinine. Factors other than tacrolimus- 
induced nephrotoxicity, such as comedication and altered hemodynamics, 
may affect renal function directly after transplant. 
Importantly, our study shows that CYP3A5 genotype and age are 
independently associated with tacrolimus disposition. As major chang-
es occur in drug disposition during development, the effect of genetic 
variation in drug disposition should be studied in the context of this age-
related variation. We observed that all CYP3A5 expressors, independent 
of age, had higher tacrolimus dosing requirements than non-expressors. 
Taking age into account further amplified the genotype effect, with 
younger CYP3A5 expressors needing, on average, tacrolimus doses that 
were 3 times higher than those needed by older CYP3A5 non-expressors. 
One limitation of our study is the relatively small sample size, which 
affected the amount of confounders we could look at. In addition, the 
drug dosing data in our study were retrospectively collected, and this 
may have introduced unknown variation in the noted vs the actually 
administered dose, such as inaccuracies with drug dispensing and 
vomiting with repeated dosing. Although we only studied oral doses of 
tacrolimus, most of the children do receive tacrolimus orally. Some children, 
however, cannot tolerate oral tacrolimus and receive intravenous 
tacrolimus. These children need to be studied separately because 
differences exist between oral doses and intravenous doses. 
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The systemic exposure is different with intravenous tacrolimus 
because the first-pass metabolism (eg, metabolism by CYP3A5 and ABCB1
transport before absorption) is bypassed, although liver metabolism 
would still occur. 
In conclusion, we showed that in the first 14 days after heart transplan-
tation, younger age and CYP3A5 expressor status were independently 
associated with higher tacrolimus dosing requirements and concentration/ 
dose ratio (as surrogate marker for clearance). Drug dosing algorithms 
need to be developed to guide initial dosing that is individualized based 
on age and genotype, with the goal of optimizing the ability to safely and 
rapidly achieve therapeutic targets.
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Abstract 
Background Tacrolimus metabolism depends on CYP3A4 and CYP3A5. 
We aimed to determine the relationship between the CYP3A4*22 
polymorphism and combined CYP3A genotypes with tacrolimus 
disposition in pediatric heart transplant recipients.
Method Sixty pediatric heart transplant recipients were included. 
Tacrolimus doses and trough concentrations were collected in the 
first 14 days post-transplantation. CYP3A phenotypes were defined as 
extensive (CYP3A5*1 carriers + CYP3A4*1/*1), intermediate (CYP3A5*3/*3 + 
CYP3A4*1/*1) and poor (CYP3A5*3/*3 + CYP3A4*22 carriers) metabolizers.
Results CYP3A4*22 carriers needed 30% less tacrolimus (p = 0.016) to 
reach similar target concentrations compared to CYP3A4*1/*1 (n=56) 
carriers. Poor CYP3A metabolizers required 17% (p =0.023) less tacrolimus 
than intermediate and 48% less (p <0.0001) than extensive metaboliz-
ers. Poor metabolizers showed 18% higher dose-adjusted concentrations 
than intermediate (p=0.35) and 193% higher than extensive metabolizers 
(p<0.0001).
Conclusion Analysis of CYP3A4*22, either alone or in combination with 
CYP3A5*3, may help towards individualization tacrolimus therapy in 
pediatric heart transplant patients.
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Introduction
Tacrolimus is the most commonly used drug for immunosuppressive 
treatment in heart transplant recipients.[1] Due to its narrow therapeutic 
window, accurate dosing and the attainment of target concentrations 
are challenging. This is true especially in the first weeks following 
transplantation where variability in drug concentrations are consider-
able and where information from therapeutic drug monitoring to guide 
therapy is limited. This early period is also marked by an increased risk 
for early organ rejection possibly due to under-dosing resulting in 
inadequate immunosuppression. Therefore, it is critical to study 
determinants of this variability in order to identify patients at risk.[2],[3]
Tacrolimus is metabolized by cytochrome P450 3A4 (CYP3A4) and 
3A5 (CYP3A5). In adult heart transplant patients, the relationship 
between CYP3A5 genotype and tacrolimus clearance rate has been well 
established.[4] [5] Two pediatric studies in heart transplant recipients have 
reported the relationship of CYP3A5 genotype with tacrolimus pharma-
cokinetics.[6] [7] Our group has shown that CYP3A5 expressers (carrying at 
least one CYP3A5*1 allele) younger than 6 years of age needed 3 times 
higher doses and achieved lower tacrolimus trough concentrations than 
CYP3A5 non-expressers older than 6 years of age in the first 14 days 
post-transplantation, consistent with an enhanced metabolism of 
tacrolimus in CYP3A5 expressors.[7] These results were similar to Zheng et 
al showing higher dosing requirements for CYP3A5 expressers compared 
to CYP3A5 non-expressers at 3, 6 and 12 months post-transplantation.[6] 
CYP3A4 is the major metabolizing enzyme of the CYP450 superfamily.[8]
Up to 100-fold inter-individual variation in activity has been reported in 
the general population.[9][10][11][12] While numerous genetic polymorphisms 
have been described for CYP3A4, the frequency of these variants is very 
low (usually <1%), except for CYP3A4*1B.  For this latter allele, however,
the clinical effect is not very clear and has in fact been suggested to 
occur due to linkage to the CYP3A5*1 allele.[101] Therefore, to date a genetic
explanation for the observed large variability in CYP3A4 activity is not 
readily available. Recently, a new single nucleotide polymorphism (SNP) 
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in intron 6 (rs35599367; 15389C>T; CYP3A4*22) was described showing 
decreased CYP3A4 mRNA hepatic expression and a lower microsomal 
CYP3A4 enzymatic activity for the T-variant allele.[13]
The effect of this newly described CYP3A4 polymorphism, and the 
combined information of CYP3A4 and CYP3A5 genotypes on tacrolimus 
dosing requirements and on trough blood concentrations in stable 
adult renal transplant recipients has recently been described.[14] Carriers
of the CYP3A4*22 allele showed significantly higher dose-adjusted 
tacrolimus trough concentrations (179.4 [111.2-289.4] ng/ml per mg/kg/day) 
compared to CYP3A4*1/*1 patients (88.9 [72.3-109.3] ng/ml per mg/kg/
day; p = 0.017). These results were more pronounced when the CYP3A4*22 
and CYP3A5*3 genotypes were combined, based on expected overall 
CYP3A activity: the predicted CYP3A poor metabolizers had significantly 
higher dose-adjusted trough concentrations (179.4 [111.2-289.4] ng/ml 
per mg/kg) compared to intermediate (110.1 [89.7-135.1] ng/ml per mg/
kg/day) and extensive metabolizers (43.9 [31.7-60.8] ng/ml per mg/kg/
day; p < 0.001).[14] In a second study, the same group reported in 185 de 
novo renal transplant recipients that the mean tacrolimus dose require-
ment when considering the first year post-transplantation was 33% 
lower for CYP3A4*22 variant allele carriers compared to CYP3A4*1/*1 
patients. Moreover, on day 3 post-transplantation the risk of presenting a 
supra-therapeutic tacrolimus trough concentration was significantly 
higher for poor (OR: 8.3 CI95% 1.3-57.0; p = 0.027) and intermediate CYP3A 
metabolizers (OR: 4.7 CI95% 1.9-13.4; p = 0.002) compared to extensive 
CYP3A metabolizers.[15]
 
These results suggest a significant role for the newly described CYP3A4 
SNP in adult renal transplant recipients. Therefore, we aimed to determine 
the relationship of this newly described CYP3A4 SNP and the combined 
CYP3A genotypes classification with tacrolimus disposition in the first 14 
days post-transplantation in pediatric heart transplant recipients. 
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Methods
Pediatric heart transplant recipients transplanted between 1995 and 2008 
at the Hospital for Sick Children, Toronto, Ontario, were eligible for this 
study if 1) the age at time of transplantation was younger than 21 years 
and 2) they had received oral tacrolimus during the first 14 days after 
transplantation. DNA samples were derived from the cohort of patients 
prospectively enrolled in the Sickkids Heart Centre Biobank. Informed 
consent was obtained from parents and/or children during enrollment. 
The study was approved by the Institutional Research Ethics Board. 
The gender, age, weight of the patient, the co-medication received 
and CYP3A4, and CYP3A5 genotypes, occurrence of rejection and renal 
function were recorded in the first two weeks post-transplantation. 
Rejection was graded according to the International Society of Heart and 
Lung Transplantation’s (ISHLT) grading system.[16] Rejection was defined 
as grade 2R or higher. Renal function was estimated with the Schwartz 
formula, using the last available serum creatinine concentration during 
the study period.[17]
Immunosuppressive protocol
All patients received induction therapy consisting of anti-thymocyte 
globulin peri-operatively and up to 2 to 5 days after transplantation. 
Tacrolimus (tablets) was started at 0.2 mg/kg/day orally on day 2 or 3 
post-transplantation. Therapeutic drug monitoring was used to adjust 
the tacrolimus dose to achieve a 12-hour post-dose trough concentration 
of 10-12 ng/ml. Additional immunosuppressive therapy consisted of a 
maintenance dose of mycophenolate mofetil (600 mg/m2 twice daily)
and a tapering steroid schedule. Tacrolimus dose (mg/kg/day) and 
tacrolimus trough concentrations were recalled from patient health 
records. Dose-adjusted tacrolimus concentrations were calculated by 
dividing the tacrolimus trough concentration by the weight-adjusted 
daily dose. 
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Tacrolimus trough concentrations
Tacrolimus blood trough concentrations were determined in ethylenedi-
aminetetraacetic acid (EDTA)-treated whole blood (0.25 ml) on the day 
of sampling, using liquid chromatography tandem mass spectrometry 
(LC-MS-MS) as previously described, as part of routine clinical care.[18]
Genotyping
Blood for genotyping was collected in EDTA-containing tubes, and 
DNA was extracted using a Magna-Pure LC (Roche Diagnostics GmbH, 
Mannheim, Germany). Genotyping for CYP3A4*22 and CYP3A5*3 were 
performed as described previously.[14],[19],[20] 
Patients were classified as a poor CYP3A metabolizer if they were a 
CYP3A5 non-expresser and carried at least one CYP3A4*22 allele, an inter-
mediate CYP3A metabolizer was defined as either CYP3A5 non-expresser 
carrying the CYP3A4*1/*1 genotype or CYP3A5 expressers carrying at least 
one CYP3A4*22 allele and extensive metabolizers as CYP3A5 expressers 
carrying the CYP3A4*1/*1 genotype, as previously described (Table 1).[14]
Statistical analysis
Data are presented as mean ± standard deviation or median and 
inter-quartile range (IQR) when the data were skewed. The groups were 
compared using the Mann-Whitney test (two-tailed) or the Kruskal-
Wallis test. A mixed-model analysis was used to compare the tacrolimus 
daily dose requirement, pre-dose concentrations and the dose-adjusted 
concentrations between different genotype groups. The mixed-model 
analysis was based on the maximum likelihood ratio, with patient CYP3A4 
genotype or CYP3A4/5 phenotype status as the fixed factor and time 
following transplantation as the repeated measurement. A diagonal 
Table 1: Genotype profiles
CYP3A4*1/*22 OR CYP3A4*22/*22
(CYP3A4*1/*22, n=4)
CYP3A4*1/*1
(n=56)
CYP3A5 non-expressers
(CYP3A5*3/*3, n=49)
Poor metabolizers 
(n= 4, 6.7%)
Intermediate metabolizers (n=45, 75%)
CYP3A5-expressers
(CYP3A5*1/*1, n=2, CYP3A5*1/*3, n=9)
Intermediate metabolizers 
(n=0, 0%)
Extensive metabolizers (n=11, 18.3%)
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Table 1: Genotype profiles
covariance structure, which assumes heterogenous variances and zero 
correlation between elements, was imposed when considering between 
and within times of follow-up of the repeated tacrolimus measurements. 
Age, sex and ethnicity of the patients were introduced as random effects 
to adjust for these covariates. Percentage differences in geometric mean 
values of untransformed outcomes were determined by back-transform-
ing coefficients estimated from mixed-model. A multivariate analysis was 
conducted to test the influence of age and genotypes on all dependent 
variables. The Hardy-Weinberg equilibrium was calculated by using the 
method of Rodriguez et al.[21] All data analyses were performed using 
Predictive Analytics Software (PASW) software, version 17.0 for Windows 
(IL, USA).
 
Results
This study is part of a larger pharmacokinetic-pharmacodynamic study; 
detailed information on the study participants can be found in a previous 
publication.[7] Sixty patients were included in the study with a median age 
of 4.0 (IQR: 12.0) years at the time of transplantation. Thirty-nine patients 
were Caucasian, 4 African-American, 3 Asians, 1 Native Canadian and for 
13 patients ethnicity was unknown (Table 2). 
DNA for CYP3A4*22 and CYP3A5*3 genotype information was available 
for all 60 patients (Table 1). The observed distribution of genotypes did 
not deviate from the Hardy-Weinberg Equilibrium (CYP3A4: χ2 = 0.07, p > 
0.05; CYP3A5: χ2 = 3.00, p > 0.05). No linkage disequilibrium was observed 
between CYP3A4*22 and CYP3A5*3 (χ2 = 0.62, p = 0.618). No significant 
differences were found between both CYP3A4 genotype groups concerning
the patients’ age (p = 0.185) and gender (p = 0.875) (Table 2). 
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Patient characteristics All patients CYP3A4*1/*1 CYP3A4*1/*22 p-value
Number 60 56 4 -
Gender (M/F) 33/27 31/25 2/2 0.875
Age (years) 4.00 (12.00) 3.00 (12.00) 8.50 (9.00) 0.185
Weight (kg) 13.30 (30.00) 12.60 (28.80) 14.15 (33.58) 0.898
Diagnosis
Dilated cardiomyopathy
Congenital heart disease
Unknown
34
26
1
31
24
1
2
2
-
0.898
Ethnicity
Caucasian
African-American
Asian
Native
Unknown
39
4
3
1
13
36
4
3
1
12
3
-
-
-
1
0.808
eGFR ml/min/1.73m2 128.70 (83.30) 128.70 (82.10) 154.85 (150.50) 0.611
Table 2: Patient demographics
All data are presented as median and interquartile range (IQR) 
CYP3A4*22 and tacrolimus disposition 
In a mixed model analysis, CYP3A4*22 allele carriers needed 30% 
lower tacrolimus doses to reach target concentrations (p = 0.016) than 
CYP3A4*1/*1 carriers when considering all follow-up time points. 
No significant difference in tacrolimus concentrations (p = 0.953) and the 
dose-adjusted concentration (p = 0.211) between CYP3A4*22 carriers and 
non-carriers was observed.
Neither tacrolimus trough concentrations nor concentration/dose ratios 
per day were significantly different between CYP3A4*1/*1 and CYP3A4*22 
allele carriers (p > 0.05, Table 3). Only on day 3 a significant association
in tacrolimus dose requirements was found between CYP3A4*1/*1 
(0.10 [IQR: 0.11] mg/kg/day) and CYP3A4*1/*22 carriers (0.02 [sd = 0.00]; 
p = 0.002).  
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Time Tac dose (mg/kg/day) Tac level (ng/ml) Concentration/Dose ratio
CYP3A4*1/*1 
carriers
CYP3A4*1/*22 
carriers
p-value CYP3A4*1/*1 
carriers
CYP3A4*1/*22 
carriers
p-value CYP3A4*1/*1 
carriers
CYP3A4*1/*22 
carriers
p-value
Day 2 0.10 (0.11) - - 3.30 (3.70) - - 81.07 (65.46) - -
Day 3 0.10 (0.11) 0.02 (0)† 0.002 6.10 (8.10) 14.40# 0.357 46.06 (75.12) 720.00# 0.074
Day 4 0.12 (0.08) 0.10 (0.11)* 0.230 10.00 (7.30) 8.15 (0.78)† 0.468 84.75 (83.42) 255.50 
(359.00)†
0.317
Day 5 0.10 (0.10) 0.10 (0.18)* 0.641 11.80 (8.45) - - 91.42 
(104.11)
- -
Day 6 0.10 (0.09) 0.09 (0.14)* 0.775 10.90 (6.20) 8.85 (7.71)† 0.852 77.86 (81.21) 64.08 
(14.83)†
0.619
Day 7 0.10 (0.08) 0.09 (0.11) 0.512 9.50 (7.60) - - 52.50 (58.71) - -
Day 8 0.10 (0.10) 0.09 (0.10) 0.457 9.40 (6.40) 8.55 (4.30) 0.852 85.83 
(108.06)
94.63 (78.56) 0.640
Day 9 0.10 (0.09) 0.10 (0.09) 0.501 9.50 (7.75) 5.60# 0.462 86.36 (94.95) 140.00# 0.462
Day 10 0.12 (0.12) 0.10 (0.09) 0.447 8.90 (5.50) 9.90# 0.800 78.57 (75.00) 99.00# 0.800
Day 11 0.14 (0.11) 0.10 (0.09) 0.265 8.60 (4.10) 8.60# 1.000 61.43 (71.67) 53.75# 0.929
Day 12 0.14 (0.10) 0.10 (0.11) 0.228 9.35 (3.35) - - 55.00 (33.74) - -
Day 13 0.14 (0.12) 0.10 (0.12) 0.240 10.30 (5.10) 11.40 (7.49)† 0.686 85.83 (92.99) 118.00 
(48.79)†
0.467
Day 14 0.15 (0.13) 0.10 (1.10)* 0.635 9.05 (5.43) 11.80 (16.90)* .412 67.50 (76.26) 96.50 
(30.41)†
0.442
Me-
dian 
Day 
4-14 
0.12 (0.10) 0.09 (0.10) 0.228 10.11 (3.27) 9.76 (4.59) 1.000 87.52 (75.10) 118.71 
(86.77)
0.380
Table 3: Relationship of CYP3A4 genotypes with tacrolimus disposition
# Only one sample available
† Only two sample available; mean and standard deviation are given instead
* Only three samples available; median and range given instead
Combined genotypes and tacrolimus disposition
In the mixed model, poor CYP3A metabolizers (CYP3A4*1/*22 and 
CYP3A5 non-expresser) required 17% less tacrolimus than intermediate 
(CYP3A4*1/*1 and CYP3A5 non-expresser, p =0.023) and 48% less than 
extensive CYP3A metabolizers (CYP3A4*1/*1 and CYP3A5-expresser, 
p <0.0001), respectively, (Figure 1). 
In addition, poor metabolizers showed 18% higher, albeit non-significant 
(p =0.35), dose-adjusted trough concentrations than intermediate 
metabolizers and 193% higher dose-adjusted concentrations (p <0.0001) 
than extensive metabolizers, respectively (Figure 2). No significant 
differences were found in tacrolimus trough concentrations between the 
combined CYP3A genotypes (p = 0.832 and p = 0.200). 
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Figure 1: Combined CYP3A4/5 genotypes and tacrolimus dosing requirements
Tacrolimus dose requirements (mg/kg) from day 4 till 14 according to 
CYP3A activity. Individual values are reported.
Figure 2: Combined CYP3A4/5 genotypes and tacrolimus concentration/dose ratio
Tacrolimus concentration/dose ratio (ng/ml per mg/kg) from day 4 
till 14 according to CYP3A activity. Individual values are reported. 
CYP3A4 *22 and CYP3A combined genotypes and tacrolimus disposition | 99 Ch
ap
te
r 5
Starting from day 6, poor CYP3A metabolizers developed significantly 
lower median dosing requirements (Day 6: 0.09 [range: 0.14] mg/kg/
day) compared to intermediate CYP3A metabolizers (0.10 [IQR: 0.06] 
mg/kg/day) and extensive CYP3A metabolizers (0.20 [IQR: 0.08] mg/
kg/day; p = 0.006). The dosing requirements for all patients gradually 
increased throughout the first two weeks post-transplant. At day 14, poor 
CYP3A metabolizers needed 0.10 mg/kg/day (range: 0.10) compared to 
intermediate CYP3A metabolizers who needed 0.12 (IQR: 0.12) and 
extensive metabolizers, who needed 0.24 (IQR: 0.16) mg/kg/day (p = 
0.003) (Table 4). Both age and the combined CYP3A genotype were inde-
pendently associated with tacrolimus dose requirements considering the 
follow-up period from day 4 till 14 (R2 = 0.346, p < 0.0001; Fage = 8.59 page = 
0.005; Fcluster = 22.78 pcluster < 0.0001) and the dose-adjusted concentrations 
day 4 till 14 (R2 = 0.273, p < 0.0001; Fage = 11.80 page = 0.001; Fcluster = 10.84 
pcluster = 0.002). 
Clinical outcome
Three patients experienced early graft rejection in the first 14 days 
post-transplantation. All patients experiencing rejection carried the 
CYP3A4*1/*1 genotype. One patient was considered an extensive 
CYP3A metabolizer and the 2 others intermediate CYP3A metabolizers. 
No significant difference was found between the combined CYP3A 
genotypes and the occurrence of rejection (χ2 = 0.627, p = 0.73). 
The median estimated glomerular filtration rate (eGFR) at the last availa-
ble serum creatinine concentration was 128.7 (IQR: 83.3) ml/min/1.73m2). 
eGFR at the last available serum creatinine concentration was not differ-
ent between CYP3A4*1/*1 homozygotes (128.7 [IQR: 82.1] ml/min/1.73m2) 
and CYP3A4*22 allele carriers (154.9 [IQR: 150.5] ml/min/1.73m2; p = 0.6). 
Similarly, no significant difference in eGFR was found between poor CYP3A 
metabolizers (154.9 [IQR: 150.5] ml/min/1.73m2), intermediate CYP3A 
metabolizers (125.2 [IQR: 79.2] ml/min/1.73m2) and extensive CYP3A 
metabolizers (130.1 [IQR: 78.0] ml/min/1.73m2, p = 0.44).
One patient had received fluconazole and two patients amiodarone, 
which are both CYP3A inhibitors. When these patients were excluded 
from the analysis, none of the results changed. 
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Discussion 
In our study, we showed that this novel CYP3A4*22 SNP is associated 
with changed tacrolimus dose requirement in pediatric heart transplant 
patients in the first 14 days after transplantation. This study is the first to 
show a relationship of this SNP in (pediatric) heart transplant recipients.
Patients carrying at least one CYP3A4*22 allele needed 30% lower 
tacrolimus doses compared to CYP3A4*1 carriers. Neither tacrolimus 
concentrations nor concentration/dose ratios differed between these two 
groups. This potential discrepancy may be explained as daily tacrolimus 
doses were available while concentrations (and consequently concentra-
tion/dose ratios) were not, as concentrations were not measured every 
day during the study period. This may have reduced the power in the 
mixed-model analyses for these two parameters.
In addition, CYP3A combined genotypes were strongly related with 
tacrolimus disposition in this population. Poor CYP3A metabolizers 
required almost 20% less tacrolimus than intermediate and approximately 
50% less than extensive metabolizers, throughout the follow-up period 
post-transplantation. 
The significant difference between poor and intermediate metabolizers in 
dosing requirements can only be contributed to the CYP3A4 genotype, as 
the only difference between poor CYP3A metabolizers and intermediate 
metabolizers in our study group is the CYP3A4 genotype.
In addition, poor metabolizers had similar dose-adjusted trough 
concentrations as intermediate metabolizers, but significantly higher 
dose-adjusted concentrations than extensive metabolizers. The difference 
between poor and extensive metabolizers in dose requirements and 
dose-adjusted concentrations is likely a combined CYP3A5 and CYP3A4 
effect. 
From day 6 onwards, weight-normalized tacrolimus dosing requirements 
for extensive CYP3A metabolizers were the highest followed by 
intermediate CYP3A metabolizers and poor CYP3A metabolizers. The lack 
of significant differences in dosing requirement on day 2 and 3 between 
genotype groups could be explained by the fact that tacrolimus dosing is 
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usually adjusted based on tacrolimus concentrations starting from day 4 
post-transplantation onwards and patients receive starting dosing in the 
first two days post-transplantation. 
Our results are similar to what has previously been reported in adult renal 
transplant recipients, where patients carrying at least one CYP3A4*22 
allele had also 33% lower mean tacrolimus dose requirement considering 
the first year post-transplantation compared to CYP3A4*1 homozygotes.[15]
The association between CYP3A4*22 and tacrolimus trough concentra-
tions instead of dose requirement is, however, in our study less clear. 
We were not able to find such an association, which is similar to the study 
by Elens et al.[14] in 49 de novo adult renal transplant recipients. However, in 
their second study, an association at day 3 post-transplantation was found, 
showing higher tacrolimus trough concentrations for carriers of at least 
one CYP3A4*22 allele (20.5 [15.2-27.7] ng/ml) compared to CYP3A4*1/*1 
homozygotes (14.9 [13.8-16.0] ng/ml, p = 0.05). However, this signifi-
cant difference disappeared from day 10 post-transplantation onwards.15 
In contrast to our results, Elens et al. were not able to find a significant 
difference in the dose-adjusted tacrolimus trough concentration between 
the two CYP3A4 genotype groups.[14],[15] Due to the limited amount of 
tacrolimus trough concentrations, the dose-adjusted tacrolimus trough 
concentrations are limited in number as well. This could explain why 
we have not been able to show an association between dose-adjusted 
tacrolimus trough concentrations and CYP3A4 genotype. 
As genotype does not change with age, it is conceivable that findings 
in adults would also be extrapolated to children, although this is not 
necessarily the case. Nonetheless, as the ontogeny of CYP3A enzymes 
is still a factor in children,[22],[23],[24] genotype might not match with the 
phenotype present at the age of the child as it does in adults. 
We have shown that age and CYP3A5 genotype appear to results in an 
additive effect on tacrolimus dosing. As CYP3A5 genotype on average 
explains a two-fold variation in tacrolimus requirements, this variation 
becomes 4-fold when age is also taken into account. Younger CYP3A5-
expressers needed 4 times higher tacrolimus doses than older CYP3A5 
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non-expressers.[7] This finding highlights the importance to study 
pharmacogenetics in children in the context of development. 
As the first weeks after transplantation are characterized by an increased 
risk of early organ rejection,[2],[3] the importance of identifying key predictors
becomes clinically valuable. As all three of our patient experiencing 
rejection where homozygous for CYP3A4*1, no analysis was done to test 
the possible influence of CYP3A4 genotype on this outcome. We failed to 
show a possible relationship of the combined CYP3A genotypes and the 
occurrence of graft rejection. 
As renal dysfunction is one of the major adverse events related to 
tacrolimus therapy, we a tested the relation between renal function as 
assessed by creatinine clearance, and the CYP3A genotypes classification.
We could not find an association between the combined CYP3A 
genotypes and renal function defined by an eGFR of the last available 
serum creatinine concentration. Nevertheless, the time window of 14 
days post-transplantation might be too short to accurately determine the 
relationship between genetic variability and renal function measured by 
serum creatinine. A decrease of about 50% of renal function is needed for 
serum creatinine concentrations to show changes.[25] Furthermore, serum 
creatinine concentration might not accurately reflect renal function until 
steady state concentrations of serum creatinine has been attained.[25]
This study has several limitations. The sample size is relatively small and 
only four carriers of the CYP3A4*22 allele (also labelled as poor metabo-
lizers) could be detected. Moreover, we did not have tacrolimus trough 
concentrations for every patient for every day. Due to the retrospective 
nature of this research we could not collect additional samples to enlarge 
our data set. The results per day have to be taken with caution as multiple 
testing was done with a limited sample size. Yet, it does provide a good 
overview of the tacrolimus disposition throughout the study period. 
Although the sample size was small, statistically significant relationships 
between the CYP3A4*22 allele as well as between the combined CYP3A 
genotype classification and tacrolimus dose requirement were observed, 
suggesting a marked effect size. The use of dose-adjusted tacrolimus 
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concentrations to determine possible associations is but one way to 
determine the genetic influence on tacrolimus disposition. Unfortunately, 
area-under-the-curves or other pharmacokinetic parameters were not 
available for our cohort. Secondly, correcting our results for co-medication 
and altered hemodynamics could not be conducted, as our sample size 
was not large enough and would have increased the risk of spurious 
associations. Thirdly, the use of serum creatinine and the Schwartz formula 
for the estimation of renal function has its limits of its own. The Schwartz 
formula may provide falsely increased GFR values in patients experiencing 
chronic renal failure. Therefore, other methods for the assessment of 
renal function, such as neutrophil gelatinase-associated lipocalin (NGAL) 
and Cystatin C, which demonstrate promising results, may be used in the 
future to determine the association between genetic variability and 
drug-induced renal function.[26] 
Conclusion
Despite the small sample size, our study shows an impact of the CYP3A4*22 
allele, as well as from the combined CYP3A4 and CYP3A5 genotypes on 
tacrolimus disposition in pediatric heart transplant recipients. To the best 
of our knowledge, this is the first study in heart transplant patients, and 
more specifically in children, that evaluates the association between the 
novel CYP3A4*22 allele and tacrolimus disposition. However, our findings 
should be interpreted with caution as data on CYP3A4*22 allele carriers 
were limited. Nonetheless, our findings are in line with previous reports in 
adults, suggesting pre-transplantation screening of patients for both the 
CYP3A4*22 and CYP3A5*3 polymorphism could potentially optimize tac-
rolimus therapy. By optimizing the individual therapy, we may minimize 
the risk for over- or under-dosing with the potential for preventing toxic-
ity or organ rejection, although these results first need to be replicated in 
a larger, prospective study. 
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Executive summary
Introduction
• CYP3A5 genotype has been associated with tacrolimus disposition in 
 pediatric heart transplant patients
• Recently, a new polymorphism in CYP3A4 (CYP3A4*22) has been 
 associated with altered tacrolimus disposition in adult renal transplant 
 recipients
Results
• In the first 14 days post-transplantation CYP3A4*22 carriers needed less 
 tacrolimus compared to CYP3A4*1 homozygotes 
• Poor metabolizers of the combined CYP3A4 and CYP3A5 genotypes 
 had lower tacrolimus dosing requirements and higher dose-adjusted 
 tacrolimus trough concentrations. 
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Abstract
Background In a recent study, POR*28 was associated with increased 
dosing requirements early after transplant in adult CYP3A5-express-
ing kidney transplant recipients. Both age and CYP3A5 genotype are 
important determinants of tacrolimus disposition in pediatric kidney 
transplant recipients. The authors aimed to evaluate the additional 
contribution of POR*28 to tacrolimus disposition in the first 14 days 
post-transplantation in pediatric kidney transplant recipients.
Method The authors studied data on tacrolimus dose and tacrolimus 
pre-dose serum concentrations in 43 pediatric kidney transplant 
recipients up to 14 days post-transplant. Recipient POR*28 and CYP3A5 
genotype were determined.
Results CYP3A5-expressers carrying at least one POR*28 allele had on 
average 18.3% lower tacrolimus pre-dose concentrations and 20.2% lower 
concentration/dose ratios compared to CYP3A5-expressers with POR*1/*1 
genotype (p = 0.002 and p = 0.001, respectively). No significant difference 
was found within the CYP3A5 non-expressers between POR genotype and 
tacrolimus disposition. 
Conclusion In this small cohort of pediatric kidney transplant 
recipients, POR*28 genotype seems to explain part of the variability 
found in tacrolimus disposition, in addition to age and CYP3A5 genotype. 
These results merit further study in a larger population to validate our 
findings and to evaluate the clinical impact of this genotype.
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Introduction
Tacrolimus is a calcineurin inhibitor (CNI) with a narrow therapeutic 
window necessitating rigorous therapeutic drug monitoring. 
However, significant variability in tacrolimus pre-dose concentrations 
still remains an important clinical challenge.1 While part of this variation 
can be explained by genetic variability in the drug metabolizing enzyme 
CYP3A5,2,3 genetic polymorphisms in genes involved in the regulation of 
CYP3A4/5 enzymes have been explored.  
P450 oxidoreductase (POR) is the protein that enables the activity of 
cytochrome P450 (CYP) enzymes by transferring electrons from NADPH 
to microsomal CYP enzymes.4 To date, 41 haplotypes in the POR 
gene have been published by the Human Cytochrome P450 Allele 
Nomenclature Committee (http://www.cypalleles.ki.se/por.htm). 
Interestingly, the POR*28 (rs1057868) SNP has been associated with 
isoform-specific effects on CYP activity. It was associated with 85% of 
wild-type in vitro activity of CYP1A2 but 113% activity of CYP2C19.5 
In vivo, the POR*28 variant was found in 19.1% of the African-Americans, 
26.4% of the Caucasians, 36.7% of the Chinese Americans and 31.0% 
of the Mexican Americans. This variant showed 56-67% of wild-type 
activity in the cytochrome c assays and 58-68% of wild-type activity in the 
P450c17 assays.6
Furthermore, homozygous carriers of the SNP (POR*28) T variant showed 
an increased in vivo CYP3A activity compared to CC carriers demonstrated 
by a 1.6-fold increase in the midazolam metabolic ratio in an adult cohort 
including heroin-dependent individuals treated with methadone as well 
as psychiatric patients receiving clozapine treatment.7  
Recently, in 298 adults of whom 52 CYP3A5-expressing renal transplant 
recipients, POR*28T (also referred to as POR*28) allele carriers had lower 
tacrolimus pre-dose concentrations in the first days post-transplantation 
and reached the target levels much later compared to POR*28CC (also 
referred to as POR*1/*1) carriers. Additionally, in the first year post-
transplantation POR*28T allele carriers had significantly higher tacrolimus 
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dosing requirements compared to POR*28CC homozygous patients. 
In CYP3A5 non-expressers the pharmacokinetics of tacrolimus was not 
different between POR*1 and POR*28 carriers.8
Previously, we have shown that dosing requirements of pediatric kidney 
transplant recipients are not only associated with CYP3A5 genotype, but 
also with age.9 Dosing requirements of CYP3A5-expressers younger than 
6 years of age were approximately four times higher than those in CYP3A5 
non-expressers older than 6 years. These results emphasize the need to 
consider maturation before extrapolating adult pharmacogenetic results 
to children.10,11,12
The objective of the present study was to determine the potential effect 
of the POR*28 genetic polymorphism on tacrolimus disposition in the first 
14 days post-transplantation in our previously studied cohort of pediatric 
kidney transplant recipients.
 
Methods
This was a retrospective cohort study in pediatric renal transplant 
recipients covering the first 14 days post-transplantation. Pediatric 
kidney transplant recipients transplanted between 2000 and 2008 were 
eligible if they were < 18 years of age at the time of transplantation and 
received tacrolimus in the first 14 days post-transplantation. All children 
were transplanted at the Hospital for Sick Children, Toronto, Ontario, 
 Canada. This was the same cohort in which we have previously shown the 
relationship between age and CYP3A5 genotype in tacrolimus disposition.9
Immunosuppressive protocol
Tacrolimus was started at 0.1 mg/kg twice daily orally. Therapeutic drug 
monitoring was used to adjust the tacrolimus dose to achieve a target 
level of 10-15 ng/ml. Additional immunosuppressive therapy consisted of 
a maintenance doses of mycophenolate mofetil and steroids. At the time 
of graft reperfusion, methylprednisolone (10 mg/kg) was administered 
intravenously and gradually tapered in the weeks after transplantation. 
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Outcome data
We collected data on tacrolimus dose and tacrolimus pre-dose levels 
in pediatric kidney transplant recipients up to 14 days post-transplant. 
Concentration/dose ratios (C/D, ng/ml per mg/kg/day) were calculated 
using tacrolimus pre-dose concentrations (ng/ml) divided by the 
tacrolimus dosing requirements (mg/kg/day), as a surrogate marker for 
tacrolimus clearance. Delayed graft function was defined as the need for 
dialysis treatment within the first week post-transplantation.13
Co-variates
The following patient characteristics were collected from SickKids 
electronic patient databases: transplant type, age at transplant, gender, 
and weight.
Tacrolimus pre-dose concentrations
Tacrolimus blood pre-dose concentrations were determined in 
ethylenediaminetetraacetic acid (EDTA)-treated whole blood (0.25 ml) on 
the day of sampling, using liquid chromatography-mass spectrometry.14 
Genotyping
For DNA analysis, blood for DNA (0.5 ml) was collected during regular 
blood work at the Transplant Outpatient Clinic. In cases where DNA 
collection from blood was not possible, saliva was collected using 
the Oragene TM DNA elf-collection kit following the manufacturer’s 
instructions (DNA Genotek, Kanata, ON). Blood and saliva were stored at 
-80°C until analysis. DNA was extracted using a Manga-Pure LC (Roche 
Diagnostics GmbH, Mannheim, Germany). Polymerase chain reactions 
(PCR)-restriction fragment length polymorphism for CYP3A5*3 were 
performed as described previously.15,16 Patients not carrying the CYP3A5*3 
allele were assigned the CYP3A5*1/1 genotype by default. POR*28 
(rs1057868) genotype determination was done on an ABI PRISM 7500® 
Fast real-time PCR Systems (Applied Biosystems, CA, USA) using 20 ng 
genomic DNA, according to the manufacturer instructions. The assay was 
validated by direct sequencing of wild type and variant samples. 
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Statistical analysis
Data are presented as mean ± standard deviation or median and 
interquartile range (IQR) when the data were skewed. The groups were 
compared using the Mann-Whitney test or the Kruskal-Wallis test. 
A mixed-model analysis was used to compare the tacrolimus dosing 
requirements, tacrolimus pre-dose concentrations and the concen-
tration/dose ratio between the different POR genotype groups. Data 
were analysed separately for CYP3A5 expressors and non-expressors. 
As patient age was not statistically different between POR genotype 
groups, age was not added to the model as co-variate. The mixed-model 
analysis was based on the maximum likelihood ratio, with patient POR 
genotype as the fixed factor and time following transplantation as the 
repeated measurement. A diagonal covariance structure, which assumes 
heterogenous variances and zero correlation between elements, was 
imposed when considering between and within times of follow-up 
of the repeated tacrolimus measurements. Percentage differences in 
geometric mean values of untransformed outcomes were determined 
by back-transforming coefficients estimated from the mixed-model. 
The Hardy-Weinberg equilibrium was calculated by using the method 
from Rodriguez et al.17 All data analyses were performed using Predictive 
Analytics Software (PASW) software, version 17.0 for Windows (IL, USA). 
 
Results
Study population
A total of 43 renal transplant patients (28 male, 15 female) with a median 
age of 140.7 (IQR: 88.3) months and weight of 34.2 (IQR: 29.3) kilograms 
were included (Table 1). Two of the patients received thymoglobulin 
during the first 14 days post-transplantation. No differences were found 
between the CYP3A5-expresser group and the CYP3A5 non-expresser
group in demographic variables. Sixteen patients were CYP3A5-
expressers and 27 CYP3A5-nonexpressers.
Within the CYP3A5-expressers group, 9 patients were homozygous 
for the POR*1 allele, 4 patients were POR*1/*28 carriers and 3 patients 
homozygous for POR*28. No difference in age was found between the 
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Table 1: demographics of the patients
CYP3A5 expressers CYP3A5 non-expressers P-value
POR*1/*1
(n=9)
POR*28
(n=7)
POR*1/*1
(n=15)
POR*28
(n=12)
Age at transplant (months) 132.57 (83.46) 136.53 (155.47) 171.19 (95.80) 132.19 (101.98) 0.851
Gender (M/F) 5/4 7/0 10/5 6/6 0.127
ICU weight (kg) 29.40 (23.13) 33.20 (41.90) 42.70 (24.50) 29.75 (39.13) 0.775
POR genotype groups. Fifteen patients within the CYP3A5-nonexpresser 
group were POR*1/*1 carriers, 7 POR*1/*28 carriers and 5 POR*28/*28 
carriers. For this group also, no difference in age was found between 
the POR genotype groups. Overall allele frequencies were CYP3A5*1 
allele: 20.5% and *3 allele: 79.5%; POR*1 allele: 69.3% and *28 allele: 30.7%, 
which are similar to what has previously been reported in Caucasian 
subjects.6,7,16, The observed distribution of genotypes did not deviate from 
the Hardy-Weinberg equilibrium (χ2 = 2.91, p = 0.088).
Genotype and tacrolimus pre-dose concentrations
In the mixed model, CYP3A5-expressers carrying at least one POR*28 
allele had on average 18.3% lower tacrolimus pre-dose concentrations 
compared to CYP3A5-expressers with the POR*1/*1 genotype (p = 0.002). 
Within the CYP3A5 non-expressers, no significant difference in tacrolimus 
Figure 1: tacrolimus levels during the first two weeks post- transplantation
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pre-dose concentrations between the POR genotype groups was found 
(p = 0.763)
When analyzed per day, POR*28 allele carriers in the CYP3A5-expressor 
groups had significantly lower tacrolimus pre-dose concentrations 
on day 6 (4.50 [IQR: 2.50] ng/ml versus 8.50 [IQR: 2.65] ng/ml, p=0.005) 
post-transplantation compared to POR*1/*1 carriers, but not on any other 
day. 
Within the CYP3A5 non-expressors, POR*28 allele carriers had significantly 
higher tacrolimus pre-dose concentrations on day 10 (13.90 [IQR: 3.90] 
ng/ml versus 10.00 [IQR: 4.25] ng/ml, p=0.025) and day 11 (12.00 [IQR: 
4.35] ng/ml versus 8.80 [IQR: 3.30] ng/ml, p=0.030) post-transplantation 
compared to POR*1/*1 carriers (Table 2). 
Genotype and tacrolimus concentration/dose ratio
In the mixed model, POR*28 allele carriers within the CYP3A5-expressers 
had on average 20.3% lower concentration/dose ratios compared to the 
POR*1/*1 genotype carriers (p = 0.001). 
Figure 2: Concentration Dose ratio during the first two weeks post-transplantation
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In contrast, no significant difference between the POR genotypes within 
the CYP3A5 non-expressers was observed (p = 0.055). 
When analyzed per day, on day 6 CYP3A5-expressers carrying the POR*28 
allele had a significantly higher concentration/dose ratio compared to 
CYP3A5-expressers homozygous for POR*1 (20.74 [IQR: 10.38] ng/ml per 
mg/kg/day per versus 29.36 [IQR: 11.37] ng/ml mg/kg/day, P=0.005). 
No significant differences were found in the CYP3A5 non-expresser group 
between POR*1/*1 carriers and POR*28 allele carriers (Table 3). 
Figure 3: Tacrolimus dosing requirements during the first two weeks post-transplantation
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Tacrolimus dosing requirements
In the mixed model no significant differences were found in the 
tacrolimus dosing requirements between the POR genotype groups 
within the CYP3A5-expressers (p = 0.16) or within the CYP3A5 non-
expressers (p = 0.25). 
The daily tacrolimus dosing requirements (mg/kg) within the first two 
weeks after transplantation are shown in Table 4. In the CYP3A5-express-
ers group a significant difference was found only on day 2 (0.15 [IQR: 
0.08] mg/kg versus 0.22 [IQR: 0.05] mg/kg, p=0.003) post-transplantation 
between POR*28 allele carriers and POR*1/*1 carriers (Table 4). 
Outcome
None of our patients experienced delayed graft function and therefore 
a possible relationship with POR*28 could not be tested. No significant 
difference was found in the last available serum creatinine (SCr) levels 
from the second week post-transplantation between CYP3A5-expressers 
(54.00 [IQR: 45.75] umol/L) and CYP3A5 non-expressers (80.00 [IQR: 50.00] 
umol/L, p=0.33). Similarly, no significant difference in the last available 
SCr level from the second week post-transplantation was found within 
the CYP3A5-expresser group between at least one POR*28 allele carriers
(44.00 [IQR: 66.00] umol/L) and POR*1/*1 carriers (59.00 [IQR: 21.50] 
umol/L, p=1.00) or within the CYP3A5 non-expresser group between 
POR*28 allele carriers (59.00 [IQR: 53.00] umol/L) and POR*1 homozygotes 
(82.00 [IQR: 45.00] umol/L, p=0.42). 
Discussion
To our knowledge, this is the first study in children exploring the 
possible association between POR*28 and tacrolimus disposition. We were 
able to show that CYP3A5-expressers carrying at least one POR*28 allele 
had 18.3% lower tacrolimus pre-dose concentrations and 20.2% lower 
concentration/dose ratios compared to CYP3A5-expressers carrying
POR*1/*1 in the first 14 days post-transplantation using mixed-model
analysis. This is similar to what was found in adult de novo renal 
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transplant recipients showing lower tacrolimus pre-dose concentrations 
in the first few days post-transplantation for CYP3A5-expressers carrying 
the POR*28 allele.8 
We were not able to find a significant association between POR geno-
type and tacrolimus dosing requirements. This is different from the 
study by de Jonge et al. where CYP3A5-expressers carrying at least one 
POR*28 allele had significantly higher dosing requirements than CYP3A5-
expressers homozygous for POR*1.8 Even though the tacrolimus pre-dose 
concentrations and concentration/dose ratios were significantly lower in 
our CYP3A5-expressers carrying at least one POR*28 allele, the tacrolimus 
dosing requirements did not differ. A possible explanation could be that 
the tacrolimus pre-dose concentrations were still within the therapeutic 
window for most of the patients and therefore the tacrolimus doses were 
probably not adjusted. 
The interplay of POR with CYP expression is not completely understood. 
The relationship with the POR*28 genotype and CYP expression seems 
to be isoform-specific. The activity of specific POR mutants assayed 
by one P450 enzyme cannot be extrapolated to other P450 enzymes. 
This is due to the alterations in the conformation of the POR/P450 contact 
sites, caused by POR missense mutations, impairing the activity to 
different degrees, depending on the electron recipients used in the assay.5,6 
In vitro data show a decrease in CYP3A4 activity by using testosterone 
and midazolam as a substrate (61-77% lower wild-type activity), but no 
difference in activity when erythromycin and quinidine were used as a 
substrate (97% and 89% of wild-type activity).18 The activity differed 
slightly between these CYP3A substrates used, suggesting that the ability 
of the POR*28 sequence variant to affect the catalytic activity of CYP3A4/5 
varied with the substrate used.18,19 
In vivo, in 251 adults treated with either methadone or clozapine, the 
POR*28 variant has been associated with increased CYP3A activity. 
The metabolic ratio of midazolam (1-OH-Midazolam/midazolam), as 
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surrogate marker of combined in vivo CYP3A4/5 activity, was 1.6-fold 
higher in POR*28 homozygotes compared to POR*1 allele carriers in 
both patient groups.7 The reason why in vitro data show a decrease 
in CYP3A4/5 activity and in vivo data an increase in CYP3A4/5 is not 
completely known. A possible reason could be that patients in the study 
done by Oneda et al.7 the patients also received other medications 
that could possibly induce CYP3A4/5 activity, resulting in difficulties 
comparing the data.
Despite the conflicting in vitro and in vivo data investigating the 
relationship of POR with individual CYP3A isoforms, our data and those 
from de Jonge suggest that this relationship is more prominent with 
CYP3A5 than with CYP3A4, as the in vivo relationship with POR and 
tacrolimus disposition was only found in the CYP3A5 expressers.8 
This suggests a relationship between POR and CYP3A5, which may be 
different than for CYP3A4. 
Although, age was not significantly different between our patient 
groups and we therefore did not correct for it in our analyses, it is a very 
important factor. The effects of CYP3A5 genotype on tacrolimus 
disposition have been reported in both adults and children.2,9,20 
As genotype does not change with age, it is conceivable that 
findings in adults would also be replicated in children. Nonetheless, as the 
ontogeny of CYP3A enzymes is still a factor in children,11,21,22 genotype 
might not match with the phenotype present at the age of the child being 
researched. Therefore, studies need to be done in children to elucidate 
the effect of age during childhood. 
As acute nephrotoxicity is an important concentration-dependent 
adverse event of tacrolimus, genetic differences in its disposition and/
or metabolite formation may explain inter-individual variation in renal 
function.23 We were not able to find a significant association between 
POR genotype and the last available serum creatinine levels in CYP3A5-
expressers and CYP3A5 non-expressers in the first 14 days post-trans-
plantation. We were not able to test the relationship with rejection 
as none of our patients experience rejection during the study period. 
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To our knowledge, this is the first study reporting on the possible associa-
tion between POR*28 genotype and the clinical outcome of the patient. 
However, our sample size is small and therefore these results need to be 
interpreted with caution. Nonetheless, the association between CYP3A5 
genotype and kidney function has been studied before. Yet, the results 
are conflicting showing an increased risk for both CYP3A5-expressers and 
CYP3A5 non-expressers, demonstrating the need for studies with bigger 
sample sizes and kidney function as the primary objective.24 
Our study has several limitations. First, a major limitation is that the 
sample size of our study is fairly small. This may explain why we only 
found a relationship between POR genotype and tacrolimus disposition
using a mixed model, but not when data were analyzed by post- 
transplantation day. Nonetheless, we were able to replicate results similar 
to the adult study by de Jonge et al., even when correcting for CYP3A5 
genotype and age.8 In addition, due to the retrospective design of the 
study, unexplained variation in dosing requirements and C/D may have 
been introduced by inaccuracies in the reporting of tacrolimus dosing, 
which are frequent in daily clinical care (e.g. mode of administration oral 
versus gastric tube, missed doses, repeated doses after vomiting).
Conclusion
In pediatric kidney transplant recipients, POR*28 genotype explains part 
of the variability in tacrolimus disposition, in addition to age and CYP3A5 
genotype. These results merit further study in a larger population to 
validate our findings and to evaluate the clinical impact of this genotype.
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Abstract
Background Post-transplant renal function decline is a major 
complication in pediatric renal transplant recipients. Potential genetic 
risk factors have recently been identified in adults. We determined the 
incidence as well as genetic risk factors of renal function decline after 
pediatric renal transplantation.
Methods In this multi-center retrospective cohort study, clinical data 
from the day of transplantation up to 10 years post-transplantation 
were analyzed. In multivariate analysis, the impact of genetic variation 
(77 SNPs) on renal function was studied using eGFR and age- and 
gender-normalized eGFR (z-scores). 
Results Data of 199 renal transplant recipients were analyzed. 
Their median age was 13.0 (IQR: 7.0) years; the median follow-up was 
0.72 years (range: 7 days–10 years). Chronic kidney disease (CKD, from 
3 months post-transplantation onwards) stages 3-5 developed in 81 
patients (40.7%): stage 3 in 55 (26.7 %); stage 4 in 17 (8.5%) and stage 5 
in 9 (4.5%). None of the genetic polymorphisms studied was significantly 
associated with renal function. 
Conclusion Renal function decline post-renal transplantation occurred 
in 40% of our pediatric renal transplant recipient cohort. Other than adult 
studies, this study failed to show a relationship of CYP3A5*3 or other 
variant alleles  tested with renal function. 
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Introduction
In kidney transplant recipients, more effective immunosuppressive 
therapy in the form of the calcineurin inhibitors tacrolimus and 
cyclosporine has greatly reduced the incidence of acute graft rejection.1 
Nonetheless, renal allograft long-term survival has barely changed in 
last few decades.2 Renal function decline can ultimately necessitate 
re-transplantation and it is associated with a higher risk of prema-
ture death if persisting for at least three months post-transplantation.3 
Studies in adult renal transplant recipients have reported stage 2 chronic 
kidney disease (CKD) in 19%-46% of the patients for; stage 3 in 48%-61%; 
and stage 4 in 1%-19%.4,5,6 Similar pediatric studies are scarce. One study 
in 23 pediatric kidney recipients reported CKD stage 2 in 35% and stage 
3 in 43% of children at 3.4 ± 2.8 years post-transplantation.7 Two other 
studies reported CKD stages 3-5 in 62% of 45, and stages 3-4 in 66% of 
129 pediatric renal transplant recipients, respectively, at least one year 
post-transplantation. 8,9 
The reported causes for CKD following renal transplantation are largely 
similar between children and adults, and include ischemia-reperfusion 
injury, acute rejection, chronic allograft nephropathy and recurrent 
renal disease.10,11 Additionally, urinary tract infections or obstruction 
damaging the graft, chronic CNI use, hypertension, diabetes mellitus and 
hepatitis C may increase the risk for CKD post-renal transplantation.11,12,13 
However, children more often than adults require renal transplantation 
for reason of congenital dysplasia, obstructive uropathy and focal 
segmental glomerulosclerosis.11,14 
Apart from clinical risk factors, several SNPs have been studied in relation 
to renal function decline post-transplantation in adults.15 Findings
regarding CYP3A5 genotype in relation to the risk of tacrolimus-induced 
nephrotoxicity were inconsistent.16,17,18,19,20 Possible explanations are the 
use of different biopsy outcome measures to define tacrolimus-induced 
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nephrotoxicity and the relatively small patient cohorts in some studies.
Data from pediatric studies are also inconclusive so far. In 50 de novo 
pediatric renal transplant recipients on tacrolimus, a non-significant trend 
towards higher creatinin clearance was found in patients carrying at least 
one CYP3A5*1 allele compared to those with the CYP3A5*3/*3 genotype.21
Pediatric kidney recipients with at least one ACE D allele showed a 
significantly steeper decline in GFR compared with homozygous carriers 
of the ACE I allele.22 Others have confirmed this association,11,23 but could 
not find associations of AGT Met235 Thr and AT1R A1166C polymor-
phisms with renal function decline in pediatric kidney recipients.11 
In 207 pediatric kidney recipients, the presence of the CCR5 wt/∆32 
genotype was associated with significantly better graft function at 1 year 
post-transplant (GFR 115.10 ± 28.40 versus 86.43 ± 29.96 ml/min/1.73m2; 
p=0.022).24 
Most of these studies, however, concerned patients receiving cyclosporine 
or a mixed population of tacrolimus and cyclosporine treated patients, 
which leaves unresolved the true contribution of tacrolimus to renal 
failure following pediatric kidney transplantation. 
Similarly, CKD prevalence following pediatric kidney transplantation has 
mainly been established in mixed populations. The calcineurin-inhibitors 
cyclosporine and tacrolimus are both associated with renal dysfunction, 
however, the responsible molecular mechanisms seem to differ between 
the two drugs, suggesting different mechanisms of toxicity.25,26,27,28,29,30 
We therefore performed a study to determine the prevalence of CKD 
following kidney transplantation in children treated with tacrolimus. 
In addition, we studied possible associations between genetic variation 
of the recipient and renal function. 
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Methods
This is a retrospective cohort study of pediatric renal transplant recipients 
transplanted between January 1994 (date of introduction of tacrolimus 
in pediatric protocols) and 2011 at the Hospital for Sick Children, 
Toronto, Ontario or at Erasmus MC Sophia Children’s Hospital, Rotterdam, 
the Netherlands. Patients were eligible for this study if 1) the age at time 
of transplantation was younger than 18 years; 2) they had received oral 
tacrolimus after their transplantation. Informed consent was obtained 
from parents and/or children during enrolment at both institutions. 
The study was approved by the Institutional Research Ethics Board of the 
Hospital for Sick Children. In Rotterdam, a waiver for REB approval was 
obtained, as only retrospective data and left over blood or saliva were 
used. 
Data collection
Clinical data were obtained through electronic patient records and paper 
chart review. Data were collected from the day of transplantation, at 1 
week, 1, 3, 6, 9 and 12 months and yearly thereafter until December 2009 
or until data was available. 
Endpoints
The primary end-point of this study was the cumulative incidence of 
chronic kidney disease following pediatric kidney transplantation by 
using the estimated glomerular filtration rate (eGFR), calculated according 
to the Schwartz formula.31 Patients were next categorized for the severity
of CKD according to the National Kidney Foundation Kidney Disease 
Outcome Quality Initiative (KDOQI) guidelines for chronic kidney 
disease.32 Our secondary endpoints were absolute eGFRs and z-scores of 
eGFR to correct for age-related changes in eGFR. To calculate the z-scores, 
reference values for the mean and standard deviation from a healthy, 
mainly Caucasian, pediatric population were used.33
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Other clinical data
Data were collected regarding patients’ characteristics, tacrolimus 
concentrations, hematology and chemistry lab, concomitant medications, 
primary diagnosis, transplant information and the patient’s outcome. 
Concomitant medication information was collected for: cyclosporine, 
gentamicin, cotrimoxazole, tobramycin, amphotericin B, valganciclovir, 
ganciclovir, spironolactone and vancomycin for their known influence on 
kidney function. If a patient received more than one renal transplant, the 
first transplantation was used in the analysis. 
Immunosuppressive protocol 
Tacrolimus was started according to the immunosuppression protocol 
from the Hospital for Sick Children or the Erasmus MC Sophia Children’s 
Hospital. In both hospitals tacrolimus was started on day 1 post- 
transplantation. Tacrolimus starting dose was 0.2-0.3 mg/kg/day divided 
in two doses. Therapeutic drug monitoring was used to adjust the 
tacrolimus dose to achieve a target level of 10-15 ng/ml in the first weeks post- 
transplantation, 6-10 ng/ml from 6 weeks post-transplantation and 4-8 ng/
ml after three months post-transplantation. Additional immunosuppres-
sive therapy consisted of a maintenance dose of mycophenolate mofetil 
(600-1000mg twice daily) and a tapering steroids schedule.
Tacrolimus trough concentrations
Tacrolimus blood trough concentrations were determined in ethylenedi-
aminetetraacetic acid (EDTA)-treated whole blood (0.25 ml) on the day 
of sampling, using liquid chromatography tandem mass spectrometry 
(LC-MS-MS) as previously described, as part of routine clinical care at 
the Hospital for Sick Children.34,35 In Rotterdam, tacrolimus whole blood 
trough concentrations were determined ethylenediaminetetraacetic acid 
(EDTA)-treated whole blood (0.50 ml) on the day of sampling, using high 
performance liquid chromatography-tandem mass spectrometry (HPLC-
MS/MS) as previously described, as part of routine care.36,37,38,39 
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Genotyping
Blood or saliva samples were collected from patients at the first visit 
after informed consent was received or, in Toronto only, by access to 
DNA samples from either the Hospital for Sick Children’s Biobank or the 
University Health Network HLA laboratory. Blood samples were collected 
in EDTA-containing tubes. Saliva samples were collected by using 
Oragene DNA OG-250 collection kits (DNA genotek, Ottawa, Ontario, 
Canada). Samples from both hospitals were stored at -80°C before 
purification of DNA using the QiaSymphony system (Qiagen, USA). 
Ninety-six SNPs were selected based on previous published associa-
tions, SNPs related to tacrolimus pharmacokinetic pathways and SNPs 
associated with renal failure (Supplemental table 1). DNA samples were 
genotyped for this custom set of 96 variants selected using BeadXpress 
genotyping platform using the manufacturer’s protocol (Illumina, CA, 
USA) at the University of British Colombia, Vancouver, BC, Canada.40
Statistical analysis
Descriptive data are presented as mean ± standard deviation or median 
(IQR) for continuous variables and as percentage for categorical variables. 
CKD stage was designated as an eGFR below the cut-off values according 
to KDOQI CKD stages on two consecutive visits from 3 months post-
transplantation onwards. Kaplan-Meier curves were plotted for the time 
course of CKD incidence. Follow-up visits were cyclosporine was used 
or tacrolimus was discontinued, temporarily or permanently, were not 
included in the analysis. 
The Hardy-Weinberg equilibrium was tested for each polymorphism 
using the method by Guo et al.41 Previously published and found to be 
significant genetic associations with eGFR were tested at a significance 
level of 0.05. All other genetic associations were tested at a significance 
threshold of 8.7 x10-4 determined using a Bonferroni correction based 
on the effective number of independent tests (Meff).
42 A univariate 
general linear mixed model was performed for the following covariates: 
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gender, age at time of transplantation, investigation site, tacrolimus levels, 
concomitant medication, year of transplantation, deceased donor, 
albumin and CRP levels, hematocrit, conversion from cyclosporin and 
the patient’s weight and height. Covariates with a p-value < 0.05 were 
considered for retention in the regression model. A mixed model for the 
continuous endpoints was used for the genetic additive effect of each 
SNP by adjusting for the covariates retained in the stepwise selection. 
All statistical analysis for the genetic variables were done using SAS 9.3. 
All other statistical analyses, including figures were done using SPSS 
version 20.0 (IBM SPSS Statistics, Armonk, NY, USA).
Results
Patient population
Informed consent was received for 199 of the 205 eligible children and 
their clinical data were analyzed. There was a male predominance (58.8%) 
and median age at time of transplantation was 13.0 years (IQR: 7.0) 
(Table 1). The median follow-up was 0.72 years (range: 7 days – 10 years). 
The most prevalent pre-transplant diagnosis was renal dysplasia, (n=45; 
22.6%) (Table 1). Ten patients (5.0%) underwent a secondary transplan-
tation and one patient (0.5%) a third. Seven patients (3.5%) received 
dialysis post-transplantation, one of whom after both the first and second 
transplantation. Graft failure at any moment during the entire study 
period had been documented for 27 patients (13.6%); acute rejection 
post-transplantation for 63 (31.7%). Converted from cyclosporin to 
tacrolimus had been documented for 48 (24.0%) children. One patient 
(0.5%) had passed away (Table 1). DNA was available for 102 children 
(51.3%). 
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Renal failure following renal transplantation
Figure 1A and 1B depict the eGFR values and eGFR z-scores during the 
study period. The median eGFR at one year post-transplantation was 96.3 
(IQR: 42.0) ml/min/1.73m2 and the median eGFR z-score -1.4 (IQR: 2.0) 
(Table 1). The prevalence of each KDOQI CKD stage at various time 
points is presented in Figure 2. The cumulative incidence of CKD stage 
3-5 was 40% (81/199) (Figure 3A). The majority of these 81 patients 
developed CKD stage 3 (55/199; 27.6%). Seventeen patients (17/199; 8.5%) 
developed CKD stage 4 and 9 patients (9/199; 4.5%) developed CKD 
stage 5 (Figure 3B). At one year post-transplantation, 7 renal transplant 
recipients (7/104; 6.7%) had moderate renal failure (Stage 3) and 2 
patients (2/104; 1.9%) CKD stage 4. At 5 years post-transplantation, 
2 patients (2/31; 6.5%) experienced CKD stage 3, 1 patient (1/31; 3.2%) 
CKD stage 4 and 2 patients CKD stage 5 (2/31; 6.5%) (Figure 2). 
Figure 1A and 1B: eGFR over time and eGFR z-scores over time
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Table 1: Demographics of the kidney population
Variable Kidney (all) Kidney (DNA)
Number 199 102
Age at time of transplant (years)
Mean ± SD
Median (IQR)
11.9 ± 5.2
13.0 (7.0)
11 ± 5.7
11.0 (8.0)
Year of transplant
Mean ± SD
Median (IQR)
Range
2004.9 ± 3.3
2005 (6)
1994-2011
2005.8 ± 3.5
2007 (4)
1994-2011
Follow-up time (years)
Mean ± SD
Median (IQR)
1.54 ± 2.11
0.72 (1.93)
1.86 ± 2.38
0.75 (2.75)
Gender (M/F) M: 117 (58.8%)
F: 82 (41.2%)
M: 59 (57.8%)
F: 43 (42.2%)
Weight (kg)
Mean ± SD
Median (IQR)  
35.7 ± 17.3
34.3 (28)
31.9 ± 18.6
25.5 (26.9)
Height (cm) 
Mean ± SD
Median (IQR) 
142.8 ± 27.2
151 (35)
138.5 ± 26.9
145.7 (42.8)
Transplant (n,%)  
1st
2nd
3rd
188 (94.5%)
10 (5%)
1 (0.5%)
95 (93.1%)
6 (5.9%)
1 (1%)
Need for dialysis before transplant (n,%) 44 (22.1%) 32 (31.4%)
Acute rejection (n,%) 63 (31.7%) 26 (25.5%)
eGFR at 1 year post-transplantation
Mean ± SD
Median (IQR)
99.62 ± 32.25
96.30 (42.0)
104.31 ± 32.77
96.33 (36.27)
eGFR z-score at 1 year post-transplantation
Mean ± SD
Median (IQR) -1.25 ± 1.33
-1.35 (2.0)
-1.05 ± 1.38
-1.36 (1.54)
Converted from CsA (n,%) 48 (24.1%) 34 (33.3%)
Mortality rate (n,%) 1 (0.5%) 1 (1.0%)
Donor age 
Mean ± SD
Median (IQR) 
32.4 ± 10.3
37.0 (10.0)
30.5 ± 12.8
31.5 (18.5)
Donor gender (M/F) M:35,
F:42
M:14,
F:18
Deceased or living-related donor (n,%) Deceased: 44 (22.1%),
Living: 130 (65.3%)
Unknown: 25 (126%)
Deceased: 27 (26.5%),
Living: 48 (47.1%)
Unknown:27 (26.5%)
Cold ischemia time (min) 
Mean ± SD
Median (IQR)  
664.4 ± 554.9
685.5 (862.5)
675.3 ± 497.3
722.5 (765)
Warm ischemia time (min) 
Mean ± SD
Median (IQR)  
56.6 ± 121.9
32 (12.5)
70.3 ± 151.8
33.5 (12)
Investigation site (n,%)
Rotterdam 
Toronto 
49 (24.6%)
150 (75.4%)
41 (40.2%)
61 (59.8%)
Primary diagnosis
Dysplasia 
Cystic kidneys 
Glomerular nefritis/FSGS 
Hemolytic-Uremic Syndrome (HUS)
Chronic renal failure 
Obstructive and reflux uropathy 
Other
45 (22.6%)
14 (7%)
3(6.5%)
6 (3%)
17 (8.5%)
36 (18.1%)
68 (34.2%)
26 (25.5%)
9 (8.8%)
4(3.9%)
2 (2%)
6 (5.9%)
13 (12.7%)
42 (41.2%)
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Figure 2: Prevalence of CKD at each time point
Risk factors of renal failure
Four SNPs in 4 genes were not in Hardy-Weinberg equilibrium; IL10 
-1082G>A (rs1800896), TLR1 239G>C (rs5743611), SLCO1B1 521T>C 
(rs4149056) and APOL1 G1 (rs73885319) (Supplementary Table 2). 
More detailed information can be found in the supplementary material.
In the univariate analysis the year of transplantation, albumin levels, 
conversion from cyclosporine and body weight were associated with 
renal function (Table 2). In addition to these covariates, sex, age at time 
of transplantation, the investigation site and the tacrolimus levels were 
also added as covariates for their potential confounding relationship with 
renal function. 
One SNP was significantly associated at the significance level of p<0.05 
with eGFR in the genetic model; VKORC1 1173C>T. Homozygote carriers
VKORC1 1173TT had lower eGFR values compared to heterozygotes and 
wild type carriers (Table 3). Nonetheless, none of the polymorphism 
reached the set significance level of 8.7 x 10-4 (Supplementary Table 3). 
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Figure 3: Kaplan-Meier curves of the cumulative incidence of CKD in 199 pediatric kidney transplant recipients
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Table 2: Univariate analysis of covariates
Variable N P-value
Gender 459 0.56
Age at time of transplantaiton 459 0.11
Investigation site 459 0.45
Tacrolimus levels 459 0.98
Concomitant medication 459 0.11
Year of transplantation 459 0.01
Deceased donor 190 0.89
Albumin levels 369 0.03
Hematocrite levels 356 0.46
CRP levels 22 0.19
Converted to CsA 459 0.04
Weight 89 0.03
Height 406 0.11
Table 3: Genetic associations renal transplant recipients
Positions based on Genome Build Version 37.1.
* Significance threshold = 0.05
Chr Position Gene SNP Genotype counts N obs N obs
Estimate
SE P-value of
additive
genetic
effect*
Minor 
homozygous
Heterozygous Major 
Homozygous
7 81700000 ABCB1 
-1236
rs1128503 24 51 27 369 4.58 4.49 0.31
7 81701000 ABCB1 
-2677
rs2032582 24 48 30 369 1.51 4.45 0.74
7 81702000 ABCB1 
-3435
rs1045642 18 56 28 369 -0.78 4.65 0.87
7 99270539 CYP3A5 rs776746 3 30 69 369 3.76 5.83 0.52
16 31104878 VKORC1* rs9934438 16 50 36 369 10.26 4.61 0.03
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Discussion
Post-transplant renal function decline is a major complication in pediatric 
renal transplant recipients. In this study, the cumulative incidence of CKD 
stages 3-5 was 40.7%, with 17 patients (8.5%) experiencing CKD stage 4 
and 9 patients (4.5%) CKD stage 5. These incidences are lower than those 
reported in other pediatric studies using eGFR; i.e. 43-66%.7,9 Previous 
studies used the last available follow-up, yet due to the small sample sizes 
the follow-up range was very wide. Therefore the time of onset of CKD 
post-transplantation is uncertain. The mixed population of cyclosporin 
and tacrolimus-treated pediatric kidney transplant recipients in one of 
the studies may also explain the higher prevalence.7
To our knowledge, we are the first to report kidney function and 
prevalence of CKD over time in addition to a cross-sectional design at one 
or five years post-transplantation. Kidney function, based on eGFR, slightly 
decreased in the first year post-transplantation and then stabilized. 
Four of 123 patients (3.3%) experienced CKD stage 3 at three months 
post-transplantation; 11 of 76 (14.5%) at 3 years post-transplantation 
(Figure 2). Prevalences of CKD stages 4 and 5 increased from three 
years post-transplantation and onwards an increase in the can be seen. 
This suggests that although the eGFR of the overall cohort seems stable, 
several patients experienced renal problems early on and then developed 
more serious renal failure. 
The true prevalence of CKD may be higher as the use of eGFR underes-
timates the GFR measured by inulin clearance.6 This is partially due to 
the serum creatinine assays used or to reduced muscle mass in some 
children.43 One of the previous studies used mGFR, determined by 99Tc 
DTPA, and found that 62% of 51 patients experienced CKD stages 3-5 at 
least one year post-transplantation. However, the sample size was small 
and patients also received cyclosporin.8 Unfortunately, mGFRs were not 
routinely done during our study period and could therefore not be used 
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in our analysis. Measuring serum cystatin C concentrations is a promising 
new method to establish CKD. It better reflects developmental changes in 
children44 and formulas incorporating cystatin C predict GFR better than 
does the Schwartz formula.45 Measuring serum cystatin C levels is there-
fore recommended in the new Kidney Disease Improving Global Outcome 
(KDIGO) guidelines.46
We also looked at genetic variation, but could not identify any SNP 
predictive of a decline in renal function. One SNP, VKORC1 1173C>T, was 
significant at the 5% level but failed to reach the set significance threshold. 
In contrast to previous studies in adults and/or children, we did not find 
significant associations of CYP3A4, CYP3A5, ABCB1, CCR5 genotypes with 
renal function.15 Nevertheless, more recent studies, too, failed to show an 
association of CYP3A5 genotype with graft outcome15,17,20,24,47,48 
One study in 61 pediatric renal transplant recipients failed to show 
associations of CYP3A5 and ABCB1 genotypes with renal function decline 
as well as 8 other polymorphisms involved in inflammatory pathways.24 
One explanation for these discrepant results on the effect of genetic 
variation in renal function post kidney transplant may be the use of 
biopsy data versus renal function as markers of tacrolimus-induced renal 
function decline. 
Several limitations of this study should be addressed. In spite of the large 
sample size the number of SNPs limits the power of the genetic model. 
Furthermore, the candidate gene approach limited the chances of 
identifying genetic risk factors. In Genome Wide Association Studies 
hits may become apparent in genes we did not consider in our study. 
Moreover, we were unable to include donor DNA in the analysis. 
Inclusion of donor DNA might have had additive value as the donor 
kidney is an important contributor to renal function. A recent study 
showed that donor genotype determined tacrolimus metabolite 
disposition in the kidney, which may be of importance as tacrolimus 
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metabolites have been suggested to be involved in the pathogenesis of 
tacrolimus-related renal dysfunction.49
The use of kidney biopsies could have aided in differentiating between 
several causes of renal failure post-transplantation. Yet, mGFRs and 
kidney biopsies were not routinely done during the study period. 
Additionally, the retrospective nature of our study results in a dependency 
on the information available in the medical charts and the impossibility to 
complete the dataset
 
Conclusion
The fact that renal failure occurred in many pediatric renal transplant 
recipients points at the necessity of close monitoring. In contrast to 
previous reports, we did not find a significant association between the 
recipient’s genetic variation and renal function. Further research could 
focus on the early detection of patients at risk for renal failure, e.g. 
with newer biomarkers such as NGAL or cystatin C. Moreover, closer 
monitoring of renal function with routinely measured GFRs or routine 
kidney biopsies may help optimize treatment. 
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Supplementary Table 1: All SNPs analyzed
Chr Position Gene SNP
1 60392494 C1orf87/CYP2J2 rs890293
1 162030688 OLFML2B/NOS1AP rs10918594
1 184911126 PTGS2 rs4648279
1 186643541 PTGS2 rs3218625
1 186643836 PTGS2 rs5272
1 186643837 PTGS2 rs5273
1 186650751 PTGS2/PLA2G4A rs689466
1 186646004 PTGS2 rs3218622
1 206946407 IL19/IL10 rs1800872
1 206946634 IL19/IL10 rs1800871
1 206946897 IL19/IL10 rs1800896
1 223285200 TLR5 rs5744168
2 228052600 COL4A3 rs2204862
2 234669144 UGT1A1 rs4148323
2 241542703 CAPN10 rs5030952
3 52261031 TWF2/TLR9 rs187084
3 119500035 NR1I2 rs3814055
3 119533733 NR1I2 rs6785049
3 119534153 NR1I2 rs2276707
3 119537254 NR1I2 rs3814057
3 121838319 CD86 rs1129055
4 38799710 TLR1 rs4833095
4 38800214 TLR1 rs5743611
4 38830350 TLR6 rs5743810
4 89052323 ABCG2 rs2231142
4 123377980 IL21/IL2 rs2069762
4 154626317 TLR2 rs5743708
4 187004074 TLR3 rs3775291
6 31241109 HLA-C rs13191343
6 31543031 TNF/LTA rs1800629
6 32809848 PSMB8 rs9357155
6 32811629 PSMB8 rs2071543
6 43736389 MRPS18A/VEGFA rs699947
6 43737830 VEGF rs1570360
6 90032942 UBE2J1/GABRR2 rs2064831
7 22766645 IL6/LOC541472 rs1800795
7 75615006 POR rs1057868
7 81700000 ABCB1 rs1128503
7 81701000 ABCB1 rs2032582
7 81702000 ABCB1 rs1045642
7 87133470 ABCB1 rs17064
7 87230193 ABCB1 rs3213619
Chr Position Gene SNP
7 99102509 CYP3A5 rs55965422
7 99194259 CYP3A4 rs17161886
7 99245013 ZNF498/CYP3A5 rs4646458
7 99245080 ZNF498/CYP3A5 rs4646457
7 99245914 CYP3A5 rs15524
7 99247772 CYP3A5 rs41279854
7 99250393 CYP3A5 rs41303343
7 99258139 CYP3A5 rs28383479
7 99262835 CYP3A5 rs10264272
7 99270539 CYP3A5 rs776746
7 99273821 CYP3A5 rs55817950
7 99325882 CYP3A7 rs2687136
7 99354114 CYP3A4/CYP3A7 rs12333983
7 99356324 CYP3A4 rs17161886
7 99358524 CYP3A4 rs4986910
7 99360870 CYP3A4 rs4646440
7 99365451 CYP3A4 rs2687117
7 99365983 CYP3A4 rs55785340
7 99366316 CYP3A4 rs35599367
7 99382096 CYP3A4/CYP3A43 rs2740574
7 99388017 CYP3A4/CYP3A43 rs2687102
8 139746208 COL22A1 rs4588898
9 120475302 TLR4 rs4986790
9 120475602 TLR4 rs4986791
9 125133507 PTGS1 rs3842787
9 125140241 PTGS1 rs3842789
9 125143707 PTGS1 rs3842792
9 125143973 PTGS1 rs5789
9 125148791 PTGS1 rs5791
9 125152507 PTGS1 rs5792
9 125152579 PTGS1 rs5793
10 90749963 FAS/ACTA2 rs1800682
10 96798749 CYP2C8 rs10509681
10 96818119 CYP2C8 rs1058930
10 101542578 ABCC2 rs717620
10 101611294 ABCC2 rs8187710
11 2857194 KCNQ1 rs2237895
11 2870108 KCNQ1 rs8234
11 17460712 ABCC8 rs2237982
11 112034988 TEX12/IL18 rs187238
11 112035458 IL18/TEX12 rs1946518
12 21329738 SLCO1B1 rs2306283
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Chr Position Gene SNP
12 21331549 SLCO1B1 rs4149056
12 68552522 IFNG rs2430561
12 79481371 SYT1 rs12300068
16 31104878 VKORC1 rs9934438
17 32579788 ACCN1/CCL2 rs1024611
19 41858921 TGF-beta rs1800470
21 28240574 ADAMTS5/AD-
AMTS1
rs229109
22 35775889 HO-1 rs3761439
22 35776672 HMOX1/TOM1 rs2071746
22 36661906 APOL1 rs73885319
22 36662046 APOL1 rs71785313
22 36751101 MYH9 rs11089788
22 36774812 MYH9 rs5756168
A total of 19 SNPs had to be removed from the analysis; 
16 SNPs had a allele frequency of 0, two SNPs had more 
than 5% missing genotypes and one SNP completely 
failed. A total of 77 SNPs were included in the analysis.
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Chr Position Gene SNP Minor 
allele
Major 
allele
MAF 
frequency
H-W
 p-value
H-W
Exact 
p-value
1 60392494 C1orf87/CYP2J2 rs890293 C A 0.082802548 0.422814461 1
1 162030688 OLFML2B/NOS1AP rs10918594 G C 0.385350318 0.9276378 1
1 186643541 PTGS2 rs3218625 G A 0.001592357
1 186650751 PTGS2/PLA2G4A rs689466 A G 0.178343949 0.812656135 1
1 206946407 IL19/IL10 rs1800872 C A 0.305111821 0.565836515 0.6167
1 206946634 IL19/IL10 rs1800871 G A 0.283333333 0.714570206 0.7858
1 206946897 IL19/IL10 rs1800896 A G 0.396496815 0.042740917 0.048
1 223285200 TLR5 rs5744168 G A 0.046178344 0.108840512 0.2074
2 228052600 COL4A3 rs2204862 A G 0.097133758 0.847978072 1
2 234669144 UGT1A1 rs4148323 G A 0.009708738 0.960122881 1
2 241542703 CAPN10 rs5030952 G A 0.012738854 0.920348217 1
3 52261031 TWF2/TLR9 rs187084 A G 0.370607029 0.088927432 0.1149
3 119500035 NR1I2 rs3814055 G A 0.404458599 0.125716199 0.1506
3 119533733 NR1I2 rs6785049 A G 0.439490446 0.22287996 0.2282
3 119534153 NR1I2 rs2276707 G A 0.208598726 0.743580897 0.7811
3 119537254 NR1I2 rs3814057 A C 0.224522293 0.846002646 0.7832
3 121838319 CD86 rs1129055 G A 0.265923567 0.565836515 0.6064
4 38799710 TLR1 rs4833095 A G 0.356687898 0.269403832 0.2933
4 38800214 TLR1 rs5743611 G C 0.071656051 0.006629165 0.0271
4 38830350 TLR6 rs5743810 G A 0.294585987 0.393132894 0.4721
4 89052323 ABCG2 rs2231142 C A 0.106687898 0.491830156 1
4 123377980 IL21/IL2 rs2069762 A C 0.341853035 0.871239769 1
4 154626317 TLR2 rs5743708 G A 0.02388535 0.759569923 1
4 187004074 TLR3 rs3775291 G A 0.277070064 0.768342843 0.8019
6 31543031 TNF/LTA rs1800629 G A 0.157643312 0.7136281 0.7081
6 32809848 PSMB8 rs9357155 G A 0.117834395 0.486261877 0.6087
6 32811629 PSMB8 rs2071543 C A 0.133757962 0.666422804 0.6497
6 43736389 MRPS18A/VEGFA rs699947 C A 0.472929936 0.843021976 0.8446
6 90032942 UBE2J1/GABRR2 rs2064831 A G 0.173566879 0.552452905 0.7367
7 22766645 IL6/LOC541472 rs1800795 C G 0.305732484 0.664357678 0.6212
7 81700000 ABCB1 ABCB1-1236CT-
r1128503
G A 0.461783439 0.993023259 1
7 81701000 ABCB1 ABCB1-2677GT-
r2032582
C A 0.453674121 0.574740542 0.5576
7 81702000 ABCB1 ABCB1-3435CT-
r1045642
A G 0.498407643 0.27230394 0.3177
7 87133470 ABCB1 rs17064 A T 0.068471338 0.892577745 1
7 87230193 ABCB1 rs3213619 A G 0.039808917 0.247176386 0.2933
7 99245013 ZNF498/CYP3A5 rs4646458 A C 0.100638978 0.129791211 0.1362
7 99245080 ZNF498/CYP3A5 rs4646457 A C 0.159235669 0.812656135 1
Supplementary Table 2: Hardy-Weinberg equilibrium
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Chr Position Gene SNP Minor 
allele
Major 
allele
MAF 
frequency
H-W
 p-value
H-W
Exact 
p-value
7 99245914 CYP3A5 rs15524 A G 0.151273885 0.90429921 1
7 99262835 CYP3A5 rs10264272 G A 0.00477707 0.960320611 1
7 99270539 CYP3A5 rs776746 G A 0.153354633 0.90429921 1
7 99325882 CYP3A7 rs2687136 A G 0.165605096 0.780523249 0.7677
7 99354114 CYP3A4/CYP3A7 rs12333983 A T 0.178913738 0.24080289 0.2574
7 99356324 CYP3A4 rs17161886 A C 0.02388535 0.960320611 1
7 99358524 CYP3A4 rs4986910 A G 0.00477707 0.960320611 1
7 99360870 CYP3A4 rs4646440 G A 0.052547771 0.06007715 0.1065
7 99365451 CYP3A4 rs2687117 G A 0.01433121 0.880181702 1
7 99366316 CYP3A4 rs35599367 G A 0.042993631 0.759569923 1
7 99382096 CYP3A4/CYP3A43 rs2740574 A G 0.060509554 0.6026503 1
7 99388017 CYP3A4/CYP3A43 rs2687102 A G 0.012738854 0.920348217 1
8 139746208 COL22A1 rs4588898 G A 0.294585987 0.876051221 0.8085
9 120475302 TLR4 rs4986790 A G 0.076433121 0.609808154 0.4734
9 120475602 TLR4 rs4986791 G A 0.070063694 0.609808154 0.474
9 125133507 PTGS1 rs3842787 G A 0.046178344 0.527897302 1
9 125143707 PTGS1 rs3842792 A C 0.001592357
9 125143973 PTGS1 rs5789 C A 0.02388535 0.759569923 1
10 90749963 FAS/ACTA2 rs1800682 A G 0.48566879 0.846002646 0.8371
10 96798749 CYP2C8 rs10509681 A G 0.087579618 0.422814461 1
10 96818119 CYP2C8 rs1058930 C G 0.049363057 0.6026503 1
10 101542578 ABCC2 rs717620 G A 0.204472843 0.662753305 1
10 101611294 ABCC2 rs8187710 G A 0.071656051 0.25358574 0.2424
11 2857194 KCNQ1 rs2237895 A C 0.420382166 0.206260662 0.224
11 2870108 KCNQ1 rs8234 A G 0.357371795 0.093965944 0.1012
11 17460712 ABCC8 rs2237982 G A 0.406050955 0.385473444 0.4118
11 112034988 TEX12/IL18 rs187238 C G 0.246815287 0.732953406 1
11 112035458 IL18/TEX12 rs1946518 C A 0.396496815 0.121764525 0.1519
12 21329738 SLCO1B1 rs2306283 A G 0.447452229 0.388524151 0.4185
12 21331549 SLCO1B1 rs4149056 A G 0.136942675 0.027409285 0.0379
12 68552522 IFNG rs2430561 A T 0.440514469 0.714876182 0.6991
12 79481371 SYT1 rs12300068 G A 0.135350318 0.299621014 0.6081
16 31104878 VKORC1 rs9934438 G A 0.415335463 0.843145878 1
17 32579788 ACCN1/CCL2 rs1024611 A G 0.340764331 0.883629595 1
21 28240574 ADAMTS5/ADAMTS1 rs229109 G A 0.304140127 0.768768069 0.817
22 35776672 HMOX1/TOM1 rs2071746 T A 0.444089457 0.214387683 0.3229
22 36661906 APOL1 rs73885319 A G 0.01433121 2.34488E-11 0.0157
22 36662046 APOL1 rs71785313 A T 0.00477707
22 36751101 MYH9 rs11089788 C A 0.445859873 0.079535725 0.0783
22 36774812 MYH9 rs5756168 A G 0.114649682 0.624316933 1
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Table 3: Genetic associations renal transplant recipients
Chr Position Gene SNP Genotype counts N obs Estimate SE P-value of
additive
genetic
effect*
Minor 
homozygous
Heterozygous Major 
Homozygous
1 60392494 C1orf87/CYP2J2 rs890293 15 87 369 1.06 9.10 0.91
1 162030688 OLFML2B/NOS1AP rs10918594 14 47 41 369 -3.20 4.61 0.49
1 186643541 PTGS2 rs3218625 102 369 0.00
1 186650751 PTGS2/PLA2G4A rs689466 3 31 68 369 3.01 6.74 0.66
1 206946407 IL19/IL10 rs1800872 8 37 57 369 -2.21 5.11 0.67
1 206946634 IL19/IL10 rs1800871 7 36 56 357 -1.90 5.38 0.72
1 206946897 IL19/IL10 rs1800896 24 40 38 369 2.68 4.22 0.53
1 223285200 TLR5 rs5744168 1 8 93 369 0.39 9.27 0.97
2 228052600 COL4A3 rs2204862 1 20 81 369 8.85 7.28 0.23
2 234669144 UGT1A1 rs4148323 1 100 365 -6.56 28.40 0.82
2 241542703 CAPN10 rs5030952 2 100 369 -11.57 22.06 0.60
3 52261031 TWF2/TLR9 rs187084 16 38 47 367 4.02 4.52 0.38
3 119500035 NR1I2 rs3814055 12 56 34 369 -8.06 5.32 0.13
3 119533733 NR1I2 rs6785049 22 44 36 369 -2.19 4.38 0.62
3 119534153 NR1I2 rs2276707 6 35 61 369 -7.85 5.11 0.13
3 119537254 NR1I2 rs3814057 6 36 60 369 -8.06 5.09 0.12
3 121838319 CD86 rs1129055 8 37 57 369 -6.71 4.97 0.18
4 38799710 TLR1 rs4833095 16 42 44 369 2.95 4.48 0.51
4 38800214 TLR1 rs5743611 3 12 87 369 0.96 8.22 0.91
4 38830350 TLR6 rs5743810 10 38 54 369 -0.38 5.02 0.94
4 89052323 ABCG2 rs2231142 13 89 369 11.30 9.62 0.24
4 123377980 IL21/IL2 rs2069762 10 45 47 369 -0.63 5.18 0.90
4 154626317 TLR2 rs5743708 6 96 369 -1.70 13.68 0.90
4 187004074 TLR3 rs3775291 8 39 55 369 -0.66 5.23 0.90
6 31543031 TNF/LTA rs1800629 3 26 73 369 -4.13 6.01 0.49
6 32809848 PSMB8 rs9357155 2 19 81 369 1.39 6.74 0.84
6 32811629 PSMB8 rs2071543 2 21 79 369 -2.34 6.54 0.72
6 43736389 MRPS18A/VEGFA rs699947 26 50 26 369 7.54 4.47 0.10
6 90032942 UBE2J1/GABRR2 rs2064831 2 30 70 369 2.49 6.49 0.70
7 22766645 IL6/LOC541472 rs1800795 8 38 56 369 -5.66 4.88 0.25
7 81700000 ABCB1 ABCB1-
1236CT-
r1128503
24 51 27 369 4.58 4.49 0.31
7 81701000 ABCB1 ABCB1-
2677GT-
r2032582
24 48 30 369 1.51 4.45 0.74
7 81702000 ABCB1 ABCB1-
3435CT-
r1045642
18 56 28 369 -0.78 4.65 0.87
7 87133470 ABCB1 rs17064 1 17 84 369 -7.18 9.47 0.45
7 87230193 ABCB1 rs3213619 1 10 91 369 -15.73 9.14 0.09
7 99245013 ZNF498/CYP3A5 rs4646458 3 18 81 369 6.87 6.55 0.30
7 99245080 ZNF498/CYP3A5 rs4646457 3 31 68 369 2.47 5.80 0.67
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Chr Position Gene SNP Genotype counts N obs Estimate SE P-value of
additive
genetic
effect*
Minor 
homozygous
Heterozygous Major 
Homozygous
7 99245914 CYP3A5 rs15524 3 30 69 369 1.97 5.88 0.74
7 99262835 CYP3A5 rs10264272 1 101 369 0.00
7 99270539 CYP3A5 rs776746 3 30 69 369 3.76 5.83 0.52
7 99325882 CYP3A7 rs2687136 5 33 64 369 1.82 5.36 0.74
7 99354114 CYP3A4/CYP3A7 rs12333983 7 31 64 369 0.65 4.98 0.90
7 99356324 CYP3A4 rs17161886 1 101 369 -6.79 27.96 0.81
7 99358524 CYP3A4 rs4986910 1 101 369 7.22 29.08 0.80
7 99360870 CYP3A4 rs4646440 2 12 88 369 0.70 7.25 0.92
7 99365451 CYP3A4 rs2687117 3 99 369 -12.99 22.81 0.57
7 99366316 CYP3A4 rs35599367 6 96 369 5.51 15.76 0.73
7 99382096 CYP3A4/CYP3A43 rs2740574 10 92 369 7.01 10.92 0.52
7 99388017 CYP3A4/CYP3A43 rs2687102 2 100 369 0.00
8 139746208 COL22A1 rs4588898 8 40 54 369 0.94 5.26 0.86
9 120475302 TLR4 rs4986790 1 14 87 369 5.37 8.04 0.51
9 120475602 TLR4 rs4986791 1 14 87 369 4.15 7.92 0.60
9 125133507 PTGS1 rs3842787 12 90 369 14.37 9.46 0.13
9 125143707 PTGS1 rs3842792 102 369 0.00
9 125143973 PTGS1 rs5789 6 96 369 -23.94 15.44 0.13
10 90749963 FAS/ACTA2 rs1800682 27 50 25 369 -1.81 4.38 0.68
10 96798749 CYP2C8 rs10509681 15 87 369 4.87 9.69 0.62
10 96818119 CYP2C8 rs1058930 10 92 369 1.51 11.22 0.89
10 101542578 ABCC2 rs717620 4 36 62 369 -3.79 5.87 0.52
10 101611294 ABCC2 rs8187710 2 16 84 369 1.93 7.49 0.80
11 2857194 KCNQ1 rs2237895 23 44 35 369 1.48 4.35 0.73
11 2870108 KCNQ1 rs8234 13 36 53 369 4.48 4.72 0.35
11 17460712 ABCC8 rs2237982 19 45 38 369 -6.88 4.39 0.12
11 112034988 TEX12/IL18 rs187238 7 42 53 369 -7.99 5.56 0.15
11 112035458 IL18/TEX12 rs1946518 16 58 28 369 -4.84 4.99 0.33
12 21329738 SLCO1B1 rs2306283 22 46 34 369 -1.09 4.49 0.81
12 21331549 SLCO1B1 rs4149056 5 20 77 369 0.19 6.90 0.98
12 68552522 IFNG rs2430561 23 48 29 356 -2.30 4.63 0.62
12 79481371 SYT1 rs12300068 19 83 369 -0.51 8.30 0.95
16 31104878 VKORC1* rs9934438 16 50 36 369 10.26 4.61 0.03
17 32579788 ACCN1/CCL2 rs1024611 12 45 45 369 1.14 5.07 0.82
21 28240574 ADAMTS5/ADAMTS1 rs229109 11 43 48 369 -1.59 5.26 0.76
22 35776672 HMOX1/TOM1 rs2071746 19 57 26 369 4.91 5.26 0.35
22 36661906 APOL1 rs73885319 1 1 100 369 -5.91 13.25 0.66
22 36662046 APOL1 rs71785313 102 369 0.00
22 36751101 MYH9 rs11089788 27 42 33 369 0.92 4.19 0.83
22 36774812 MYH9 rs5756168 1 23 78 369 2.15 8.29 0.80
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Abstract
Background Deterioration in renal function is a major complication in 
pediatric liver transplant recipients, which has been partially attributed 
to the nephrotoxic effects of the immunosuppressant tacrolimus. We 
aimed to determine the prevalence as well as genetic risk factors for renal 
function decline after pediatric liver transplantation.
Methods This retrospective cohort study considered clinical data, 
including renal function data, from the day of transplantation up to 
10 years post-transplantation. In multivariate analysis, the impact of 
genetic variation (77 SNPs) on renal function was studied using eGFR and 
age-normalized eGFR (z-scores).
Results 135 liver transplant recipients treated with tacrolimus were 
included; their median age was 2.5 years (IQR: 8.2) and the median 
follow-up was 0.77 years (range: 7 days-10 years). Chronic kidney disease 
(CKD stages 3-5, at least 3 months post-transplant) had developed in 32 
patients (24%). None of the polymorphisms studied were significantly 
associated with decrease in renal function.  
Conclusion Renal function decline, a major complication in pediatric 
liver transplant recipients, occurred in 24% of the patients. In contrast to 
studies in adults, we were not able to show an effect of CYP3A5*3 or other 
variant alleles on renal function. 
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Introduction
The reported prevalence of chronic renal failure following liver 
transplantation in adults ranges from 10% to 93%1,2,3 and in children 
from 0%-88.5%.4,5,6,7,8,9,10 This wide range may be explained by patient 
selection bias, differences in definitions of renal dysfunction, and 
differences in follow-up time.1,10 The Studies in Pediatric Liver 
Transplantation (SPLIT) registry recently published a new report on the 
outcome of children receiving liver transplant in the United States and 
Canada. At 5-years post-transplantation, 45 children (13%) had an eGFR 
<90 ml/min/1.73m2; at 10 years post-transplantation this was the case 
for 11 children (9%).11,12 In a recent review of the pediatric literature we 
found reported prevalences of CKD stages 3-5), defined as an eGFR <60 
ml/min/1.73m2, ranging between 1.67% and 17%.10 Hence, renal function 
decline after liver-transplantation is often seen.1,13 Ultimately, decline can 
lead to end-stage renal disease and is associated with an elevated risk of 
death if persisting for at least three months post-transplantation.1,14
Clinical factors associated with renal dysfunction after liver transplantation 
can be categorized into pre-, peri- and post-operative factors. 
In addition to sex and race, pre-existing renal injury of the recipient, 
underlying metabolic disease, prior exposure to nephrotoxic medica-
tions and cirrhosis have been associated with post-transplant renal 
dysfunction.14 Peri-operative hypotension and blood loss resulting in 
hemodynamic instability may result in renal function decline due to a 
decrease in renal blood flow and GFR.14 Lastly, the chronic use of 
calcineurin inhibitors and hypertension may be considered post-operative 
factors.14 
All such risk factors for pediatric liver transplant recipients have recently 
been reviewed by Matloff et al.15 Some factors, however, may be less 
common in children, notably hepatitis C infection (HCV) and HIV.15,16 
Additionally, some metabolic diseases have been associated with 
post-transplantation renal function decline in children.15,17 
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To improve the long-term outcome of pediatric liver transplantation 
we need to further individualize current patient management. The fast 
developing field of pharmacogenetics may be of help here as it has the 
potential to “identify the right drug and the right dose for the individual 
patient”.23 
In adult liver transplant recipients, associations between the recipient 
CYP3A5, ABCB1, CYP2C8, and ACE genotypes and tacrolimus-induced 
nephrotoxicity have been reported.24,25,26,27,28 These genotypes are of interest,
as tacrolimus is a substrate for CYP3A5 as well as ABCB1, and CYP2C8 
and ACE are involved in renal hemeostasis.26,27,29 However, sample sizes
in these studies were relatively small and definitions of renal failure 
varied, thereby limiting interpretation of these results. In 51 pediatric liver 
transplant recipients, an association was reported between ABCB1 and 
tacrolimus-induced nephrotoxicity.30 For in those who were ABCB1 T-T-T 
haplotype carriers, tacrolimus-induced nephrotoxicity was more often 
diagnosed than in the control group at 6 months post-transplantation. 
However, at one year post-transplantation this difference was no longer 
significant.24,30 
Outcomes and genetic predictors of renal function after liver transplant 
may be affected by the calcineurin inhibitor administered. In adult liver 
transplant patients, administration of tacrolimus was associated with 
better renal function than administration of cyclosporine.22 The molecular
mechanisms by which these drugs may cause chronic kidney disease (CKD) 
are not fully understood but seem to differ between the two drugs.18,19,20,21 
As cyclosporine-treated patients are overrepresented in most adult, but 
also pediatric, studies, the results of these studies may not necessarily 
reflect outcome and risk factors in tacrolimus-treated pediatric liver 
transplant recipients.
In this study we aimed to identify CKD prevalence and genetic risk factors 
for post-transplantation renal function decline in pediatric liver recipients 
receiving tacrolimus. 
Risk factors for renal failure in liver transplant patients | 159 Ch
ap
te
r 8
Methods
We performed a retrospective cohort study of pediatric liver transplant 
recipients transplanted between January 1998 and June 2009 at the 
Hospital for Sick Children (Toronto, Canada). Patients were eligible for this 
study if 1) they were younger than 18 years at the time of transplantation 
and 2) they received oral tacrolimus after their transplantation. 
DNA samples were obtained if consent was provided. Informed consent 
was obtained from parents and/or children during enrolment. The study 
was approved by the Institutional Research Ethics Board of the Hospital 
for Sick Children. 
Data collection
Clinical data were retrieved from electronic patient records and paper 
charts pertaining to the day of transplantation, 1 week, 1, 3, 6, 9 and 12 
months and yearly thereafter until December 2009 or until available. 
End-points
The primary end-point was the prevalence of CKD was established by the 
estimated glomerular filtration rate (eGFR) calculated according to the 
Schwartz formula.31 Patients were categorized by CKD severity according
to the National Kidney Foundation Kidney Disease Outcome Quality 
Initiative (KDOQI) guidelines, which distinguish 5 stages. The first is 
kidney damage with normal or elevated GFR (> 90 ml/min/1.73m2); the 
second is kidney damage with mildly decreased GFR (60-89 ml/min/1.73 m2);
the third is moderate renal failure (GFR 30-59 ml/min/1.73m2), the 
fourth is severe renal failure (15-29 ml/min/1.73m2); and the fifth is 
complete renal failure (GFR < 15 ml/min/1.73m2 or dialysis).32 
The secondary end-points were the absolute eGFR and z-scores of eGFRs. 
The z-scores served to correct for age-related changes in eGFR and were 
based on reference values for the mean and standard deviation from a 
healthy pediatric, mainly Caucasian, population.33
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Other clinical data
Other data collected concerned patients’ demographic characteristics, 
tacrolimus levels, hematology and chemistry laboratory results, concomitant 
medications, primary diagnosis, transplant information and outcome. 
Information on concomitant medication known for nephrotoxic potential 
was collected: i.e. cyclosporin, gentamicin, cotrimoxazole, tobramycin, 
amphotericin B, valganciclovir, ganciclovir, spironolactone and vancomycin. 
Follow-up visits where cyclosporine was used or tacrolimus was discontinued, 
temporarily or permanently, were not included in the analysis. If a patient 
received more than one liver transplant, the most recent transplantation was 
used in the analysis.  
Immunosuppressive protocol
Tacrolimus was started according to the immunosuppression protocol 
of the Hospital for Sick Children at the day of transplantation at 0.2 mg/
kg/day twice daily. Therapeutic drug monitoring was used to adjust the 
tacrolimus dose to achieve a target level of 12-15 ng/ml in the first month 
post-transplantation, 10-12 ng/ml in the second and third months post-
transplantation and a target level of 5-15 ng/ml afterwards. Additional 
immunosuppressive therapy consisted of a tapering steroid schedule. 
Tacrolimus analysis
Tacrolimus serum concentrations were determined in ethylenediami-
netetraacetic acid (EDTA)-treated whole blood (0.25 ml) on the day of 
sampling, using liquid chromatography tandem mass spectrometry 
(LC-MS-MS) as previously described, as part of routine clinical care.34,35
Genotyping
Blood or saliva samples were collected from patients at the first visit after 
informed consent was received or by access to DNA samples from either 
the Hospital for Sick Children’s Biobank or the University Health Network 
HLA laboratory. Blood samples were collected in EDTA-containing tubes. 
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Saliva samples were collected using Oragene DNA OG-250 collection kits 
(DNA genotek, Ottawa, Ontario, Canada). Samples were stored at -80ºC 
before purification of DNA using the QiaSymphony system (Qiagen, 
USA). Ninety-six SNPs were selected based on previous published asso-
ciations, SNPs related to tacrolimus pharmacokinetic pathways and SNPs 
associated with renal function (Supplemental table 1). DNA samples were 
genotyped for this custom set of 96 variants using BeadXpress genotyping 
platform using the manufacturer’s protocol (Illumina, CA, USA) at the 
University of British Columbia, Vancouver, BC, Canada.36
Statistical analysis
Descriptive data are presented as mean ± standard deviation or median 
(IQR) for continuous variables and as percentage for categorical variables. 
Kaplan-Meier curves were plotted for the time-course of CKD incidence. 
CKD stage was designated as an eGFR below the cut-off values according to 
CKD stages on two consecutive visits from 3 months post-transplantation 
onwards. The patient’s sex, age at time of transplantation, investigation site, 
tacrolimus levels, concomitant medication, year of transplantation, albumin 
and CRP levels, hematocrit, conversion from cyclosporine, and weight and 
height were tested in a univariate general linear mixed model. Covariates 
with a p-value < 0.05 were considered for retention in the regression model. 
The Hardy-Weinberg equilibrium was tested for each polymorphism using 
the method by Guo et al.37 Previously published24 significant genetic associa-
tions with eGFR were tested at a significance level of 0.05. All other genetic 
associations were tested at a significance threshold of 8.7 x10-4 determined 
by a Bonferroni correction based on the effective number of independent 
tests (Meff).
38 A mixed model for the continuous endpoints served to 
analyze the genetic additive effect of each SNP by adjusting for the covariates 
retained in the stepwise selection. All statistical analyses for the genetic 
variables were done using SAS 9.3 (SAS institute Inc, Cary, NC, USA). 
All other statistical analyses, including figures were done using SPSS 
version 20.0 (IBM SPSS Statistics, Armonk, NY, USA).
162 | Chapter 8
Results
Patient population
One hundred and fifty-two patients were eligible for inclusion. 
Informed consent was received for 135 patients and they were included 
in the study. The median age was 2.5 years (IQR: 8.2); the median weight 
was 20.8 kg (IQR: 24.0) and 51.1% were females (Table 1). The median 
follow-up time was 0.77 years (range: 7 days – 10 years). The most 
common primary diagnosis for liver transplantation was biliary atresia 
(40.8%) (Table 1). Eleven patients (8.1%) were converted from cyclosporine 
to tacrolimus during the follow-up interval and 14 patients (10.3%) passed 
away (Table 1). Seven patients (5.2%) underwent re-transplantation. 
Recipient DNA was available for 78 patients. 
Figure 1A and 1B: eGFR over time and eGFR z-scores over time
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Table 1: Demographics of the patient population (continued)
Variable Liver (All) Liver (DNA)
Number 135 78
Age at time of transplant (years)
Mean ± SD
Median (IQR)
5.2 ± 5.2
2.5 (8.2)
4.4 ± 4.5
2.5 (4.8)
Year of transplant
Median
(Q1,Q3)
Range
2005
(2001, 2007)
(1995, 2009)
2004
(2001, 2007)
(1995, 2009)
Follow up (year)
Mean ± SD
Median (IQR)
1.96 ± 2.51
0.74 (2.77)
2.2 ± 2.69
0.76 (3.67)
Gender M: 69 (48.9%)
F: 66 (51.1%)
M: 42 (53.8%)
F: 36 (46.2%)
Weight (kg)
Mean ± SD
Median (IQR)
26.8 ± 18.1
20.8 (24.0)
25.2 ± 16.8
20.0 (18.1)
Height (cm)
Mean ± SD
Median (IQR)
113.8 ± 34.1
113.0 (58.0)
110.5 ± 32.2
109.7 (48.4)
Transplant (n, %)
1st
2nd
128 (94.8%)
7 (5.2%)
71 (91.0%)
7(9.0%)
eGFR at 1 year post-transplantation
Mean ± SD
Median (IQR)
146.8 ± 80.5
134.4 (58.0)
148.1 ± 38.0
140.0 (50.0)
Need for dialysis before transplant (n,%) 0 (0%) 0 (0%)
Converted from CsA (n,%) 11 (8.1%) 6 (7.7%)
Mortality rate (n,%) 14 (10.3%) 9 (11.5%)
Donor age 
Mean ± SD
Median (IQR)
30.70 ± 17.8
33.0 (31.0)
27.95 ± 18.7
28.0 (34.0)
Donor gender M: 26 (39%)
F: 40 (61%)
M: 14 (40%)
F: 21 (60%)
Deceased or living-related donor (n,%) Deceased: 22 (16.3%)
Living: 113 (83.7%)
Deceased: 7 (9.0%)
Living: 71 (91.0%)
Cold ischemia time (min)
Mean ± SD
Median (IQR)
466.8 ± 227.8
500.0 (346.0)
488.8 ± 239.6
503.0 (378.3)
Warm ischemia time (min)
Mean ± SD
Median (IQR)
60.1 ± 19.9
59.0 (22.0)
64.2 ± 21.4
61.0 (20.0)
Primary diagnosis
Biliary atresia 
Auto-immune 
Hepatoblastoma 
Fulminant liver failure 
Chronic liver failure 
Tyrosinemia 
Congenital 
Cholangitis 
Other
60 (40.8%)
2 (1.4%)
12 (8.2%)
15 (10.2%)
13 (8.8%)
2 (1.4%)
4 (2.7%)
9 (6.1%)
30 (20.4%)
38 (48.7%)
0 (0%)
7 (8.9%)
6 (7.7%)
8 (10.3%)
2 (2.6%)
2 (2.6%)
4 (5.1%)
11 (14.1%)
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Renal failure following liver transplantation
None of the patients required dialysis before or after transplantation. 
The median eGFR for the 87 patients with data available at one year post-
transplantation was 134.4 (IQR: 58.0) ml/min/1.73m2 (Table 1) (Figures 1A 
and 1B). The incidences of the KDOQI CKD stages at various time points 
are presented in Figure 2. The cumulative incidence of CKD stages 3-5 
is shown in Figure 3A. Thirty-two patients developed CKD stages 3-5. 
The majority of these 32 patients experienced CKD stage 3 (22.2%); and 
2 patients developed stage 4 (1.5%) (Figure 3B). None of the patients 
experienced CKD stage 5. At 1 year post-transplantation only 5 patients (5.7%) 
patients experienced CKD stage 2, and none CKD stages 3-5. At 5 years post-
transplantation none of the patients experienced CKD stages 2-5. 
Figure 2: Incidence of CKD at each time point
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Predictors of renal failure
Four SNPs in genes were not in Hardy-Weinberg equilibrium in our cohort: 
UGT1A1*6 (rs4148323), CYP3A4*3 (rs4986910), CYP3A4*22 (rs35599367) 
and CYP3A4 rs2687102 (Supplementary Table 2). In univariate analysis, 
tacrolimus trough concentrations, albumin levels, hematocrit and height 
and weight were significantly associated with eGFR (Table 2). In addition, 
sex and age at time of transplantation were entered into the regres-
sion model for their known influence of renal function. Two SNPs in two 
genes were significantly below the significance level of 0.05 in the genetic 
model; TLR9 -1486C/T (rs187084) and IFN-gamma 874A/T (rs2430561). 
IFN-gamma 874 and TLR9 -1486 variant carriers had lower eGFR values 
compared to their respective wild-type carriers (Table 3). Nonetheless, 
none of the polymorphisms tested reached the set significance level for 
multiple testing of 8.7 x 10-4 (Supplementary table 3).
Figure 3: Kaplan-Meier curves of the cumulative incidence of CKD in 135 pediatric liver transplant recipients
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Table 2: Univariate analysis of the covariates
Variable N P-value
Gender 466 0.47
Age at time of transplantation 466 0.77
Tacrolimus levels 466 <0.001
Concomitant medication 466 0.11
Year of transplantation 466 0.46
Albumin levels 405 0.002
Hematocrit levels 321 <0.001
Converted to CsA 466 0.38
Weight 140 0.001
Height 466 <0.001
Converted to CsA 459 0.04
Weight 89 0.03
Height 406 0.11
Table 3: Genetic association results
Chr Position Gene SNP Genotype counts N obs N obs
Esti-
mate
SE P-value 
of
additive
genetic
effect*
Minor 
homozygous
Hetero-
zygous
Major 
Homozygous
3 52261031 TWF2/
TLR9*
rs187084 11 36 31 288 12.73 5.86 0.03
3 121838319 CD86 rs1129055 8 28 42 288 -11.01 5.83 0.06
6 31543031 TNF/LTA rs1800629 2 17 59 288 13.79 8.10 0.09
7 81700000 ABCB1 
-1236CT
rs1128503 16 42 20 288 -5.11 6.18 0.41
7 81701000 ABCB1 
-2677GT
rs2032582 17 39 22 288 1.93 6.23 0.76
7 81702000 ABCB1 
-3435CT
rs1045642 18 45 15 288 0.84 6.88 0.90
7 99270539 CYP3A5 rs776746 1 26 50 285 -0.83 7.97 0.92
10 90749963 FAS/
ACTA2
rs1800682 20 37 21 288 10.43 5.75 0.07
12 68552522 IFNG* rs2430561 15 32 30 286 13.61 5.38 0.01
17 32579788 ACCN1/
CCL2
rs1024611 11 34 33 288 10.33 5.76 0.08
Adjusted for gender, age at time of transplantation, tacrolimus level, albumin level, hematocrite level and 
patient’s height. Positions based on Genome Build Version 37.1. 
* Significant at the level of 0.05
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Discussion
The prevalence of CKD in in this pediatric cohort was quite high: 32 of 
the 135 patients (23.7%) experienced CKD stage 3-5, 2 (1.5%) experienced 
CKD stage 4, and none stage 5. Still, the cumulative incidence of CKD 
stages 4-5 was much lower than that reported by Ojo et al. (27%) in adult 
transplant recipients.1 
Our results are similar to previous studies, which reported prevalences 
of moderate-severe CKD, defined as eGFR <60 ml/min/1.73m2, ranged 
between 1.67% and 17%.10 However, these prevalences were established 
at the time of the last available follow-up, which widely varied between 
patients and papers. Hence, it is hardly possible to identify a time window 
in which post-transplantation renal failure is of particular concern. 
The prevalences of mild renal failure (CKD stage 2) at one year and 5 years 
post-transplantation in the present study were 5.7% and 0%, respectively. 
The SPLIT study reported a 13% prevalence of CKD stage 2 at 5 years 
post-transplantation and a 9% prevalence at 10 years.11,12 The discrepancy 
between studies for the 5-years prevalence could be due to the fact that 
our sample at that time was relatively small compared to the SPLIT study 
(49 versus 352 patients).11 
In contrast to the previous studies, we established the cumulative 
incidence as well as the prevalence of renal failure at several time points 
in the same cohort. The mean eGFR proved stable throughout the 
study period and the eGFR z-scores deviated little from those of healthy 
children. CKD stages 2 and 3 were more frequently seen in the first 
year post-transplantation than in later years. In the later years a smaller 
proportion of patients had renal failure. This approach represents the 
post-transplant outcome of liver transplant recipients more accurately 
than that in which patients with different follow-up periods are grouped 
together. 
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Two SNPs in the genetic model were significant at the 5% level for 
renal damage: IFN-γ 874A/T and TLR9 -1486C/T. Yet these are probably 
chance findings as the significance threshold for multiple testing was 
not reached. The results did not show a significant association between 
recipient CYP3A5, CYP2C8, ACE and also the ABCB1 genotype, as has been 
suggested in studies in adults and, for ABCB1, in one previous pediatric
study.24 Two of the adult studies, however, unselectively pooled data 
from both cyclosporine and tacrolimus-treated patients, which brings 
into question the association between ABCB1 and ACE genotypes with 
tacrolimus-related nephrotoxicity. Additionally, the definitions of renal 
failure were largely based on serum creatinine cut-offs.24 The previous 
pediatric study only showed an association between ABCB1 genotype 
and tacrolimus-induced nephrotoxicity at 6 months post-transplantation, 
which disappeared at one year post-transplantation. Hence, the genetic 
association of ABCB1 genotype may not be relevant over the longer term 
post-transplantation.30 
Several limitations of our study should be acknowledged. The limited 
sample size may have resulted in missing more subtle recipient genetic 
effects on renal function. Because we did not include donor DNA in our 
analysis, the donor contribution could not be established. The candidate 
gene approach of our study limits the detection of genetic risk factors to 
the genes included in the assay. A Genome Wide Association Study could 
perhaps reveal other candidates not yet thought of. The retrospective 
nature of the study limited us to the information available in database 
and medical charts, which did not include drug dosing, liver size and 
pre-transplant information. This was a single center study, and it could well 
be that similar studies in other transplant centers would yield different 
results. On the other hand, this study is the first of its kind determined 
genetic factors in relation to renal function for a prolonged period of time 
post-transplantation. Moreover, using eGFR and not CKD stage to identify 
association between genetic variation with renal dysfunction, increased 
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the sensitivity of our analyses. Nevertheless, the use of eGFR may not 
reflect the true prevalence of CKD in liver transplant recipients as this 
measure tends to overestimate the true glomerular filtration rate.15 
The “gold standard” of measured GFR (mGFR) would be preferable as it 
has been shown to result in a higher rate of CKD.15 
In conclusion, this is the first pediatric liver transplant study reporting 
on the prevalence of CKD as well as genetic risk factors associated with 
decline in renal function. The higher CKD stages (4 or 5) were rare; 
however 24% of patients still experienced CKD stage 3. None of the SNPs 
studied were significantly associated with decline in renal function. 
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Supplementary Table 1: All SNPs analyzed
Chr Position Gene SNP
1 60392494 C1orf87/CYP2J2 rs890293
1 162030688 OLFML2B/NOS1AP rs10918594
1 184911126 PTGS2 rs4648279
1 186643541 PTGS2 rs3218625
1 186643836 PTGS2 rs5272
1 186643837 PTGS2 rs5273
1 186650751 PTGS2/PLA2G4A rs689466
1 186646004 PTGS2 rs3218622
1 206946407 IL19/IL10 rs1800872
1 206946634 IL19/IL10 rs1800871
1 206946897 IL19/IL10 rs1800896
1 223285200 TLR5 rs5744168
2 228052600 COL4A3 rs2204862
2 234669144 UGT1A1 rs4148323
2 241542703 CAPN10 rs5030952
3 52261031 TWF2/TLR9 rs187084
3 119500035 NR1I2 rs3814055
3 119533733 NR1I2 rs6785049
3 119534153 NR1I2 rs2276707
3 119537254 NR1I2 rs3814057
3 121838319 CD86 rs1129055
4 38799710 TLR1 rs4833095
4 38800214 TLR1 rs5743611
4 38830350 TLR6 rs5743810
4 89052323 ABCG2 rs2231142
4 123377980 IL21/IL2 rs2069762
4 154626317 TLR2 rs5743708
4 187004074 TLR3 rs3775291
6 31241109 HLA-C rs13191343
6 31543031 TNF/LTA rs1800629
6 32809848 PSMB8 rs9357155
6 32811629 PSMB8 rs2071543
6 43736389 MRPS18A/VEGFA rs699947
6 43737830 VEGF rs1570360
6 90032942 UBE2J1/GABRR2 rs2064831
7 22766645 IL6/LOC541472 rs1800795
7 75615006 POR rs1057868
7 81700000 ABCB1 rs1128503
7 81701000 ABCB1 rs2032582
7 81702000 ABCB1 rs1045642
7 87133470 ABCB1 rs17064
7 87230193 ABCB1 rs3213619
Chr Position Gene SNP
7 99102509 CYP3A5 rs55965422
7 99194259 CYP3A4 rs17161886
7 99245013 ZNF498/CYP3A5 rs4646458
7 99245080 ZNF498/CYP3A5 rs4646457
7 99245914 CYP3A5 rs15524
7 99247772 CYP3A5 rs41279854
7 99250393 CYP3A5 rs41303343
7 99258139 CYP3A5 rs28383479
7 99262835 CYP3A5 rs10264272
7 99270539 CYP3A5 rs776746
7 99273821 CYP3A5 rs55817950
7 99325882 CYP3A7 rs2687136
7 99354114 CYP3A4/CYP3A7 rs12333983
7 99356324 CYP3A4 rs17161886
7 99358524 CYP3A4 rs4986910
7 99360870 CYP3A4 rs4646440
7 99365451 CYP3A4 rs2687117
7 99365983 CYP3A4 rs55785340
7 99366316 CYP3A4 rs35599367
7 99382096 CYP3A4/CYP3A43 rs2740574
7 99388017 CYP3A4/CYP3A43 rs2687102
8 139746208 COL22A1 rs4588898
9 120475302 TLR4 rs4986790
9 120475602 TLR4 rs4986791
9 125133507 PTGS1 rs3842787
9 125140241 PTGS1 rs3842789
9 125143707 PTGS1 rs3842792
9 125143973 PTGS1 rs5789
9 125148791 PTGS1 rs5791
9 125152507 PTGS1 rs5792
9 125152579 PTGS1 rs5793
10 90749963 FAS/ACTA2 rs1800682
10 96798749 CYP2C8 rs10509681
10 96818119 CYP2C8 rs1058930
10 101542578 ABCC2 rs717620
10 101611294 ABCC2 rs8187710
11 2857194 KCNQ1 rs2237895
11 2870108 KCNQ1 rs8234
11 17460712 ABCC8 rs2237982
11 112034988 TEX12/IL18 rs187238
11 112035458 IL18/TEX12 rs1946518
12 21329738 SLCO1B1 rs2306283
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Chr Position Gene SNP
12 21331549 SLCO1B1 rs4149056
12 68552522 IFNG rs2430561
12 79481371 SYT1 rs12300068
16 31104878 VKORC1 rs9934438
17 32579788 ACCN1/CCL2 rs1024611
19 41858921 TGF-beta rs1800470
21 28240574 ADAMTS5/AD-
AMTS1
rs229109
22 35775889 HO-1 rs3761439
22 35776672 HMOX1/TOM1 rs2071746
22 36661906 APOL1 rs73885319
22 36662046 APOL1 rs71785313
22 36751101 MYH9 rs11089788
22 36774812 MYH9 rs5756168
22 36751101 MYH9 rs11089788
22 36774812 MYH9 rs5756168
A total of 19 SNPs had to be removed from the analysis; 
16 SNPs had a allele frequency of 0, two SNPs had more 
than 5% missing genotypes and one SNP completely 
failed. A total of 77 SNPs were included in the analysis. 
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Chr Position Gene SNP Minor 
allele
Major 
allele
MAF 
frequency
H-W
 p-value
H-W
Exact 
p-value
1 60392494 C1orf87/CYP2J2 rs890293 C A 0.082802548 0.588700555 1
1 162030688 OLFML2B/NOS1AP rs10918594 G C 0.385350318 0.337620766 0.3326
1 186643541 PTGS2 rs3218625 G A 0.001592357 0.954561842 1
1 186650751 PTGS2/PLA2G4A rs689466 A G 0.178343949 0.69337799 1
1 206946407 IL19/IL10 rs1800872 C A 0.305111821 0.48443888 0.477
1 206946634 IL19/IL10 rs1800871 G A 0.283333333 0.648531759 0.6269
1 206946897 IL19/IL10 rs1800896 A G 0.396496815 0.979868635 1
1 223285200 TLR5 rs5744168 G A 0.046178344 0.816215886 1
2 228052600 COL4A3 rs2204862 A G 0.097133758 0.290239465 0.3133
2 234669144 UGT1A1 rs4148323 G A 0.009708738 2.22436E-05 0.0421
2 241542703 CAPN10 rs5030952 G A 0.012738854 0.862516403 1
3 52261031 TWF2/TLR9 rs187084 A G 0.370607029 0.915853751 1
3 119500035 NR1I2 rs3814055 G A 0.404458599 0.200626485 0.2444
3 119533733 NR1I2 rs6785049 A G 0.439490446 0.733967333 0.8194
3 119534153 NR1I2 rs2276707 G A 0.208598726 0.416170618 0.465
3 119537254 NR1I2 rs3814057 A C 0.224522293 0.238968827 0.2268
3 121838319 CD86 rs1129055 G A 0.265923567 0.315567024 0.3974
4 38799710 TLR1 rs4833095 A G 0.356687898 0.496905848 0.4923
4 38800214 TLR1 rs5743611 G C 0.071656051 0.014156525 0.058
4 38830350 TLR6 rs5743810 G A 0.294585987 0.442440668 0.7195
4 89052323 ABCG2 rs2231142 C A 0.106687898 0.175696998 0.1702
4 123377980 IL21/IL2 rs2069762 A C 0.341853035 0.865134745 1
4 154626317 TLR2 rs5743708 G A 0.02388535 0.862516403 1
4 187004074 TLR3 rs3775291 G A 0.277070064 0.341201578 0.5601
6 31543031 TNF/LTA rs1800629 G A 0.157643312 0.568614962 0.6143
6 32809848 PSMB8 rs9357155 G A 0.117834395 0.674910112 0.6373
6 32811629 PSMB8 rs2071543 C A 0.133757962 0.997848331 1
6 43736389 MRPS18A/VEGFA rs699947 C A 0.472929936 0.587040519 0.6306
6 90032942 UBE2J1/GABRR2 rs2064831 A G 0.173566879 0.055846195 0.0564
7 22766645 IL6/LOC541472 rs1800795 C G 0.305732484 0.786758383 1
7 81700000 ABCB1 -1236CT rS1128503 G A 0.461783439 0.48115569 0.6428
7 81701000 ABCB1 -2677GT rs2032582 C A 0.453674121 0.970930985 1
7 81702000 ABCB1 -3435CT rs1045642 A G 0.498407643 0.16949463 0.2538
7 87133470 ABCB1 rs17064 A T 0.068471338 0.199695327 0.2568
7 87230193 ABCB1 rs3213619 A G 0.039808917 0.678204173 1
7 99245013 ZNF498/CYP3A5 rs4646458 A C 0.100638978 0.867957935 1
7 99245080 ZNF498/CYP3A5 rs4646457 A C 0.159235669 0.16949463 0.2799
7 99245914 CYP3A5 rs15524 A G 0.151273885 0.204608211 0.458
Supplementary Table 2: Hardy-Weinberg equilibrium
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Chr Position Gene SNP Minor 
allele
Major 
allele
MAF 
frequency
H-W
 p-value
H-W
Exact 
p-value
7 99262835 CYP3A5 rs10264272 G A 0.00477707
7 99270539 CYP3A5 rs776746 G A 0.153354633 0.236443241 0.4366
7 99325882 CYP3A7 rs2687136 A G 0.165605096 0.639487504 1
7 99354114 CYP3A4/CYP3A7 rs12333983 A T 0.178913738 0.442232307 0.748
7 99356324 CYP3A4 rs17161886 A C 0.02388535 0.816215886 1
7 99358524 CYP3A4 rs4986910 A G 0.00477707 1.03041E-18 0.0067
7 99360870 CYP3A4 rs4646440 G A 0.052547771 0.390537276 0.3644
7 99365451 CYP3A4 rs2687117 G A 0.01433121 0.908684346 1
7 99366316 CYP3A4 rs35599367 G A 0.042993631 1.7105E-05 0.0426
7 99382096 CYP3A4/CYP3A43 rs2740574 A G 0.060509554 0.390537276 0.3783
7 99388017 CYP3A4/CYP3A43 rs2687102 A G 0.012738854 1.03041E-18 0.0067
8 139746208 COL22A1 rs4588898 G A 0.294585987 0.301771484 0.2938
9 120475302 TLR4 rs4986790 A G 0.076433121 0.502860562 1
9 120475602 TLR4 rs4986791 G A 0.070063694 0.588700555 1
9 125133507 PTGS1 rs3842787 G A 0.046178344 0.954561842 1
9 125143707 PTGS1 rs3842792 A C 0.001592357 0.954561842 1
9 125143973 PTGS1 rs5789 C A 0.02388535 0.816215886 1
10 90749963 FAS/ACTA2 rs1800682 A G 0.48566879 0.651605163 0.6539
10 96798749 CYP2C8 rs10509681 A G 0.087579618 0.633082669 1
10 96818119 CYP2C8 rs1058930 C G 0.049363057 0.678204173 1
10 101542578 ABCC2 rs717620 G A 0.204472843 0.585992222 1
10 101611294 ABCC2 rs8187710 G A 0.071656051 0.588700555 1
11 2857194 KCNQ1 rs2237895 A C 0.420382166 0.609665876 0.6424
11 2870108 KCNQ1 rs8234 A G 0.357371795 0.187623417 0.2336
11 17460712 ABCC8 rs2237982 G A 0.406050955 0.609665876 0.6257
11 112034988 TEX12/IL18 rs187238 C G 0.246815287 0.389689196 0.4982
11 112035458 IL18/TEX12 rs1946518 C A 0.396496815 0.604954536 0.7997
12 21329738 SLCO1B1 rs2306283 A G 0.447452229 0.528145106 0.5049
12 21331549 SLCO1B1 rs4149056 A G 0.136942675 0.147061143 0.3436
12 68552522 IFNG rs2430561 A T 0.440514469 0.232560522 0.2356
12 79481371 SYT1 rs12300068 G A 0.135350318 0.239968341 0.3572
16 31104878 VKORC1 rs9934438 G A 0.415335463 0.64827917 0.6507
17 32579788 ACCN1/CCL2 rs1024611 A G 0.340764331 0.640627488 0.6254
21 28240574 ADAMTS5/ADAMTS1 rs229109 G A 0.304140127 0.315567024 0.4008
22 35776672 HMOX1/TOM1 rs2071746 T A 0.444089457 0.472641902 0.6404
22 36661906 APOL1 rs73885319 A G 0.01433121 0.954561842 1
22 36662046 APOL1 rs71785313 A T 0.00477707
22 36751101 MYH9 rs11089788 C A 0.445859873 0.934129709 1
22 36774812 MYH9 rs5756168 A G 0.114649682 0.825252819 0.5694
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Table 3: Genetic associations renal transplant recipients
Chr Position Gene SNP Genotype counts N obs Estimate SE P-value of
additive
genetic
effect*
Minor 
homozygous
Heterozygous Major 
Homozygous
1 60392494 C1orf87/CYP2J2 rs890293 9 69 288 0.22 13.95 0.99
1 162030688 OLFML2B/NOS1AP rs10918594 12 32 34 288 2.92 5.90 0.62
1 186643541 PTGS2 rs3218625 1 77 288 31.07 32.04 0.34
1 186650751 PTGS2/PLA2G4A rs689466 2 24 52 288 4.20 7.50 0.58
1 206946407 IL19/IL10 rs1800872 13 34 31 288 -6.35 5.49 0.25
1 206946634 IL19/IL10 rs1800871 11 33 31 280 -7.75 5.63 0.17
1 206946897 IL19/IL10 rs1800896 10 36 32 288 5.18 6.01 0.39
1 223285200 TLR5 rs5744168 4 74 288 2.31 17.18 0.89
2 228052600 COL4A3 rs2204862 1 9 68 288 -10.40 10.70 0.33
2 234669144 UGT1A1 rs4148323 1 2 73 281 15.66 14.40 0.28
2 241542703 CAPN10 rs5030952 3 75 288 25.38 24.07 0.30
3 52261031 TWF2/TLR9* rs187084 11 36 31 288 12.73 5.86 0.03
3 119500035 NR1I2 rs3814055 10 43 25 288 -7.75 6.66 0.25
3 119533733 NR1I2 rs6785049 16 37 25 288 -3.67 5.55 0.51
3 119534153 NR1I2 rs2276707 4 22 52 288 -4.89 6.84 0.48
3 119537254 NR1I2 rs3814057 6 24 48 288 -3.04 6.33 0.63
3 121838319 CD86 rs1129055 8 28 42 288 -11.01 5.83 0.06
4 38799710 TLR1 rs4833095 15 35 28 288 -6.14 5.64 0.28
4 38800214 TLR1 rs5743611 2 8 68 288 6.80 10.13 0.50
4 38830350 TLR6 rs5743810 2 27 49 288 2.79 7.97 0.73
4 89052323 ABCG2 rs2231142 3 16 59 288 4.99 7.67 0.52
4 123377980 IL21/IL2 rs2069762 9 34 35 288 9.48 6.01 0.12
4 154626317 TLR2 rs5743708 3 75 288 -43.46 29.99 0.15
4 187004074 TLR3 rs3775291 4 34 40 288 -2.58 6.88 0.71
6 31543031 TNF/LTA rs1800629 2 17 59 288 13.79 8.10 0.09
6 32809848 PSMB8 rs9357155 2 18 58 288 -5.34 8.56 0.53
6 32811629 PSMB8 rs2071543 2 21 55 288 -4.18 8.25 0.61
6 43736389 MRPS18A/VEGFA rs699947 16 36 26 288 1.93 5.65 0.73
6 90032942 UBE2J1/GABRR2 rs2064831 5 18 55 288 4.65 6.80 0.50
7 22766645 IL6/LOC541472 rs1800795 6 33 39 288 1.68 6.70 0.80
7 81700000 ABCB1 -1236CT rs1128503 16 42 20 288 -5.11 6.18 0.41
7 81701000 ABCB1 -2677GT rs2032582 17 39 22 288 1.93 6.23 0.76
7 81702000 ABCB1 -3435CT rs1045642 18 45 15 288 0.84 6.88 0.90
7 87133470 ABCB1 rs17064 1 8 69 288 14.05 10.92 0.20
7 87230193 ABCB1 rs3213619 7 71 288 -3.50 14.80 0.81
7 99245013 ZNF498/CYP3A5 rs4646458 1 17 60 288 2.35 8.80 0.79
7 99245080 ZNF498/CYP3A5 rs4646457 1 28 49 288 0.94 7.94 0.91
7 99245914 CYP3A5 rs15524 1 27 50 288 -1.72 8.01 0.83
7 99262835 CYP3A5 rs10264272 78 288 0
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Chr Position Gene SNP Genotype counts N obs Estimate SE P-value of
additive
genetic
effect*
Minor 
homozygous
Heterozygous Major 
Homozygous
7 99270539 CYP3A5 rs776746 1 26 50 285 -0.83 7.97 0.92
7 99325882 CYP3A7 rs2687136 3 28 47 288 -4.70 7.17 0.51
7 99354114 CYP3A4/CYP3A7 rs12333983 3 30 44 283 0.90 7.19 0.90
7 99356324 CYP3A4 rs17161886 4 74 288 27.32 17.72 0.13
7 99358524 CYP3A4 rs4986910 1 77 288 -18.22 16.70 0.28
7 99360870 CYP3A4 rs4646440 1 10 67 288 17.15 10.24 0.10
7 99365451 CYP3A4 rs2687117 2 76 288 20.89 27.65 0.45
7 99366316 CYP3A4 rs35599367 1 2 75 288 -23.90 15.20 0.12
7 99382096 CYP3A4/CYP3A43 rs2740574 1 10 67 288 7.91 10.03 0.43
7 99388017 CYP3A4/CYP3A43 rs2687102 1 77 288 7.33 16.72 0.66
8 139746208 COL22A1 rs4588898 9 29 40 288 7.12 5.95 0.24
9 120475302 TLR4 rs4986790 11 67 288 -15.91 12.04 0.19
9 120475602 TLR4 rs4986791 9 69 288 -16.99 13.53 0.21
9 125133507 PTGS1 rs3842787 1 77 288 23.42 42.52 0.58
9 125143707 PTGS1 rs3842792 1 77 288 14.66 33.45 0.66
9 125143973 PTGS1 rs5789 4 74 288 16.24 21.49 0.45
10 90749963 FAS/ACTA2 rs1800682 20 37 21 288 10.43 5.75 0.07
10 96798749 CYP2C8 rs10509681 8 70 288 -2.37 13.78 0.86
10 96818119 CYP2C8 rs1058930 7 71 288 -22.91 14.52 0.12
10 101542578 ABCC2 rs717620 2 25 50 287 9.78 8.07 0.23
10 101611294 ABCC2 rs8187710 9 69 288 -17.26 12.90 0.19
11 2857194 KCNQ1 rs2237895 13 35 30 288 -4.63 6.08 0.45
11 2870108 KCNQ1 rs8234 15 31 30 283 -4.33 5.86 0.46
11 17460712 ABCC8 rs2237982 13 35 30 288 -0.38 6.14 0.95
11 112034988 TEX12/IL18 rs187238 5 24 49 288 10.34 6.98 0.14
11 112035458 IL18/TEX12 rs1946518 9 38 31 288 4.10 6.30 0.52
12 21329738 SLCO1B1 rs2306283 18 36 24 288 -1.64 5.90 0.78
12 21331549 SLCO1B1 rs4149056 22 56 288 0.21 9.11 0.98
12 68552522 IFNG* rs2430561 15 32 30 286 13.61 5.38 0.01
12 79481371 SYT1 rs12300068 3 17 58 288 4.91 7.68 0.52
16 31104878 VKORC1 rs9934438 16 36 25 278 6.43 5.77 0.27
17 32579788 ACCN1/CCL2 rs1024611 11 34 33 288 10.33 5.76 0.08
21 28240574 ADAMTS5/ADAMTS1 rs229109 8 28 42 288 9.93 6.02 0.10
22 35776672 HMOX1/TOM1 rs2071746 12 41 25 288 9.75 6.26 0.12
22 36661906 APOL1 rs73885319 1 77 288 14.66 33.45 0.66
22 36662046 APOL1 rs71785313 78 288 0
22 36751101 MYH9 rs11089788 15 38 25 288 6.91 6.11 0.26
22 36774812 MYH9 rs5756168 1 14 63 288 -11.41 9.32 0.23
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Abstract 
Background Pediatric heart transplant recipients receiving tacrolimus 
are at risk of renal failure. We determined the prevalence as well as 
genetic risk factors of renal function decline in pediatric heart transplant 
recipients. 
Methods In this multi-center retrospective cohort study, clinical data 
from medical records from the day of transplantation up to 10 years post-
transplantation were collected. In multivariate analysis, the impact of 
genetic variation on renal function was studied using age-normalized 
eGFR and the examination of 77 SNPs relevant to drug biotransformation 
or toxicity. 
Results We analyzed data on 161 heart transplant recipients with a median
age of 2.31 years (IQR: 9.89) and a median follow-up time of 0.78 years 
(range: 7 days – 10 years). Chronic kidney disease (CKD: eGFR<60 ml/
min/1/73m2 at two consecutive visits at least 3 months post-transplanta-
tion) developed in 55 patients (34.2%), 7 of whom (4.3%) developed stage 
4 and one (0.6%) stage 5. None of the genetic polymorphisms studied 
were significantly associated with renal function. 
Conclusion Chronic kidney disease occurred in 34.2% of pediatric heart 
transplant recipients in this study. Genetic risk factors were not identified. 
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Introduction
Renal failure is a serious complication following adult cardiac transplan-
tation1, as shown from the 6.9% five-year cumulative incidence reported 
in the landmark study by Ojo et al.2 The International Society for Heart 
and Lung Transplantation reported that 6% of pediatric heart transplant 
recipients experienced renal failure at 1 year post-transplantation and 
10% at both 5 and 10 years post-transplantation.3,4 Reported prevalences 
in other pediatric studies  range from 6.8%-46%.5,6,7,8 Selection bias as well 
as different definitions for renal failure and different follow-up times may 
contribute to this wide variation.8
In pediatric cardiac transplant recipients, pre-transplant dialysis, hyper-
trophic cardiomyopathy, race, diabetes,  pre-transplant extracorporeal 
membrane oxygenation treatment and previous transplant experience 
may be associated with risk of chronic kidney disease (CKD).9 
These risk factors largely parallel risk factors reported in adult patients. 
Additional risk factors in adults are calcineurin inhibitor use and 
nephrotoxic co-medication.2,10,11
In addition to clinical risk factors, there may be a role for genetic variation.12 
In adult heart transplant recipients, CYP3A5*1 carriers had higher estimated
glomerular filtration rates (eGFR) compared to CYP3A5*3 carriers up to 5 
years post-transplantation.13 Additionally, Pro-carriers of TGF-β codons 10 
and 25 had an increased risk for end-stage renal disease.14 Nonetheless, 
others failed to find associations of CYP3A5, ABCB1 and TGF-β genotypes 
with renal function in adult heart transplant recipients.15
Interestingly, pediatric heart transplant recipients identified as TGF-β high 
producers (TGF-β codons 10 and 25; TC/GG, TT/GG) had significantly lower 
creatinine clearance rates up to 6 years post-transplantation compared to 
intermediate/low TGF-β producers. CYP3A5 and ABCB1 genotypes have 
been associated with altered tacrolimus disposition in pediatric heart 
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transplant recipients,16,17 but a recent study found no associations of 19 
SNPs, including CYP3A5, ABCB1 and TGF-β genotypes, with eGFR after 
adjusting for age at time of transplantation, race and sex in 302 pediat-
ric heart transplant recipients.18 In this study, however, the majority of 
patients received cyclosporine. 
Both cyclosporine and tacrolimus are believed to contribute to the 
development of CKD following heart transplantation.2,10 These drugs 
exert similar effects on the immune system, but seem to differ in the 
molecular mechanisms causing CKD.19,20,21,22 Moreover, tacrolimus was 
associated with lower risk of CKD in adult liver recipients in comparison 
with cyclosporine.23 So far, however, most of the relevant studies 
concerned patients receiving cyclosporine, even though tacrolimus 
currently is the calcineurin inhibitor of choice in pediatric heart trans-
plant recipients. Hence, we aimed to determine the prevalence as well as 
genetic risk factors of renal function decline in pediatric heart transplant 
recipients.
Methods
This was a retrospective cohort study of pediatric heart transplant 
recipients transplanted between January 1998 and June 2009 at the 
Hospital for Sick Children, Toronto, Ontario, Canada or at the Erasmus 
MC - Sophia Children’s Hospital, Rotterdam, the Netherlands. Patients 
were eligible for this study if 1) they were under 18 years of age at time of 
transplantation and 2) they had received oral tacrolimus for immuno-
suppression. At both institutions informed consent was obtained from 
parents and/or children at enrolment. The study was approved by 
the Institutional Research Ethics Board of the Hospital Sick Children. 
In Rotterdam, a waiver for REB approval was obtained, as only retrospective 
data and left-over blood or saliva samples were used. 
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Clinical variables
Clinical data were retrieved from electronic patient records and paper 
charts. Data were collected at the day of transplantation; at 1 week, 1, 3, 
6, 9 and 12 months and yearly thereafter until December 2009 or until 
unavailable. 
End-points
The primary end-point was renal dysfunction defined by using the 
estimated glomerular filtration rate (eGFR), calculated according to 
the Schwartz formula.24 The severity of CKD was rated based on to the 
National Kidney Foundation Kidney Disease Outcome Quality Initiative 
(KDOQI) guidelines for chronic kidney disease. The KDOQI guidelines have 
categorized the renal function into 5 stages of severity. The first stage 
is kidney damage with a normal or elevated GFR (>90 ml/min/1.73m2). 
The second stage, are patients with kidney damage with a mild decreased 
GFR (60-89 ml/min/1.73m2); the third stage is moderate renal failure (GFR 
30-59 ml/min/1.73m2), the fourth stage severe renal failure (15-29 ml/
min/1.73m2) and the fifth stage is complete renal failure (GFR <15 ml/
min/1.73m2 or dialysis).25 Our secondary end-points were the absolute 
eGFR and eGFR z-scores. Data were also analyzed using z-scores of eGFR 
to correct for age-related changes in eGFR. To calculate the z-scores, 
reference values from a healthy, mainly Caucasian, pediatric population 
were used.26
Other clinical data
Other data collected concerned patients’ characteristics, tacrolimus dose 
schedule and serum concentrations during routine therapeutic drug 
monitoring, hematology and chemistry laboratory results, concomitant 
medications, primary diagnosis, transplant information and outcome 
Concomitant medication information was collected for cyclosporine, 
gentamicin, cotrimoxazole, tobramycin, amphotericin B, valganciclovir, 
ganciclovir, spironolactone and vancomycin as they are all potential 
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nephrotoxins as individual drugs or in conjunction with other nephro-
toxic agents. If a patient received more than one heart transplant, the first 
transplantation was used in the analysis.
Immunosuppressive protocol
Immunosuppression was started according to either hospitals’ protocols. 
Tacrolimus was started at 0.1-0.3 mg/kg/day divided into two doses. 
Therapeutic drug monitoring was used to achieve a target level of 12-
15 ng/ml in the immediate post-transplant period and a target level of 
9-12 ng/ml from 3-6 months post-transplantation. After six months 
post-transplantation, tacrolimus target concentrations were 6-8 ng/ml. 
Additional immunosuppressive therapy consisted of a maintenance dose of 
mycophenolate mofetil (600 mg/m2 twice daily), anti-thymocite globulin 
(0.5 ml/kg/day up to 7 days) and a tapering steroid schedule. 
Tacrolimus analysis
Tacrolimus serum trough concentrations were determined in ethylenedi-
aminetetraacetic acid (EDTA)-treated whole blood (0.25 ml) on the day 
of sampling, using liquid chromatography tandem mass spectrometry 
(LC-MS-MS) as previously described, as part of routine clinical care.27,28 
In Rotterdam, tacrolimus whole blood trough concentrations were 
determined in ethylenediaminetetraacetic acid (EDTA)-treated whole 
blood (0.50 ml) on the day of sampling, using high performance liquid 
chromatography-tandem mass spectrometry (HPLC-MS/MS), as part of 
routine care.29,30,31,32 
Genotyping
Blood or saliva samples were collected from patients at the first visit 
after informed consent was received or, in Toronto only, by access to DNA 
samples from either the Hospital for Sick Children’s Biobank or the 
University Health Network HLA laboratory. Blood samples were collected in 
EDTA-containing tubes. Saliva samples were collected by using Oragene 
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DNA OG-250 collection kits (DNA genotek, Ottawa, Ontario, Canada). 
Samples were stored at -80°C before purification of DNA using the 
QiaSymphony system (Qiagen, USA). Ninety-six SNPs were selected 
based on previous published associations, SNPs related to tacrolimus 
pharmacokinetic pathways and SNPs associated with renal failure 
(Supplemental table 1).DNA samples were genotyped for this custom set of 
96  variants using BeadXpress genotyping platform using the manufacturer’s 
protocol (Illumina, CA, USA) at the University of British Columbia, 
Vancouver, BC, Canada.33
Statistical analysis
Descriptive data are presented as mean ± standard deviation or median 
(IQR) for continuous variables and as percentage for categorical 
variables. Kaplan-Meier curves were plotted for the time course of the CKD 
incidence. CKD stage was designated as an eGFR below the cut-offs values 
according to CKD stages on two consecutive visits. A univariate general 
linear mixed model was performed for the following covariates: sex, age at 
time of transplantation, investigation site, tacrolimus levels, concomitant 
medication, year of transplantation, albumin and CRP levels, hematocrit, 
conversion from cyclosporine and weight and height. Covariates with 
a p-value < 0.05 were considered for retention in the regression model. 
The Hardy-Weinberg equilibrium was tested for each polymorphism 
using the method by Guo et al.34 Previously identified significant genetic 
associations with eGFR were tested at a significance level of 0.05. All other 
genetic associations were tested at a significance threshold of 8.7 x10-4 
determined using a Bonferroni correction based on the effective number 
of independent tests (Meff).
35 A mixed model for the continuous endpoints 
was used to test the genetic additive effect of each SNP by adjusting for 
the covariates retained in the stepwise regression. All statistical analyses 
for the genetic variables were done using SAS 9.3 (SAS institute Inc, Cary, 
NC, USA). All other statistical analyses, including figures were done using 
SPSS version 20.0 (IBM SPSS Statistics, Armonk, NY, USA).
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Results
Patient population (Table 1)
One hundred and seventy-four pediatric heart transplant recipients were 
eligible for inclusion. Informed consent was received for 161 patients 
and these were included in the study. The median age was 2.3 years (IQR: 
9.9) with a median weight of 18.0 kg (IQR: 24.0) (Table 1). The median 
follow-up time was 0.78 years (range: 7 days – 10 years). The most 
common primary diagnosis was dilated cardiomyopathy (48.2%). Eleven 
children (6.8%) had undergone a second transplantation. Twenty-one 
(13%) patients had passed away (Table 1). Recipient DNA was available 
for 117 heart transplant recipients. 
Figure 1A and 1B: eGFR over time and eGFR z-scores over time
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Table 1: Demographics of the patient population
Variable Heart (All) Heart (DNA)
Number 161 117
Age at time of transplant (years)
Mean ± SD
Median (IQR)
5.2 ± 5.5
2.3 (9.9)
4.8 ± 5.3
1.9 (8.5)
Year of transplant
Median
(Q1,Q3)
Range
2005
(2001, 2007)
(1994, 2010)
2004
(2001, 2007)
(1995, 2009)
Follow up (year)
Mean ± SD
Median (IQR)
2.15 ± 2.61
0.78 (2.88)
2.16 ± 2.58
0.77 (2.81)
Gender M: 86 (53.4%)
F: 75 (46.6%)
M: 60 (51.3%)
F: 57 (48.7%)
Weight (kg)
Mean ± SD
Median (IQR)
21.4 ± 2.0
13.7 (25.7)
19.4 ± 2.1
12.3 (23.3)
Height (cm)
Mean ± SD
Median (IQR)
100.9 ± 33.3
90.5 (73.7)
98.7 ± 38.5
88.0 (69.9)
Transplant (n, %)
1st
2nd
150 (93.2%)
11 (6.8%)
112 (95.7%)
5 (4.3%)
eGFR at 1 year post-transplantation
Mean ± SD
Median (IQR)
130.9 ± 43.2
126.5 (53.0)
132.8 ± 44.5
127.9 (53.0)
eGFR z-score at 1 year post-transplantation
Mean ± SD
Median (IQR)
-0.3 ± 1.68
-0.19 (2.0)
0.05 ± 1.73
-0.19 (1.93)
Need for dialysis before transplant (n,%) 0 (0%) 0 (0%)
Converted from CsA (n,%) 49 (30.4%) 32 (27.4%)
Mortality rate (n,%) 21 (13.0%) 15 (12.8%)
Donor age 
Mean ± SD
Median (IQR)
63.3 ± 5.9
60.5 (30.0)
65.9 ± 8.2
61.0 (32)
Donor gender M: 62 (53.0%)
F: 54 (47.0%)
M: 45 (52.3%)
F: 41 (47.7%)
Deceased (D) or living-related donor (L) 
(n,%)
D: 22 (13.7%)
L: 139 (86.3%)
D: 14 (12.0 %)
L: 103 (88.0%)
Cold ischemia time (min)
Mean ± SD
Median (IQR)
220.9 ± 118.9
197.0 (176.0)
234.9 ± 121.9
226.5 (209.8)
Warm ischemia time (min)
Mean ± SD
Median (IQR)
65.0 ± 33.4
59.0 (36.0)
59.3 ± 29.6
57.0 (37.0)
Primary diagnosis
Dilated cardiomyopathy 
Congenital heart disease 
VSD 
Congestive heart failure 
Other
76 (47.2%)
58 (36.0%)
5 (3.1%)
1 (0.6%)
21 (13.0%)
58 (49.6%)
42 (35.9%)
3 (2.6%)
1 (0.9%)
13 (11.1%)
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Renal failure following cardiac transplantation
None of the patients received dialysis either pre-or post-transplantation. 
At one year post-transplantation (n=102), the median eGFR was 126.5 
(IQR: 53.0) ml/min/1.73m2 and the median eGFR z-score -0.19 (IQR: 2.0) 
(Figures 1A and 1B). The incidences of the five CKD stages at the various 
time points are shown in Figure 2. Fifty-five patients (34.2%) developed 
CKD stages 3-5 (Figure 3A), i.e. 47 stage 3 (47/161; 29.2%); 7 stage 4 
(7/161; 4.3%) and 1 stage 5 (1/161; 0.6%) (Figure 3B). At one year post- 
transplantation, the prevalence of CKD stage 2 was 8.8% (n=9); that of 
CKD stage 3 was 2.9% (n=3) (Table 2). At 5 years post-transplantation, 4 
patients (7.0%) experienced CKD stage 2 and 1 patient (1.8%) CKD stage 
5 (Figure 2). 
Figure 2: Incidence of CKD at each time point
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Figure 3: Kaplan-Meier curves of the cumulative incidence of CKD in 161 pediatric heart transplant recipients
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Risk factors of renal failure
None of the SNPs deviated from the Hardy-Weinberg equilibrium 
(Supplementary Table 2). In the univariate analysis, age at the time 
of transplantation, height and weight, tacrolimus levels, year of 
transplantation, albumin levels and hematocrit were associated with renal 
function. As weight and height highly correlated, height only was entered 
into the multivariate analysis (Table 2). The number of determinations of 
albumin level was too small to incorporate in the multivariate analysis. 
In addition to the above-mentioned covariates, sex and investigation site 
were included in the multivariate analysis. 
One polymorphism met the corrected significance level: APOL1 G1 
(rs73885319) showing a positive association (β=52.32; p=0.0001) with 
eGFR (Table 3). However, only one patient was homozygous for the 
variant and two patients were heterozygotes. The eGFR of the 
homozygous patient was significantly higher at all time points com-
pared to the heterozygote and wild-type homozygous patients (Table 4). 
Nonetheless, at various time points no eGFR values were available for 
APOL G1 allele carriers. In addition, the eGFRs of heterozygotes were very 
similar to wild-type carriers, suggesting the association is most likely a 
type I error.
Three other SNPs were significant at the significance level of 0.05: 
TLR2 R753Q (rs5743708), KCNQ1 A/C (rs2237895) and ABCB1 G1199T/A 
(rs229109). Carriers of the ABCB1 1199 variant showed higher eGFR 
levels compared to wild-type carriers (β=10.64; p=0.04). Variant carriers 
of TLR2 (β=-54.72; p=0.001) or KCNQ1 (β=-11.06; p=0.01) had lower eGFR 
values compared to their wild-type carriers (Table 3). None of these SNPs 
reached the pre-defined significance threshold of 8.7 x10-4 (Supplementary
table 3)
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Table 2: Univariate analysis of the covariates
Variable N P-value
Gender 534 0.57
Age at time of transplantation 534 <0.001
Investigation site 534 0.73
Tacrolimus levels 534 <0.001
Concomitant medication 534 0.60
Year of transplantation 534 0.06
Albumin levels 73 <0.001
Hematocrite levels 461 <0.001
CRP levels 25 0.06
Converted to CsA 534 0.52
Weight 196 <0.001
Height 502 <0.001
Height 406 0.11
Table 3: Genetic association results
Chr Position Gene SNP Genotype counts N obs Estimate SE P-value of
additive
genetic
effect*
Minor 
homozygous
Heterozygous Major 
Homozygous
4 89052323 ABCG2 rs2231142 4 22 91 432 11.43 6.60 0.09
4 154626317 TLR2* rs5743708 0 6 111 432 -54.72 16.34 0.001
7 81700000 ABCB1 
-1236
rs1128503 23 57 37 432 -2.65 4.91 0.59
7 81701000 ABCB1 
-2677
rs2032582 24 53 39 431 -3.24 4.75 0.50
7 81702000 ABCB1 
-3435
rs1045642 36 49 32 432 5.74 4.50 0.21
7 99270539 CYP3A5 rs776746 6 16 95 432 -0.23 6.46 0.97
10 101611294 ABCC2 rs8187710 0 13 104 432 -12.65 10.66 0.24
11 2857194 KCNQ1* rs2237895 22 51 44 432 -11.06 4.44 0.014
21 28240574 ABCB1* 
-1199
rs229109 11 51 55 432 10.64 5.12 0.040
22 36661906 APOL1** rs73885319 1 2 111 432 52.32 13.13 0.0001
Adjusted for gender, age at transplant, site, tacrolimus level, hematocrit level, and height. Positions based on 
Genome Build Version 37.1. 
* Significance threshold = 0.05 
**Significance threshold = 0.00087;
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Discussion
We evaluated the prevalence of renal failure and potential genetic risk 
factors for renal function decline in pediatric heart transplant population 
and found a 34.2% cumulative incidence of CKD stages 3-5, with 7 
patients (4.3%) experiencing CKD stage 4 and one patient (0.6%) CKD 
stage 5. In our recent review of the pediatric literature the prevalence 
of moderate-severe renal failure (CKD stages 3-5) ranged from 6.8% to 
46% and that of mild renal failure (CKD stages 2-5) from 22.7% to 40%.8 
The cumulative incidence of CKD stages 4-5 was much lower than the 
18% reported by Ojo et al in adult heart transplant patients.2 
The prevalence of CKD stages 3-5 at one year post-transplantation was 
2.9% and the 1.7% prevalence of CKD stages 3-5 at five years  were both 
lower compared to previous reports.8 The prevalence of renal dysfunction 
reported in the Registry Reports of the International Society for Heart 
and Lung Transplantation from 2006 and 2010 was 10% at 5 and 10 years 
post-transplantation.3,4 The discrepancy with our findings may be due to 
SNP Visit N eGFR
Wildtype Heterozygotes Homozygotes
APOL1 G1
(rs73885319)
1 week 54 102.7±47..3 318.2*
1 month 68 113.0±43.8 141.6±33.8 321.1*
3 months 51 124.9±47.7 126.3*
6 months 28 131.5±47.4
9 months 29 113.8±40.3 328.8*
1 year 73 128.8±45.8 266.2*
2 years 57 139.4±42.0 138.2* 278.7*
3 years 50 137.8±27.3 114.6* 309.5*
4 years 35 133.9±33.8 258.0*
5 years 25 134.1±28.7
6 years 19 132.7±31.6
7 years 17 132.5±19.1
8 years 15 135.7±36.9
9 years 10 139.8±17.3
10 years 3 128.9±9.5
Table 4: eGFR values for each visit by genotype
* Only one patient available
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a higher proportion of patients receiving cyclosporine than tacrolimus 
in the Registry Reports. Other than previous reports, we established the 
cumulative incidence of renal failure as well as the prevalence of renal 
failure at several time points. Throughout the study period, the eGFR 
and eGFR z-scores were stable. However, several patients had already 
developed mild CKD (stage 2) early after transplantation, which persisted 
throughout the study period. Only few patients experienced CKD stage 
4 or 5 throughout the study period. We conclude that although the 
cumulative incidence was high, most patients experienced mild CKD. 
One polymorphism met our significance threshold corrected for multiple 
testing; APOL1 G1 (rs73885319). Our results showed a positive association
of APOL1 G1 with eGFR. Yet, only one patient was homozygous for the 
APOL1 G1 allele and two patients were heterozygous. Therefore, the 
effect of APOL1 G1 may be considered to be a patient-related factor rather 
than a genetic-related factor. Future studies with a higher allele frequency 
for APOL G1 may elucidate this finding. Three other SNPs (TLR2 R753Q, 
KCNQ1 rs2237895 and ABCB1 G1199T/A) were associated with eGFR at the 
significance level of 0.05. These findings were probably due to chance as 
the significance threshold for multiple testing was not reached. 
In contrast to results in adult heart transplant recipients, we failed to 
show an association between CYP3A5 genotype and renal function.13 
This may be explained by differences in population characteristics and 
immunosuppressive regimens. Nonetheless, the association reported 
by De Denus et al13 is surprising as the majority of the patients received 
cyclosporine as immunosuppressive therapy and CYP3A5 does not ap-
pear to play a major role in the metabolism of cyclosporine. The lack of 
associations in our study are similar to those reported in both adults and 
children,15,18 but these studies pooled patients treated with tacrolimus 
together with those treated with cyclosporine. We are the first to include 
a large number of potential relevant SNPs in the analysis. 
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Our study has several limitations, of which the limited with sample size is the 
most important as it may obscure subtle genetic effects on renal function. 
The study design was retrospective and included a candidate gene 
approach, limiting the data set to the available information in medical 
records and the identification of genetic risk factors to those genes the 
investigators thought important. A Genome Wide Association Study could 
reveal different candidates never before associated with renal failure. 
The use of eGFRs may underestimate the extent of renal failure following 
pediatric heart transplant recipients, as the Schwartz formula is known to 
overestimate GFR by approximately 20%.36 Indeed, in 91 pediatric heart 
transplant recipients the Schwartz formula overestimated the measured 
GFR (99mTc DTPA method) by 33 ± 26 ml/min/1.73m2.37 This difference 
is approximately equal to one severity group higher on the CKD KDOQI 
classification. Therefore, measured GFR values are preferable, although 
this is an invasive procedure requiring a full day at the hospital. As this is 
quite burdensome it is not routinely done in clinical practice. 
 
In conclusion, we showed that one third of the pediatric heart transplant 
patients experienced CKD stages 3-5, at least 3 months after transplant 
at two consecutive time points, which may present an important clinical 
problem. However, only few experienced CKD stage 4 or 5. None of the 
SNPs studied were significantly associated with renal function. 
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Supplementary Table 1: All SNPs analyzed
Chr Position Gene SNP
1 60392494 C1orf87/CYP2J2 rs890293
1 162030688 OLFML2B/NOS1AP rs10918594
1 184911126 PTGS2 rs4648279
1 186643541 PTGS2 rs3218625
1 186643836 PTGS2 rs5272
1 186643837 PTGS2 rs5273
1 186650751 PTGS2/PLA2G4A rs689466
1 186646004 PTGS2 rs3218622
1 206946407 IL19/IL10 rs1800872
1 206946634 IL19/IL10 rs1800871
1 206946897 IL19/IL10 rs1800896
1 223285200 TLR5 rs5744168
2 228052600 COL4A3 rs2204862
2 234669144 UGT1A1 rs4148323
2 241542703 CAPN10 rs5030952
3 52261031 TWF2/TLR9 rs187084
3 119500035 NR1I2 rs3814055
3 119533733 NR1I2 rs6785049
3 119534153 NR1I2 rs2276707
3 119537254 NR1I2 rs3814057
3 121838319 CD86 rs1129055
4 38799710 TLR1 rs4833095
4 38800214 TLR1 rs5743611
4 38830350 TLR6 rs5743810
4 89052323 ABCG2 rs2231142
4 123377980 IL21/IL2 rs2069762
4 154626317 TLR2 rs5743708
4 187004074 TLR3 rs3775291
6 31241109 HLA-C rs13191343
6 31543031 TNF/LTA rs1800629
6 32809848 PSMB8 rs9357155
6 32811629 PSMB8 rs2071543
6 43736389 MRPS18A/VEGFA rs699947
6 43737830 VEGF rs1570360
6 90032942 UBE2J1/GABRR2 rs2064831
7 22766645 IL6/LOC541472 rs1800795
7 75615006 POR rs1057868
7 81700000 ABCB1 rs1128503
7 81701000 ABCB1 rs2032582
7 81702000 ABCB1 rs1045642
7 87133470 ABCB1 rs17064
7 87230193 ABCB1 rs3213619
Chr Position Gene SNP
7 99102509 CYP3A5 rs55965422
7 99194259 CYP3A4 rs17161886
7 99245013 ZNF498/CYP3A5 rs4646458
7 99245080 ZNF498/CYP3A5 rs4646457
7 99245914 CYP3A5 rs15524
7 99247772 CYP3A5 rs41279854
7 99250393 CYP3A5 rs41303343
7 99258139 CYP3A5 rs28383479
7 99262835 CYP3A5 rs10264272
7 99270539 CYP3A5 rs776746
7 99273821 CYP3A5 rs55817950
7 99325882 CYP3A7 rs2687136
7 99354114 CYP3A4/CYP3A7 rs12333983
7 99356324 CYP3A4 rs17161886
7 99358524 CYP3A4 rs4986910
7 99360870 CYP3A4 rs4646440
7 99365451 CYP3A4 rs2687117
7 99365983 CYP3A4 rs55785340
7 99366316 CYP3A4 rs35599367
7 99382096 CYP3A4/CYP3A43 rs2740574
7 99388017 CYP3A4/CYP3A43 rs2687102
8 139746208 COL22A1 rs4588898
9 120475302 TLR4 rs4986790
9 120475602 TLR4 rs4986791
9 125133507 PTGS1 rs3842787
9 125140241 PTGS1 rs3842789
9 125143707 PTGS1 rs3842792
9 125143973 PTGS1 rs5789
9 125148791 PTGS1 rs5791
9 125152507 PTGS1 rs5792
9 125152579 PTGS1 rs5793
10 90749963 FAS/ACTA2 rs1800682
10 96798749 CYP2C8 rs10509681
10 96818119 CYP2C8 rs1058930
10 101542578 ABCC2 rs717620
10 101611294 ABCC2 rs8187710
11 2857194 KCNQ1 rs2237895
11 2870108 KCNQ1 rs8234
11 17460712 ABCC8 rs2237982
11 112034988 TEX12/IL18 rs187238
11 112035458 IL18/TEX12 rs1946518
12 21329738 SLCO1B1 rs2306283
Chr Position Gene SNP
12 21331549 SLCO1B1 rs4149056
12 68552522 IFNG rs2430561
12 79481371 SYT1 rs12300068
16 31104878 VKORC1 rs9934438
17 32579788 ACCN1/CCL2 rs1024611
19 41858921 TGF-beta rs1800470
21 28240574 ADAMTS5/ADAMTS1 rs229109
22 35775889 HO-1 rs3761439
22 35776672 HMOX1/TOM1 rs2071746
22 36661906 APOL1 rs73885319
22 36662046 APOL1 rs71785313
22 36751101 MYH9 rs11089788
22 36774812 MYH9 rs5756168
A total of 19 SNPs had to be removed from 
the analysis; 16 SNPs had a allele frequency 
of 0, two SNPs had more than 5% missing 
genotypes and one SNP completely failed. 
A total of 77 SNPs were included in the 
analysis. 
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Chr Position Gene SNP Minor 
allele
Major 
allele
MAF 
frequency
H-W
 p-value
H-W
Exact 
p-value
1 60392494 C1orf87/CYP2J2 rs890293 C A 0.0828 0.294514598 0.2523
1 162030688 OLFML2B/NOS1AP rs10918594 G C 0.3854 0.85275999 1
1 186643541 PTGS2 rs3218625 G A 0.0016
1 186650751 PTGS2/PLA2G4A rs689466 A G 0.1783 0.266723957 0.3508
1 206946407 IL19/IL10 rs1800872 C A 0.3051 0.892703129 1
1 206946634 IL19/IL10 rs1800871 G A 0.2833 0.224341594 0.3039
1 206946897 IL19/IL10 rs1800896 A G 0.3965 0.469494315 0.5694
1 223285200 TLR5 rs5744168 G A 0.0462 0.49124341 1
2 228052600 COL4A3 rs2204862 A G 0.0971 0.677391602 1
2 234669144 UGT1A1 rs4148323 G A 0.0097 0.96264964 1
2 241542703 CAPN10 rs5030952 G A 0.0127 0.925707324 1
3 52261031 TWF2/TLR9 rs187084 A G 0.3706 0.976596504 1
3 119500035 NR1I2 rs3814055 G A 0.4045 0.968185753 1
3 119533733 NR1I2 rs6785049 A G 0.4395 0.505925593 0.5728
3 119534153 NR1I2 rs2276707 G A 0.2086 0.041724997 0.0729
3 119537254 NR1I2 rs3814057 A C 0.2245 0.006540498 0.0086
3 121838319 CD86 rs1129055 G A 0.2659 0.072277541 0.0959
4 38799710 TLR1 rs4833095 A G 0.3567 0.391351606 0.5236
4 38800214 TLR1 rs5743611 G C 0.0717 0.524598008 1
4 38830350 TLR6 rs5743810 G A 0.2946 0.797272822 0.84
4 89052323 ABCG2 rs2231142 C A 0.1067 0.085807717 0.0888
4 123377980 IL21/IL2 rs2069762 A C 0.3419 0.375008162 0.4317
4 154626317 TLR2 rs5743708 G A 0.0239 0.775913232 1
4 187004074 TLR3 rs3775291 G A 0.2771 0.888283895 1
6 31543031 TNF/LTA rs1800629 G A 0.1576 0.953675674 1
6 32809848 PSMB8 rs9357155 G A 0.1178 0.603041666 0.6329
6 32811629 PSMB8 rs2071543 C A 0.1338 0.446390914 0.4219
6 43736389 MRPS18A/VEGFA rs699947 C A 0.4729 0.641539871 0.7136
6 90032942 UBE2J1/GABRR2 rs2064831 A G 0.1736 0.629176447 1
7 22766645 IL6/LOC541472 rs1800795 C G 0.3057 0.336271939 0.4201
7 81700000 ABCB1 ABCB1-1236CT-
r1128503
G A 0.4618 0.90111287 1
7 81701000 ABCB1 ABCB1-2677GT-
r2032582
C A 0.4537 0.446590836 0.4563
7 81702000 ABCB1 ABCB1-3435CT-
r1045642
A G 0.4984 0.080819886 0.0928
7 87133470 ABCB1 rs17064 A T 0.0685 0.49124341 1
7 87230193 ABCB1 rs3213619 A G 0.0398 0.775913232 1
7 99245013 ZNF498/CYP3A5 rs4646458 A C 0.1006 0.599685701 0.4655
7 99245080 ZNF498/CYP3A5 rs4646457 A C 0.1592 0.000147298 0.0013
Supplementary Table 2: Hardy-Weinberg equilibrium
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Chr Position Gene SNP Minor 
allele
Major 
allele
MAF 
frequency
H-W
 p-value
H-W
Exact 
p-value
7 99245914 CYP3A5 rs15524 A G 0.1513 0.106817362 0.1181
7 99262835 CYP3A5 rs10264272 G A 0.0048 0.925707324 1
7 99270539 CYP3A5 rs776746 G A 0.1534 0.000147298 0.0016
7 99325882 CYP3A7 rs2687136 A G 0.1656 0.364329751 0.2901
7 99354114 CYP3A4/CYP3A7 rs12333983 A T 0.1789 0.026959652 0.0431
7 99356324 CYP3A4 rs17161886 A C 0.0239 1.58455E-12 0
7 99358524 CYP3A4 rs4986910 A G 0.0048
7 99360870 CYP3A4 rs4646440 G A 0.0525 0.850785939 1
7 99365451 CYP3A4 rs2687117 G A 0.0143 0.850785939 1
7 99366316 CYP3A4 rs35599367 G A 0.0430 0.49124341 1
7 99382096 CYP3A4/CYP3A43 rs2740574 A G 0.0605 0.000370758 0.0099
7 99388017 CYP3A4/CYP3A43 rs2687102 A G 0.0127 0.888283895 1
8 139746208 COL22A1 rs4588898 G A 0.2946 0.399086195 0.4975
9 120475302 TLR4 rs4986790 A G 0.0764 0.312063228 1
9 120475602 TLR4 rs4986791 G A 0.0701 0.367382156 1
9 125133507 PTGS1 rs3842787 G A 0.0462 0.510901745 0.4255
9 125143707 PTGS1 rs3842792 A C 0.0016
9 125143973 PTGS1 rs5789 C A 0.0239 0.850785939 1
10 90749963 FAS/ACTA2 rs1800682 A G 0.4857 0.316701146 0.3491
10 96798749 CYP2C8 rs10509681 A G 0.0876 0.613470663 1
10 96818119 CYP2C8 rs1058930 C G 0.0494 0.003880649 0.0343
10 101542578 ABCC2 rs717620 G A 0.2045 0.041724997 0.073
10 101611294 ABCC2 rs8187710 G A 0.0717 0.524598008 1
11 2857194 KCNQ1 rs2237895 A C 0.4204 0.297820652 0.339
11 2870108 KCNQ1 rs8234 A G 0.3574 0.469593802 0.5597
11 17460712 ABCC8 rs2237982 G A 0.4061 0.033352558 0.038
11 112034988 TEX12/IL18 rs187238 C G 0.2468 0.329778441 0.4502
11 112035458 IL18/TEX12 rs1946518 C A 0.3965 0.786839966 0.8397
12 21329738 SLCO1B1 rs2306283 A G 0.4475 0.227416861 0.2526
12 21331549 SLCO1B1 rs4149056 A G 0.1369 0.30566877 0.3786
12 68552522 IFNG rs2430561 A T 0.4405 0.801878879 0.8566
12 79481371 SYT1 rs12300068 G A 0.1354 0.455403676 0.4824
16 31104878 VKORC1 rs9934438 G A 0.4153 0.617298743 0.7017
17 32579788 ACCN1/CCL2 rs1024611 A G 0.3408 0.605177623 0.6956
21 28240574 ADAMTS5/ADAMTS1 rs229109 G A 0.3041 0.867700558 1
22 35776672 HMOX1/TOM1 rs2071746 T A 0.4441 0.453426626 0.5772
22 36661906 APOL1 rs73885319 A G 0.0143 1.07086E-07 0.0263
22 36662046 APOL1 rs71785313 A T 0.0048 0.925707324 1
22 36751101 MYH9 rs11089788 C A 0.4459 0.617478246 0.705
22 36774812 MYH9 rs5756168 A G 0.1146 0.603041666 0.6396
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Table 3: Genetic associations renal transplant recipients
Chr Position Gene SNP Genotype counts N obs Estimate SE P-value of
additive
genetic
effect*
Minor 
homozygous
Heterozygous Major 
Homozygous
1 60392494 C1orf87/CYP2J2 rs890293 2 18 97 432 -2.17 7.74 0.78
1 162030688 OLFML2B/NOS1AP rs10918594 18 57 42 432 4.12 4.91 0.40
1 186643541 PTGS2 rs3218625 0 0 117 432 0
1 186650751 PTGS2/PLA2G4A rs689466 2 38 77 432 -6.70 6.49 0.30
1 206946407 IL19/IL10 rs1800872 8 46 62 431 -4.24 5.46 0.44
1 206946634 IL19/IL10 rs1800871 4 45 62 407 -5.95 6.33 0.35
1 206946897 IL19/IL10 rs1800896 17 60 40 432 7.19 4.94 0.15
1 223285200 TLR5 rs5744168 0 14 103 432 9.34 10.69 0.38
2 228052600 COL4A3 rs2204862 1 24 92 432 -6.41 7.57 0.40
2 234669144 UGT1A1 rs4148323 0 1 114 428 -35.51 34.40 0.30
2 241542703 CAPN10 rs5030952 0 2 115 432 -2.83 24.59 0.91
3 52261031 TWF2/TLR9 rs187084 17 55 45 432 1.46 5.00 0.77
3 119500035 NR1I2 rs3814055 20 57 40 432 6.10 4.92 0.22
3 119533733 NR1I2 rs6785049 24 54 39 432 5.25 4.97 0.29
3 119534153 NR1I2 rs2276707 8 30 79 432 7.31 5.80 0.21
3 119537254 NR1I2 rs3814057 10 29 78 432 5.95 5.51 0.28
3 121838319 CD86 rs1129055 12 38 67 432 4.48 4.85 0.36
4 38799710 TLR1 rs4833095 10 55 52 432 -1.07 5.30 0.84
4 38800214 TLR1 rs5743611 0 13 104 432 -6.61 11.07 0.55
4 38830350 TLR6 rs5743810 15 52 50 432 -4.47 4.99 0.37
4 89052323 ABCG2 rs2231142 4 22 91 432 11.43 6.60 0.09
4 123377980 IL21/IL2 rs2069762 13 58 45 428 -1.51 5.37 0.78
4 154626317 TLR2* rs5743708 0 6 111 432 -54.72 16.34 0.0011
4 187004074 TLR3 rs3775291 9 48 60 432 5.37 5.52 0.33
6 31543031 TNF/LTA rs1800629 3 32 82 432 6.00 6.76 0.38
6 32809848 PSMB8 rs9357155 2 22 93 432 -1.57 7.42 0.83
6 32811629 PSMB8 rs2071543 3 25 89 432 -2.65 6.76 0.70
6 43736389 MRPS18A/VEGFA rs699947 27 61 29 432 -3.26 4.95 0.51
6 90032942 UBE2J1/GABRR2 rs2064831 3 36 78 432 -7.18 6.30 0.26
7 22766645 IL6/LOC541472 rs1800795 12 58 47 432 1.38 5.33 0.80
7 81700000 ABCB1 ABCB1-
1236CT-
r1128503
23 57 37 432 -2.65 4.91 0.59
7 81701000 ABCB1 ABCB1-
2677GT-
r2032582
24 53 39 431 -3.24 4.75 0.50
7 81702000 ABCB1 ABCB1-
3435CT-
r1045642
36 49 32 432 5.74 4.50 0.21
7 87133470 ABCB1 rs17064 0 14 103 432 13.90 10.82 0.20
7 87230193 ABCB1 rs3213619 0 6 111 432 4.33 16.11 0.79
7 99245013 ZNF498/CYP3A5 rs4646458 1 15 101 432 1.06 8.82 0.90
7 99245080 ZNF498/CYP3A5 rs4646457 6 16 95 432 -0.23 6.46 0.97
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Chr Position Gene SNP Genotype counts N obs Estimate SE P-value of
additive
genetic
effect*
Minor 
homozygous
Heterozygous Major 
Homozygous
7 99245914 CYP3A5 rs15524 3 19 95 432 -4.65 7.47 0.53
7 99262835 CYP3A5 rs10264272 0 2 115 432 4.94 42.91 0.91
7 99270539 CYP3A5 rs776746 6 16 95 432 -0.23 6.46 0.97
7 99325882 CYP3A7 rs2687136 2 19 96 432 -3.17 8.08 0.70
7 99354114 CYP3A4/CYP3A7 rs12333983 4 19 94 432 -0.47 6.73 0.94
7 99356324 CYP3A4 rs17161886 3 3 111 432 13.71 9.47 0.15
7 99358524 CYP3A4 rs4986910 0 0 117 432 0
7 99360870 CYP3A4 rs4646440 0 4 113 432 -23.04 18.09 0.21
7 99365451 CYP3A4 rs2687117 0 4 113 432 0.90 21.34 0.97
7 99366316 CYP3A4 rs35599367 0 14 103 432 -5.69 11.39 0.62
7 99382096 CYP3A4/CYP3A43 rs2740574 3 10 104 432 -12.41 8.95 0.17
7 99388017 CYP3A4/CYP3A43 rs2687102 0 3 114 432 -12.38 24.14 0.61
8 139746208 COL22A1 rs4588898 8 52 57 432 5.75 5.47 0.30
9 120475302 TLR4 rs4986790 0 20 97 432 9.34 8.79 0.29
9 120475602 TLR4 rs4986791 0 18 99 432 5.12 9.04 0.57
9 125133507 PTGS1 rs3842787 1 14 102 432 -2.70 8.76 0.76
9 125143707 PTGS1 rs3842792 0 0 117 432 0
9 125143973 PTGS1 rs5789 0 4 113 432 5.49 17.75 0.76
10 90749963 FAS/ACTA2 rs1800682 20 63 34 432 6.19 5.00 0.22
10 96798749 CYP2C8 rs10509681 1 25 91 432 2.26 7.50 0.76
10 96818119 CYP2C8 rs1058930 2 9 106 432 -0.88 9.30 0.92
10 101542578 ABCC2 rs717620 8 30 79 432 -1.64 5.44 0.76
10 101611294 ABCC2 rs8187710 0 13 104 432 -12.65 10.66 0.24
11 2857194 KCNQ1* rs2237895 22 51 44 432 -11.06 4.44 0.014
11 2870108 KCNQ1 rs8234 18 51 48 432 1.33 4.89 0.79
11 17460712 ABCC8 rs2237982 27 46 44 432 -0.16 4.46 0.97
11 112034988 TEX12/IL18 rs187238 5 47 65 432 4.21 5.97 0.48
11 112035458 IL18/TEX12 rs1946518 18 54 45 432 0.10 4.93 0.98
12 21329738 SLCO1B1 rs2306283 25 51 41 432 5.95 4.65 0.20
12 21331549 SLCO1B1 rs4149056 3 23 91 432 -3.45 6.70 0.61
12 68552522 IFNG rs2430561 22 59 36 432 3.09 5.07 0.54
12 79481371 SYT1 rs12300068 4 29 84 432 -4.21 6.33 0.51
16 31104878 VKORC1 rs9934438 21 54 42 432 -5.08 4.69 0.28
17 32579788 ACCN1/CCL2 rs1024611 16 51 50 432 -0.21 5.03 0.97
21 28240574 ADAMTS5/ADAMTS1* rs229109 11 51 55 432 10.64 5.12 0.040
22 35776672 HMOX1/TOM1 rs2071746 20 61 35 431 2.39 4.95 0.63
22 36661906 APOL1** rs73885319 1 2 111 432 52.32 13.13 0.0001
22 36662046 APOL1 rs71785313 0 2 115 432 -27.18 26.84 0.31
22 36751101 MYH9 rs11089788 24 55 38 432 1.58 4.71 0.74
22 36774812 MYH9 rs5756168 2 22 93 432 2.08 7.57 0.78
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Abstract 
Background Urinary neutrophil gelatinase-associated lipocalin 
(uNGAL) is a promising biomarker to monitor acute kidney injury (AKI). 
However, the pattern of uNGAL levels in the first 14 days after pediatric 
transplantation is not known. We aimed to describe the pattern of uNGAL 
levels in this population.
Method In this pilot study, we evaluated daily uNGAL, lnNGAL and 
uNGAL/Cr levels up to 14 days in 10 kidney (KT) and 12 liver transplant 
recipients (LT) receiving tacrolimus. uNGAL cut-offs of 2.2 and 135 ng/
ml were used, as previously found in healthy children (<2.2 ng/ml) and 
children at risk for AKI (>135 ng/ml). 
Results In KT recipients, the median uNGAL level was 14.9 (IQR: 29.6) ng/
ml and the median uNGAL/Cr level 161.3 (IQR: 294.1) ng/mg. Sixty-two 
of the uGNAL measurements (92.5%) were above the 2.2 ng/ml and 
three (4.5%) in two KT patients were above 135 ng/ml. All KT patients 
had an uNGAL >2.2 ng/ml at least once during the first 14 days after 
transplantation. In LT recipients, the median uNGAL level was 13.6 (IQR: 
21.9) ng/ml and the median uNGAL/Cr level 43.6 (IQR: 96.8) ng/mg. 
Ninety percent of all uNGAL measurements were above the 2.2 ng/ml. 
Seven uNGAL measurements (7%) in two LT patients were above the 
uNGAL 135 ng/ml. 
Conclusion This is the first study in pediatric solid organ transplant 
recipients reporting uNGAL levels up to 14 days post-transplantation. 
Most liver and kidney recipients have higher than normal uNGAL levels, 
but infrequently uNGAL levels that were previously associated with AKI. 
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Introduction
Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein 
and member of the lipocalin superfamily. It is bound to gelatinase from 
neutrophils and expressed at low levels in the human kidney, lung and 
gastro-intestinal tract.1,2 Serum NGAL is scarcely excreted in the urine as 
it is filtered by the glomerulus but then captured by the proximal tubule. 
Urinary NGAL is produced in the thick limbs of Henle and the collecting 
ducts and exclusively excreted in the urine.3,4,5 The synthesis of NGAL is 
markedly induced in injured proximal tubular epithelial cells.3,6  
Urinary NGAL can be detected early after transplant surgery. In adult 
kidney transplant (KT) recipients, uNGAL appears to be a good predictor 
of delayed graft function (OR = 5.1)7 or acute rejection (ROCAUC = 0.98).
8 
In adult liver transplant (LT) recipients the uNGAL/urinary creatinine 
ratios appears to correlate with the occurrence of Acute Kidney 
Injury (AKI) within a few hours post-transplantation.9,10 This mechanism 
suggests a role for NGAL following AKI, where the initial damage is targeted 
to the renal tubules. A previous animal study has shown that NGAL can 
be detected in the urine within 2 hours following ischemic kidney injury.3 
In children undergoing cardiopulmonary bypass surgery for congenital 
heart disease, uNGAL at 2 hours post surgery was an independent 
predictor for AKI.11,12,13,14 Additionally, the increase in uNGAL was more 
pronounced at 4 hours (25-fold) and 6 hours (26-fold) after surgery in 
patients who developed AKI.12 The odds ratio (OR) for AKI increased 
by 32% for every 10 ng/ml increase in 2-hour uNGAL (OR:  1.32).13 
Furthermore, pediatric septic patients had a higher mean and peak 
uNGAL concentration than patients without sepsis.14
With regard to pediatric transplant recipients even fewer data are available. 
In pediatric, deceased donor, KT recipients (8-19 yrs) NGAL staining 
of the kidney transplant appears to be an early predictor for kidney 
failure.15 NGAL staining intensity was significantly associated with both peak 
post-transplant SCr levels and dialysis requirements 2-3 days post- 
transplantation.15 Furthermore, every 100 ng/mg increase in uNGAL/Cr in 
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the first 24 hours after KT was associated with a 20% increase in the odds 
of delayed graft function in a mixed population of adults and children.16 
In 79 pediatric heart transplant recipients at least 3 months post- 
transplantation with chronic kidney disease, 87% had an uNGAL level above 
2.2 ng/ml17 a level considered as the cut-off value in healthy children.11
Hence, a possible relationship between early uNGAL levels and the renal 
outcome of the patients has been reported. However, no study looking 
into patterns and reference levels of uNGAL has been done in pediatric 
liver or kidney transplant recipients up to 14 days post-transplantation. 
Therefore, the aim of this pilot study was to determine the pattern of 
uNGAL concentrations in this population.
 
Methods 
Patients and setting
This was a prospective cohort study approved by the Institutional Research 
Ethics Board of the Hospital for Sick Children, Toronto, Ontario, Canada. 
This study was conducted in accordance with the ethical standards of the 
Helsinki Declaration. Patients were eligible for participation if they were 
0-18 years of age at the time of their liver or kidney transplantation and 
if they received tacrolimus during the first 14 days following transplanta-
tion. This study was done in the Intensive Care Unit of the Hospital for Sick 
Children, Toronto, Ontario, Canada. Informed consent was obtained from 
all parents/legal guardians and/or children. 
Immunosuppressive protocol
The transplant physician started all patients on tacrolimus, methyl- 
prednisolone and mycophenolate mofetil (MMF). The tacrolimus starting 
dose was 0.1 mg/kg orally twice daily for all patients. Therapeutic drug 
monitoring was used to adjust the tacrolimus dose to a target level of 
10-15 ng/ml for both liver and kidney transplant recipients within the 
first two weeks after transplantation. Methylprednisolone (10 mg/kg) was 
intravenously administered at the time of graft reperfusion and gradually 
tapered after transplant. The use of induction therapy was left to the 
discretion of the attending physician. 
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Clinical data collection
All data were collected up to 14 days post-transplantation or for the 
duration of hospital stay in case a patient was discharged home before 
week 2. Patient’s age, sex, weight, transplant type, tacrolimus dose 
and co-medication as well as SCr and tacrolimus concentrations were 
retrieved from the electronic patient chart. Urine aliquots (10ml) were 
taken daily (when practically feasible) from 24-hour urine collections for 
urinary NGAL (ng/ml) and urinary creatinine (mmol/L) for up to 14 days 
post-transplantation. 
Laboratory measurements
Urine was stored at -80°C until urinary NGAL levels were determined using 
the NGAL kit from Abbott on an ARCHITECT® analyzer (Abbott Diagnostics, 
USA) at the Department of Clinical Chemistry, Erasmus MC, Rotterdam, 
the Netherlands. Tacrolimus blood concentrations were determined 
in ethylenediaminetetraacetic acid (EDTA)-treated whole blood (0.25 
ml) on the day of sampling, using liquid chromatography tandem mass 
spectrometry (LC-MS-MS) as previously described.18 Serum and 
urinary creatinine concentrations were measured by the hospital clinical 
laboratory. 
Statistical analyses
Data are presented as mean plus standard deviation in case of a Normal 
distribution or as medians plus interquartile range (IQR) when data were 
not normally distributed. We determined the proportion of samples and 
patients with an uNGAL level above 2.2 ng/ml, which was reported to be 
the upper level of the healthy pediatric population.17 A cut-off of >135.0 
ng/ml was used to determine the proportion of patients with an increased 
risk of developing AKI.19 Even though this cut-off value was established 
with an ELISA assay in children, no cut-off value for children is known for 
the ARCHITECT assay. To establish a cut-off for the ARCHITECT assay we 
have used the formula by Grenier et al which resulted in a cut-off >129.8 
ng/ml.20 Groups were compared by using the Chi-square test. All analyses 
were done using PASW 20.0 software (IBM, Chicago, IL, USA). 
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Results
Liver transplant recipients 
Twelve LT recipients (5 male, 7 female) with a median age at the time of 
transplant of 5.5 (IQR: 14.8) years and a median weight of 20.4 (IQR: 43.1) 
kg were included in the study (Table 1). By day 14, ten patients had been 
discharged. Three patients received basiliximab and one patient received 
thymoglobulin.
The median uNGAL level was 13.6 (IQR: 21.9) ng/ml (Figure 1A), the 
median uNGAL/Cr level 43.6 (IQR: 96.8) ng/mg up to 14 days after trans-
plantation. The daily NGAL levels can be found in Table 2a and Figure 1. 
On day 2, 3 and 6, NGAL levels were available for 9 out of the 12 patients. 
On day 2, 3 and 6; the median uNGAL levels were 12.1 (IQR: 16.2) ng/ml, 
9.8 (IQR: 22.8) ng/ml and 13.8 (41.0) ng/ml, respectively.
Table 1: Demographics of the patients
Variable All
(n=22)
Liver
(n=12)
Kidney
(n=10)
Gender (M/F) 13/9 5/7 8/2
Age at time of transplant (years) 15.3 (IQR: 15.6) 5.5 (IQR: 14.8) 17.1 (IQR: 8.9)
Weight (kg) 28.0 (IQR: 44.1) 20.4 (IQR: 43.1) 43.0 (IQR: 45.3)
Days in ICU (days) 3.0 (IQR: 4.5) 5.0 (IQR: 8.3) 2.5 (IQR: 2.5)
Primary diagnosis
Biliary atresia 5 (22.7%) 5 (41.7%) -
Genetic 3 (25.0%) 2 (16.7%) 1 (10.0%)
Auto-immune 3 (25.0%) 2 (16.7%) 1 (10.0%)
Hepatoblastoma 1 (4.5%) 1 (8.3%) -
Congenital 2 (9.0%) - 2 (20.0%)
Glomerulonephritis 1 (4.5%) - 1 (10.0%)
Unknown 1 (4.5%) - 1 (10.0%)
Nephropathy 4 (18.2%) - 4 (40.0%)
Donor
Deceased 15 (68.2%) 12 (100.0%) 3 (30.0%)
Living-related 3 (13.6%) 0 (0.0%) 3 (30.0%)
Unknown 4 (18.2%) 4 (40.0%)
Retransplantation (yes/no) 1/22 0/12 1/10
All data are presented as median and interquartile range (IQR), unless noted otherwise. 
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Within the study period 90% of all uNGAL measurements (90/100) were 
above 2.2 ng/ml. All patients (100%) had an increased uNGAL (> 2.2 ng/
ml) at least once during the first 14 days after transplantation. 
No significant difference in having increased serum creatinine levels was 
found between the groups with or without uNGAL levels above 2.2 ng/ml 
(Χ2 = 0.34, P = 0.73). 
Table 3a: Cut-off levels and increased serum creatinine levels in the liver transplant recipients
Increased Serum Creatinine
uNGAL>2.2 ng/ml Yes No
Yes 3 87
No 0 10
uNGAL >135 ng/ml Yes No
Yes 0 7
No 3 90
Seven uNGAL measurements (7/100) in two patients were above the 
uNGAL cut-off of 135 ng/ml. Patients with or without an uNGAL above 
135 ng/ml were not significantly different in having increased serum 
creatinine concentrations (Χ2 = 0.23, P = 0.80) (Table 3a). As this cut-off 
suggest a high risk of kidney injury, we also looked at the serum creatinin 
levels of these patients. One of these patients experienced uNGAL levels 
above 135 ng/ml on day 7 and 8 with increased serum creatinine levels 
on day 9, 11 and 13. Yet, the second patient did not experience increased 
serum creatinine levels after having increased uNGAL (>135 ng/ml) on 
day 3, 7, 11, 12 and 13. 
To correct for the use of a different assay, we also determined the 
proportion of patients with an uNGAL level >129.8 ng/ml. However, the 
results did not change with this new cut-off. 
Kidney transplant recipients 
We included ten KT recipients (8 male, 2 female) with a median age at 
time of transplantation of 17.1 (IQR: 8.9) years and a median weight of 
43.0 (IQR: 45.3) kg (Table 1). Two patients were still admitted at day 14 
post-transplantation, the other patients had been discharged home. 
Two patients received thymoglobulin. 
uNGAL levels in pediatric kidney and liver transplant recipients | 211 Ch
ap
te
r 1
0
The median uNGAL level was 14.9 (IQR: 29.6) ng/ml (Figure 2C), the 
median uNGAL/Cr level 161.3 (IQR: 294.1) ng/mg and the median lnNGAL 
level was 2.7 (IQR: 1.7) ng/ml for the first 14 days after transplantation. 
On day 4 and 5, NGAL levels for 8 out of the 10 kidney transplant patients 
were available. The daily levels for every day are found in Table 2b and 
Figure 2. On day 4 and 5, the median uNGAL levels were 10.0 (IQR: 22.1) 
ng/ml and 6.5 (IQR: 9.3) ng/ml, respectively. 
Sixty-two of the uGNAL measurements (62/67; 92.5%) were above the 2.2 
ng/ml. One hundred percent of the patients had an uNGAL >2.2 ng/ml at 
least once during the first 14 days after transplantation. Patients with an 
increased serum creatinine did not have an uNGAL above 2.2 ng/ml more 
frequently than patients without an increased serum creatinine (Χ2 = 2.30, 
P = 0.16). Three uNGAL measurements (3/67; 4.5%) in two patients were 
above the 135 ng/ml (Table 3b).These results were also not significantly 
different (Χ2 = 1.34, P = 0.34).
None of the two patients with an increased uNGAL levels (>135 ng/nl) 
showed an increase in serum creatinine levels thereafter. The results did 
not change when using the for assay-corrected uNGAL cut-off of 129.8 
ng/ml. 
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Discussion
This is the first study reporting daily urinary NGAL levels up to 14 days 
post-transplantation in pediatric LT and KT recipients. We present uNGAL 
levels for every day in the first two weeks post-transplantation. In both 
the liver and kidney transplant patients a tentative pattern can be seen 
where the uNGAL levels initially decrease, only to start to increase again 
on day 10 in liver transplant recipients and day 8 in kidney transplant 
recipients. However, due to the limited sample size we have not been able 
to test this pattern statistically. 
All patients had at least one uNGAL level >2.2 ng/ml during the first 
14 days after transplantation, which is similar to the 87% reported by 
Abraham et al. at least 3 months post-transplantation in pediatric heart 
transplant recipients with chronic kidney disease.17 These results show 
that the majority of our patients exhibited increased NGAL levels for 
the first 14 days post-transplantation compared to the healthy pediatric 
population. 
These higher than normal uNGAL levels are not unexpected and may be 
due to pre-existing renal disease,21 systemic or urinary tract infections 
or chronic kidney disease from the native kidneys.22 Furthermore, a liver 
transplantation is a major surgical procedure and associated with hemo-
dynamic changes possibly affecting the kidney that could account for the 
high uNGAL levels right after transplantation.9 
Our results are in line with adult data showing similar uNGAL levels in 
the first week following transplantation.7,8,9,10,16 However, most of the adult 
studies only present data within the first 24 hours, showing high uNGAL 
levels in the immediate post-transplant period. Unfortunately, we only 
had 1 patient with an uNGAL level at day 0 and therefore our results can 
not be compared with the literature. 
As can be seen in figures 1 and 2 two liver and two kidney patients 
experienced high uNGAL levels (>135 ng/ml) in the last couple of days 
of the two week follow-up period. Interestingly, only one liver transplant 
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recipient experienced increased serum creatinine levels following those 
days. We speculate that either, the 135 ng/ml cut-off for AKI may be used 
directly (<6hrs) after transplant but is less useful thereafter, or, that the 
effect of kidney injury, as diagnosed by an increased NGAL level, on 
kidney function as diagnosed by an increase in serum creatinin further 
lags behind than one or three days.
This study has several limitations. The follow-up of our patients was 
only for 14 days limiting the possibility of determining the long-term 
outcome of the patients. Additionally, we were underpowered to conduct 
significant statistical analysis to better elucidate the predictive effect of 
uNGAL (i.e. ROC curves). 
Even though the cut-off of uNGAL used in our population is determined 
by an ELISA assay in the original study,17 we have tried to correct for this by 
converting the cut-off levels by using the formula reported by Grenier et 
al.20 The results did not change by using this new cut-off. Nevertheless, the 
ELISA cut-off determined in the meta-analyses by Haase et al.19 was based 
on studies reporting uNGAL levels within the first 6 hours post-surgery 
to determine the predictive value of uNGAL for renal function during 
follow-up time. Consequently, the predictive value of uNGAL levels 
in the first 14 days post-transplantation still needs to be established. 
Moreover, it would be favourable to have cut-off established by the 
ARCHITECT assay itself as this assay is also one of the assays used in 
clinical laboratories in contrast to the ELISA assays. 
Conclusion
This is the first study in children reporting uNGAL levels in the first 14 days 
post-transplantation. This pilot study shows that a large proportion of 
pediatric LT and KT recipients have higher than normal uNGAL levels, but 
not necessarily above the increased uNGAL level (>135 ng/ml) in the first 
week after transplantation.  
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Personalized tacrolimus therapy in pediatric solid organ 
transplant recipients: current state and future directions.
Solid organ transplantation
With the first successful kidney transplantation in 1954, a new treatment 
for end-stage organ failure was introduced. At this time, transplantation 
is the treatment of choice in adults and children for end-stage organ 
failure.1 
The number of transplantations performed each year is still increasing, 
reaching about a thousand transplantations done in 2011 in Ontario, 
Canada (Trillium Gift of Life reports). At the Hospital for Sick Children in 
Toronto 71 children received a solid organ transplant, with the majority a 
liver or kidney transplant. In the same year in the Netherlands, also about 
a thousand transplantation were done, however, only a small portion 
was done in children (n=25) according to the reports by Eurotransplant 
(www.eurotransplant.org). 
The introduction of immunosuppressive therapy (azathioprine, 
calcineurin inhibitors) has significantly improved the short-term outcome 
of transplant recipients.1 Yet, the long-term outcome (patient and graft 
survival) of pediatric transplant recipients has remained stable.2,3 
Need for research in children
Over the last few decades we have realized that children have different 
needs when administering drugs and they may react different to drugs 
compared to adults.4 However, far less information is available for the 
use of drugs in children compared to the use adults. This lack of evidence 
based knowledge has been recognized internationally, resulting in a 
number of new legislations both in the USA (best pharmaceuticals for 
children act 2007) and in Europe (EMA 2007). Unfortunately, even today, 
off-label and unlicensed use of pediatric drugs is very common.5,6
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Administration of appropriate dose schedules  to children is challenging 
due to the many developmental changes. The different processes involved in 
the absorption of drugs (e.g. gastric pH, gastric emptying, intestinal transit 
time, drug transport and metabolism) have not been extensively studied 
in a  systematic way, but seem to show different developmental patterns.4,7 
In addition, the body composition changes with age, with relatively 
higher water in neonates. Water soluble drugs, such as aminoglycosides, 
need to be dosed higher to reach similar concentrations.4 The amount of 
circulating plasma protein levels in neonates and young infants is lower 
compared to adults, which could lead to a difference in the distribution 
of drugs that are highly protein bound.4 The metabolism of drugs is done 
by Phase I and Phase II metabolizing enzymes. Both groups undergo 
maturation processes that appear to be isoform specific.8,9,10 Due to these 
developmental changes drug metabolism mediated clearance may differ 
among  children as well as the specific metabolites formation.11 
Drugs are eliminated either by renal or bile excretion. The clearance 
of renal cleared drugs is lower in neonates, as both GFR and also renal 
secretion are immature at birth.4
Prescribing and administrating drugs in children is even more complicated 
in patients with complex diseases. Renal failure, hepatic dysfunction and 
cardiac failure may all lead to altered drug clearance and are associated 
with critical illness.12 The inflammatory processes underlying critical illness 
also contribute to the altered drug disposition due to a down regulation 
of major metabolizing enzymes.13 However, data on changes required in 
the drug treatment of these children is lacking.13
In conclusion, simply extrapolating adult dosing guidelines to children 
may expose them to ineffective or drug dose schedules. Hence, it is 
key to study children in addition to adults for the disposition and the 
therapeutic/toxic effects of drugs.14
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Tacrolimus in solid organ transplantation 
Being introduced in 1995,15 tacrolimus (a calcineurin inhibitor) has 
become the drug of choice in pediatric solid organ transplant recipients.2,3 
Although extensively studied in adults, data in children on the disposition 
and effect of tacrolimus in solid organ transplantation are scarce. 
Tacrolimus is a highly protein bound drug with variable absorption rates.15 
It is metabolized by CYP3A4 and CYP3A5, and is a substrate for the efflux 
pump, ABCB1.16 Developmental changes in absorption, distribution and 
metabolism could therefore affect tacrolimus disposition, however, data 
on this is currently lacking. 
Developmental changes do not only impact the way the body handles 
the drug (pharmacokinetics), but also how the drug impacts the body 
(pharmacodynamics). The mechanism of action of tacrolimus involves 
the inhibition of T-cells by blocking the signalling pathway.17 However, 
the immune system also undergoes developmental changes with high 
T-cell levels in the first year of life and decreases afterwards to reach adult 
levels in school children.18 This immunological maturation may also impact 
tacrolimus efficacy. Interestingly, the therapeutic range for tacrolimus has 
never been determined in children of different ages. 
Inter- and Intra-variability in tacrolimus disposition
Genetically driven inter-patient variability has been reported in 
tacrolimus disposition in children (Chapter 4-6).19,20 Intra-patient 
variability further complicates the patient management and increases the 
risk of graft failure or toxicity.17,21 Understanding factors that cause this 
variability will aid in a better management of the individual patient. 
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Tacrolimus disposition in children
Kidney transplant recipients
We previously showed that renal kidney transplant patients younger than 
5 years of age need higher bodyweight-normalized tacrolimus levels 
than older children.19 Also, supra-therapeutic tacrolimus levels have been 
reported more often in older children (<12 years)22 and the tacrolimus 
area under the concentration-time  curve was significantly larger in older 
children compared to children less than 6 years of age.23 Body weight and 
hematocrit levels have also been related to the apparent oral clearance 
(CL/F) of tacrolimus.24,25 
In addition to age, CYP3A5 expressers (CYP3A5*1 allele carriers) have higher 
weight normalized oral clearance, resulting in higher tacrolimus dose re-
quirements to achieve similar tacrolimus trough concentrations,24,19,26,27,28 
and lower tacrolimus trough levels26 compared to CYP3A5 non-expressers 
(CYP3A5*3/*3 carriers).29 In contrast, no relationship has been found for 
CYP3A4*1B, ABCB1 and ABCC2 genotypes and tacrolimus dispositions in 
pediatric kidney recipients.19,25,28 
The effect of age and CYP3A5 genotype in children show an important 
aspect of the dangers in extrapolating adult pharmacogenetic data to 
children. In particular, we showed previously that CYP3A5-expressers 
younger than 5 years of age need four times higher tacrolimus doses 
compared to CYP3A5 non-expressers older than 5 years of age, as for each 
of the factors alone (age or CYP3A5 genotype), the effect is two-fold.19 
The variability in tacrolimus disposition can only partly be explained 
by genetic variation in CYP3A5. Hence, polymorphisms in the gene 
encoding the P450 oxidoreductase (POR) protein that enables the 
activity of CYP enzymes may be of interest. We show (Chapter 6) that 
in addition to the CYP3A5 genotype, the POR*28 allele is also related 
to tacrolimus disposition. CYP3A5-expressers also carrying at least one 
POR*28 allele had on average 18.3% lower tacrolimus trough concen-
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trations and 20.3% lower concentration/dose ratios (C/D) compared 
to CYP3A5-expressers carrying the POR*1/*1 genotype. However, this 
additional influence could not be found in CYP3A5 non-expressers, 
suggesting that an interaction between POR and CYP3A5 is needed to 
show the additional effect of the POR genotype on tacrolimus disposition. 
Heart transplant recipients
Similar to kidney transplant recipients, a significant negative correlation 
exists between age and weight-normalized tacrolimus dosing require-
ments (r2 = -0.447, p = 0.004) and a positive correlation between age and 
the C/D ratio (r2 = 0.351, p = 0.029) in the first 14 days after heart trans-
plantation (Chapter 4). In addition to a confirmation of the influence of 
age, we have also been able to confirm previous findings by Zheng et al.30 
that CYP3A5-expressers needed higher tacrolimus doses (mg/kg) and had 
lower weight-normalized C/D ratios compared to CYP3A5 non-expressers.
An important new finding was the observation that age and CYP3A5 
genotype were independent factors related to tacrolimus disposition. 
No significant effect of the ABCB1 genotype could be found (Chapter 
4).20 In 2010, a novel single nucleotide polymorphism (SNP) in CYP3A4 
(CYP3A4*22) was discovered, associated with decreased CYP3A4 mRNA 
expression and activity.31 We are the first to report that in addition to 
the CYP3A5 genotype, this new SNP also influences tacrolimus dosing 
requirements in (pediatric) heart transplant recipients (Chapter 4). More-
over, when combining the CYP3A4*22 genotype with the CYP3A5 genotype 
the results were more pronounced with poor metabolizers (CYP3A4*1/*22 
and CYP3A5 non-expresser) needing significantly less tacrolimus and 
showed higher C/D ratios compared to intermediate (CYP3A4*1/*1 and 
CYP3A5 non-expresser) and extensive metabolizers (CYP3A4*1/*1 and 
CYP3A5-expresser) and had higher C/D ratios (Chapter 5). The more 
pronounced effect of the combined CYP3A genotypes suggests that 
patients should be screened for these genotypes a priori to estab-
lish a more individualized tacrolimus dosing regimen. The age of the 
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children should also be incorporated into the dosing adaptations to further 
optimize the immunosuppressive treatment of pediatric heart transplant 
recipients. 
Liver transplant recipients 
Similar to pediatric kidney and heart transplant recipients, higher 
body-weight corrected tacrolimus doses are needed in younger (< 5 
years) pediatric liver transplant recipients. These children also show higher 
clearance rates compared to older children.19,32,33 In addition, the apparent
total clearance (CL/F) is higher in pediatric whole liver transplant 
recipients, but decreases with higher aspirate aminotransferase (AST) 
values, and increases with higher gamma-glutamyl transpeptide (GGT) 
values.34 The volume of distribution (L) is negatively affected by the 
body-surface area and the bioavailability negatively affected by total 
bilirubin levels in pediatric liver transplant recipients.32 
The association between the ABCB1 genotype and tacrolimus disposition
is unclear as the functionality of these variants is not completely 
known.16,35 In addition, the mRNA expression of ABCB1 does not seem to 
be influenced by genetic variation in ABCB1.36 Pediatric liver recipients
with CYP3A5*1 carrying donor livers had two-fold higher tacrolimus 
clearance than those with the CYP3A5*3/*3 genotype.36 Yet, no relation-
ship has been found between the recipient’s CYP3A5 genotype and 
tacrolimus disposition.19,36 The donor genetic make-up may be an 
important determinant of tacrolimus disposition in liver transplant 
recipients and it is therefore important to collect donor DNA to determine 
the influence of genetic variation of the donor on tacrolimus disposition. 
For all organs studied, it is obvious that children 1-6 years of age need 
higher tacrolimus doses (per kg) than older children, which is a reflection 
of faster tacrolimus clearance rate. The underlying mechanisms  for this 
observed faster clearance is unclear. It may be related to a relative large 
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liver:body size ratio and age-related changes in drug metabolism.4,37 
The larger liver:body size ratio results in an increased hepatic clearance of 
drugs. This ratio reaches its maximum around 2 to 3 years of age, partially 
explaining the high clearance of drugs in young children.4
Nevertheless, the purative between genotypes and tacrolimus have 
to be taken with caution. As we, and others, have shown, an additive 
effect of CYP3A5 genotype and children’s age in tacrolimus dosing 
requirements is present. However, the relative contribution of the 
genotype may be less prominent in children younger than one year of 
age as the ontogeny of CYP3A has not yet been completed.24,38 Therefore, 
at this age the children may present as poor metabolizers, which is of 
particular concern in pediatric heart transplant recipients as a 
proportion of these patients are less than one year of age at the time of 
transplantation. In addition, the number of patients carrying POR*28 or 
CYP3A4*22 allele in our cohort was very small and consequently we could 
not analyse all genotype groups. 
Post-transplantation decline in renal function
The definition problem
Even though renal dysfunction post-transplantation is a widely acknowl-
edged adverse  effect of tacrolimus, its relative contribution to renal 
dysfunction is still controversial. This debate has resulted in the questions: 
• Does renal dysfunction caused by tacrolimus really exist? 
• How to separate it from the adverse effect of low rate graft versus 
 host disease (GVHD) and /or rejection of the kidney? 
Several methods are currently being used to determine the kidney 
function, including histopathological changes and clinical markers 
(serum creatinine and GFR). 
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Histo-pathological changes
The Banff criteria for renal allograft pathology, are probably the most widely 
used guideline for defining pathological changes in kidney biopsies. 
Over the years, the criteria have version introduced  several times 
with the latest change in 2007.39 Poor inter-observer agreement and 
reproducibility have been major limitations of this staging tool.40,41,42,43
Four histological signs have been associated with CNI-toxicity; arteriolar 
hyalinosis, coarse vacuolization, interstitial fibrosis and tubular 
atrophy.44,45,46,47,48,49,50 Recently, however, the specificity of these markers 
for CNI toxicity have been questioned.51,45,52,53,54 Additionally, the use of
biopsies for the diagnosis of CNI-induced nephrotoxicity has been a topic 
of discussion.2,55 
All of the histo-pathological studies suffer from limitations. The diagnostic 
criteria and histological confirmations are very heterogenic, 
complicating comparison of the papers and results in variable 
evidence on the progressions of the classic histological signs and other 
non-specific factors.56 Additionally, the majority of the articles include 
kidney transplant recipients and no other solid organ transplant 
recipients. In non-renal transplant recipients, renal failure thought 
to be cause due to CNI use may be the result of other factors, such as 
undiagnosed CKD pre-transplantation.56 Therefore, the use of biopsies 
for the diagnosis of CNI-induced nephrotoxicity has currently no added 
benefit. 
Considering the difficulty and controversy related to the diagnosis of 
CNI-induced toxicity, in our studies we have chosen to use the term “renal 
failure” or “renal dysfunction” in tacrolimus-treated patients instead. 
Clinical markers of renal function
Despite the ongoing debate on the relative impact of tacrolimus on 
renal function in (pediatric) organ transplant recipients, it remains a 
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fact that solid organ transplant is associated with renal dysfunction and 
end-stage renal failure in a subset of patients. To adequately identify risk 
factors to further personalize tacrolimus therapy, different clinical markers 
of renal function have been used; serum creatinine and the glomerular 
filtration rate (GFR). The use of these different markers appears to result in 
potentially large variations in renal dysfunction prevalence (Chapter 1). 
Serum creatinine
Serum creatinine has been the most widely used clinical tool to 
determine renal function. The extra-renal clearance of creatinine is 
relatively small in people with a normal kidney function, but about 
two-thirds of the total daily creatinine excretion can occur by extra-renal 
elimination in patients with CKD.57 Serum creatinine has also been used 
to define renal function by setting a cut-off or following the change in 
serum creatinine. Although the most widely used marker of renal function, 
it is important to realize that serum creatinine levels can be misleading in 
several conditions, including in malnourishment and in liver or heart 
failure58 and during renal replacement therapy such as CVVH. 
Additionally, the use of serum creatinine in kidney patients is inaccurate 
due to contributing factors from the kidney (i.e. tubular or glomerular 
damage affecting filtration and secretion) as well as other factors.59,60 
Serum creatinine concentrations do not accurately reflect renal function 
unless steady state concentrations have been reached.59,60 Moreover, the 
precision of the creatinine assay determines the results.61 Especially with 
low serum creatinine levels, the creatinine values measured with the 
enzymatic method can run lower compared to those creatinine levels 
measured by the Jaffe methods.62,63 Therefore, using serum creatinine 
as a tool for defining renal dysfunction is suboptimal, especially to 
detect fast changes in renal function and patients with multiple underlying 
conditions and/or nephrotoxic drugs. 
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Glomerular filtration rate
The glomerular filtration rate is currently considered the gold standard to 
reflect renal function. The GFR can be determined by direct measurement 
(mGFR) or by estimation using a formula (eGFR). 
Measuring GFR
Over the years, many methods ways of measuring GFR have been 
discovered and used in clinical practice. An ideal marker for GFR is not pro-
tein bound and is freely filtered by the glomerulus. In addition, the markers 
should not be secreted, metabolized or reabsorbed by the renal tubules.64
The golden standard for measuring GFR is inulin clearance. However, 
the collection of timed urine specimens is very challenging in children 
who have not yet mastered toilet training or have conditions affect-
ing the urine (i.e neurogenic bladder, dysfunctional voiding).61 The inulin 
clearance can also be measured by a constant infusion technique 
estimating the plasma clearance from blood concentrations.65 Yet, obtaining
a constant inulin plasma or serum concentrations during intravenous 
infusion is difficult.66 Steady-state concentrations are required, because
unequilibrated samples will show lower or higher concentrations 
leading to an apparent over or underestimation of GFR.66 Even though inulin 
clearance is probably the most accurate method for determining GFR, it is an 
invasive procedure and therefore not very frequently used in children.67 
Another approach is the use of radioisotopes or other markers, such as 
51Cr EDTA clearance, 99Tc DTPA clearance and 125I iothalamate clearance. 
Nonetheless, the radioistopes are not available in every country67 and 
there are some handling challenges.67 The last method used to date is 
“cold” iothalamate and iohexol.66 It has an advantage over the other 
methods since no radioactivity is involved and cold methods are equally 
accurate. A disadvantage for this method is the need to measure the 
compound in blood instead of a relatively simple radioactivity count. 
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The accuracy of all these GFR measurements methods is affected by 
the exact time and frequency of sampling. Poor standardization among 
centers and the inaccuracies introduced due to the different commercial 
products used are major hurldes.68 To interpret the results, a single 
compartment model is used. However, the use of the single compartment 
model may result in overestimation of GFR.66 Therefore, despite their 
technical advantages, each of these methods have several limitations.67 
Estimating GFR
To estimate the GFR from serum creatinine levels, many formulas 
have been developed over the years with the Schwartz formula being 
especially designed for the use in children. To correct for age and gender, 
as a surrogate marker of the development change in muscle mass, an 
empirical constant “k” was added.61 Logically, the same limitations 
pertaining the analytical method to measure serum creatinine and 
clinical factors impacting serum creatinine apply to estimated GFR.69,70,71 
The analytical limitations impacting serum creatinine concentrations, as 
described before, can lead to an overestimation of the eGFR.61 Children 
with reduced muscle mass and CKD may also lead to an overestimation 
of the eGFR.61
Consensus
A consensus on the definition of renal dysfunction is highly desirable. 
There has been an ongoing discussion as described above. Several efforts 
have been made for standardization.
KDOQI
In 2002, the United States National Kidney Foundation published the 
Kidney Disease Outcome Quality Initiative (KDOQI) guidelines on the 
definition, classification and evaluation of CKD. Since its publication, 
many clinical practices and researcher have implemented this guideline. 
However, the staging of CKD is based on eGFR values, with all its 
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limitations. The validity of the KDOQI guidelines are in question if they 
are implemented in the current form, due to accuracy levels not being 
reached by several formulas used to date.70 CKD stages 3-5 are of particular
concern as with a GFR of 30-59 ml/min/1.73m2 (CKD stage 3) the kidney 
function has deteriorated too much and an active management is started 
to treat complications. A decline in GFR to 15-29 ml/min/1.73m2 (CKD 
stage 4) the patient needs to be prepared for renal replacement therapy 
and a further decline, GFR is <15 ml/min/1.73m2 (CKD stage 5) the patient 
has complete renal failure and renal replacement is needed.72
KDIGO
The Kidney Disease: Improving Global Outcome (KDIGO) group is a global 
non-profit foundation committed to improving the care and outcomes of 
patients with kidney disease worldwide73 Recently, they have published 
their guidelines for the evaluation and management of CKD, an update of 
the 2002 KDQOI guidelines. These new guidelines introduced a subgroup 
of CKD stage 3, separating patients with a GFR of 45-59 ml/min/1.73m2 
(CKD stage 3a) and those with a GFR of 30-44 ml/min/1.73m2 (CKD stage 
3b). The use of cystatin C has also been incorporated in these new guide-
lines as an additional tool for determining CKD. The use of these new 
guidelines in future research would aid in the possibilities of conducting 
meta-analyses to future understand the processes involved in CKD and 
improve the patient’s outcome.
“Renal dysfunction” in tacrolimus-treated patients
Tacrolimus has been very successful in improving the outcome of pediatric 
transplant recipients. Nevertheless, it is associated with serious adverse 
effects including renal dysfunction.52 This is important as the kidney is 
still developing during childhood as reflected in a change in glomerular 
filtration rates (GFRs) and renal excretion.74 
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Data on the prevalence of chronic kidney disease (CKD) after renal and 
non-renal transplantation in children are scarce and vary widely. We 
have shown in a systematic review of the literature an extremely wide 
prevalence of renal failure in pediatric non-renal transplant recipients 
(0%-90%). After adjusting for follow-up time (> one year) and severity of 
kidney disease, the reported prevalence narrowed to mild CKD ranging 
from 21.7% to 40% and severe CKD ranging from 1.67% to 46% (Chapter 
2).75 However, these studies were presented with several limitations, in-
cluding patient selection biases, methodological differences in definition 
and tools used to measure renal function. 
The majority of pediatric studies have examined a mixed populations 
of cyclosporine and tacrolimus treated children. In a recent Cochrane 
review, tacrolimus was found to be superior to cyclosporine with a lower 
risk of CKD in liver transplant recipients.76 Therefore, studies in patients 
only treated with tacrolimus are needed to have a better understanding 
of CKD in this population. 
In an effort to achieve some clarity on the extent of renal failure post-trans- 
plantation , we reported the prevalence of CKD in pediatric solid organ 
recipients treated with tacrolimus (Chapters 7-9). In a large, retrospective,
multicenter, cohort study, we included 495 transplant recipients (135 
liver, 161 heart and 199 kidney) with a follow-up time up to 10 years 
post-transplantation. The cumulative incidence of CKD stage 3-5 at least 
3 months post-transplantation was 24% for liver, 34.2% for heart and 
40% for renal transplant recipients. Although rare, CKD stage 4 and 5 are 
prevalent in pediatric solid organ transplant recipients. At one year 
post-transplantation, 6.7% of the pediatric kidney transplant recipients 
experienced CKD stage 3 and 1.9% CKD stage 4 and at five years post-
transplantation 6.5% stage 3, 3.2% stage 4 and 6.5% stage 5. In liver trans-
plant recipients none of the patients experienced CKD stage 3-5 at one or 
five years post-transplantation. The prevalence of CKD stage 3 was 2.9% 
 General Discussion | 233 Ch
ap
te
r 1
1
at one year post-transplantation and the prevalence of CKD stage 5 1.8% 
at five years post-transplantation in pediatric heart transplant recipients. 
However, our sample size at 10 years post-transplantation was limited 
as the majority of the children were transplanted in the recent years, 
resulting in a median time from transplantation of only 8 months! 
In addition, the median follow-up time was less than one year post- 
transplantation. Nonetheless, these numbers show that a significant 
proportion of pediatric solid organ transplant recipients will develop CKD 
post-transplantation. The prevalence of CKD may even be greater than 
we have reported as we used estimated GFR, which can overestimate 
the actual GFR measured by inulin clearance, as discussed above.61,77,78 
These findings illustrate the importance of monitoring the kidney 
function following pediatric solid organ transplantation. Although more 
invasive, routine mGFRs will better reflect the actual kidney function and 
should be considered in high risk patients. 
Risk factors for renal failure
Causes of renal dysfunction
Despite the fact that tacrolimus therapy is associated with renal toxicity, 
it is not the only cause for kidney dysfunction in solid organ trans-
plant recipients. It is probably multi-factorial as renal function can be 
cumulatively affected by intra-operative factors (hypotension and need 
for dialysis), post-operative factors (acute renal failure), concomitant 
 disease, immunomodulation (e.g. rejection in kidney transplant and long 
term exposure to calcineurin inhibitors like tacrolimus.58,79 Differentiating 
renal dysfunction caused by chronic use of tacrolimus from other causes 
is very challenging. In particular, in renal transplant recipients the under-
lying disease requiring transplantation and immune and non-immune 
related organ rejection can be major contributors.58 In addition, liver trans-
plant recipients tend to have pre-existing glomerular diseases as a result 
of inadequate clearance of immune complexes caused by liver disease.58 
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In pediatric solid organ transplant recipients, similar risk factors for 
developing renal failure post-transplantation as in adults have been 
reported.78,80,81 Yet, we speculate that the chronic use of tacrolimus might 
be more important in children as the concomitant disease associated 
with renal dysfunction (e.g. diabetes, HCV-associated glomerulonephritis, 
atherosclerosis) are less common in children compared to adults. 
Non-adherence is of particular concern in adolescents and young 
adults82,83 and may result in sub-therapeutic tacrolimus exposure and 
consequently increase the chances of renal dysfunction caused by 
rejection of the donated kidney. It may also lead to greater intra-patient 
variability in tacrolimus concentrations, possibly resulting in a higher 
risk for developing renal failure, in addition to the risk of transplant 
rejection.17,21 
Pharmacogenetics and renal function
Genetic polymorphisms in metabolizing enzymes (CYP3A4, CYP3A5) 
and drug transporters (ABCB1) have been shown to influence tacrolimus 
disposition in both adults and children. Yet, the influence of genetic 
variation on the outcome of transplant patients is less well known. 
In Chapter 3, we reviewed the available literature for promising gene 
candidates in relation to the risk of renal dysfunction after solid organ 
transplants, with tacrolimus therapy. Although both cyclosporine and 
tacrolimus are calcineurin inhibitors, they are different in physiological 
pathways which may explain their differential side effect profiles.52,84,85,86,87,88 
Hence, we tried to delineate the contribution of genetic variation, using 
a targeted gene approach, on renal function and an emphasis on 
tacrolimus. 
In adult transplant recipients associations between CYP3A5, ABCB1, TGF-β, 
CYP2C8 and ACE have been reported in liver, kidney and heart recipients.
Results for CYP3A5 and ABCB1 were conflicting in kidney transplant 
recipients, associations between a higher risk of developing renal 
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dysfunction and CYP3A5-expressers has been reported89,90 as well as with 
CYP3A5 non-expressers.91 In liver and heart transplant recipients, only one 
study has reported, showing an increased risk for CYP3A5 non-express-
ers in liver transplant recipients92 and no association in heart transplant 
recipients.93 The ABCB1 genotype also showed contradictory results with 
two studies (one kidney and one liver) showing that the T-variant in 
ABCB1 3435 and ABCB1 2677 is associated with an increased risk for renal 
dysfunction54,94 while three other studies could not confirm such an 
association.89,90,93 The associations found in the other genes, have only 
been reported in one study to date. 
In pediatric kidney transplant recipients, carriers of the CCR5∆32 geno-
type were more frequently diagnosed with nephrotoxicity compared to 
those carrying the wildtype.95 This study showed some methodological
short-comings, which may reduce the certainty of the finding. At 6 
months post-transplantation, pediatric liver recipients carrying the ABCB1 
T-T-T haplotype were more frequently diagnosed with tacrolimus-induced 
nephrotoxicity. However, this significance disappeared at one year post-
transplantation, suggesting that the protective effect of ABCB1 on the 
kidney may only be important in the first 6 months post-transplantation.96 
However, the possible protective effect of ABCB1 in the years following 
pediatric solid organ transplantation have not been studied yet.  
Although, these results suggest promising genes for understanding the 
mechanisms behind renal dysfunction in transplant recipients, not all studies 
have shown consistency and  methodological quality. The methods also 
differed considerably hampering meta -analysis. Many different definitions 
for renal function were used as well as varying follow-up times 
(Chapter 3).97 As a next step, including all previously associated genes in one 
analysis in a large, preferably a multicentre, study would be interesting. 
This candidate gene approach may be more feasible compared to a 
Genome Wide Association Study (GWAS) as the pediatric transplant 
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population may not be large enough for a GWAS study design. We have 
been able to conduct a candidate gene approach study in pediatric liver, 
heart and kidney transplant recipients (Chapters 7-9). 
We created an elaborate list of genetic polymorphisms, including all 
previously associated and published polymorphism as well as 
polymorphisms related to tacrolimus pharmacokinetic pathways and 
polymorphisms associated with renal function. For the first time, a total 
of 77 polymorphisms were analysed in relation to renal function (eGFR) in 
pediatric solid organ transplant recipients. Although, initial results were 
promising with several polymorphisms associated at the significance 
level of 0.05, only one polymorphism in pediatric heart transplant 
recipients was significantly associated at the set significance threshold 
corrected for multiple testing (Chapters 7-9). We used a targeted gene 
approach and could therefore have missed polymorphisms that have not 
been previously known to correlate with renal function. Genome-wide 
association studies or next generation sequencing are newer techniques 
in which hundreds of polymorphisms can be studied at once in large 
populations and potentially result in new disease or transplant related 
prognostic factors identifying patients at risk for developing renal failure. 
Biomarkers
An optimal biomarker to monitor renal (dys)function is lacking. Recently, 
new potential biomarkers have been identified. The validation of these 
biomarkers is in different stages of development. At this time, the best 
validated marker is neutrophil gelatinase-associated protein (NGAL). 
In adult kidney transplant recipients, uNGAL directly post-transplantation 
has been shown to be a good predictor for delayed graft failure (DGF), 
acute rejection and AKI.98,99,100,101 In pediatric kidney transplant recipients, 
donor kidney NGAL staining has been shown to be an early predictor of 
kidney failure.102 Additionally, an increase of 100 ng/mg in urinary creati-
nine-corrected uNGAL levels in the first 24 hours after kidney transplanta-
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tion, has been associated with a 20% increase in the risk of developing 
DGF.103 In pediatric heart transplant recipients experiencing CKD, uNGAL 
levels at least 3 months post-transplantation were above 2.2 ng/ml,104 
which is considered to be the cut-off in healthy children.105 
Pediatric kidney and liver transplant recipients are at an increased risk 
for renal damage due to the surgery itself or the high tacrolimus concen-
trations in the first 14 days post-transplantation.19 Hence, we aimed to 
explore the uNGAL levels in the immediate post-transplant period 
(Chapter 10). Although our study was a pilot study, in both the liver and 
kidney transplant recipients the majority of the patients exhibited uNGAL 
levels above 2.2 ng/ml, but not above 135 ng/ml, a cut-off associated with an 
increased risk of developing AKI in children.106 This may suggest subclinical
renal damage In contrast to previous reports, we failed to find an 
association between high tacrolimus concentrations and high uNGAL 
levels or between high uNGAL levels and AKI (Chapter 10). Our study 
has several limitations. Due to limited sample size, we were unable 
to establish ROC curves to determine the sensitivity of the early marker 
uNGAL. For future studies, it would be interesting to see if a rise in uNGAL 
can be detected when the tacrolimus concentrations rise in the absence 
of a rise in serum creatinine. This way, an early marker for acute tacrolimus 
nephrotoxicity could be established and possibly minimize the damage 
to the kidney. Nonetheless, knowledge about the natural evolution of 
uNGAL in several conditions is needed to distinguish between the 
natural pattern of uNGAL levels and other possible causes for the rise in the 
uNGAL levels. Yet, this natural pattern is currently not known. 
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THE FUTURE
The missing variables and tacrolimus pharmacokinetics
Clinical factors
We have demonstrated that children younger than 6 years of age needed 
higher tacrolimus doses compared to older children; hence adaptation 
of the starting dose of tacrolimus seems to be the next logical step. 
The effects of these dosing changes on the long-term outcome of 
children have not been studied. Moreover, as older children are at an 
increased risk for developing renal failure post-transplantation, a prospective 
study aimed to further delineate the reasons for this vulnerability is 
needed. Although many efforts are already being taken by the caregivers 
to increase the adherence to drugs in adolescents,107 a focus group 
consisting of adolescent transplant recipients recipients to delineate their 
challenges to adhere to their medication, may reveal new reasons that 
can be incorporated into their care. 
In the first two years of life, children eat differently compared to adults. 
The influences of breast milk, baby formula and non-solid foods on 
tacrolimus disposition are currently not known, but are important to take 
into account especially in pediatric heart transplant recipients, where a 
considerable proportion of the patients are less than one year of age. 
Additionally, children in the ICU often receive supplemental tube feeding, 
yet it is currently unknown if the composition of the enteral nutrition 
in these patients would affect tacrolimus absorption and therefore 
tacrolimus dosing requirements. The use of a buccal tube resulted in 
similar tacrolimus trough concentrations compared to the use of a 
nasogastric tube, suggesting the type of tube does not impact tacrolimus 
absorption.108 An in vitro model to determine the influence of tube-feeding
and different leading regimens on tacrolimus absorption may help us 
understand food related variation in tacrolimus disposition in children.
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Some foods (grapefruit, pomelo, turmeric, ginger) are known to interact 
with these proteins and could therefore influence the tacrolimus 
disposition.109,110,111,112,113,114,115,116,117 In animal studies, the influence of these 
types of food have been shown to increase the area-under-the-concentra-
tion-time-curve (AUC) of tacrolimus compared to those animals treated 
with water.118 Yet, to our knowledge, none of these foods have been studied
in humans in a systematic way and integrated in follow-up protocols to 
determine the influence on tacrolimus disposition and the frequency of 
the use of these foods in transplant recipients. 
Inflammation has been associated with altered drug metabolism in both 
animal and human adult studies. C-reactive protein (CRP), a marker of 
inflammation, is associated with significantly lower CYP3A4 expression 
in adult liver tissue samples.119 Similarly, in critically ill pediatric patients, 
the clearance of midazolam, a model drug for CYP3A4/5 activity, was 
significantly lower compared to children who underwent elective major 
craniofacial surgery or pediatric oncology patients.120 In addition, higher 
degrees of organ dysfunction were associated with decreased metabolic 
clearance in pediatric intensive care patients.121 Bilirubin, was also associ-
ated with lower CYP3A4 expression in liver tissue samples.119 Although 
a relationship between bilirubin and tacrolimus disposition has been 
shown in adults,122,123 contradictory results have been reported in pedi-
atric transplant recipients.33,124 A dosing algorithm incorporating all these 
factors amy be important. 
Currently, tacrolimus is measured in whole blood samples. However, 
tacrolimus is highly protein and erythrocyte bound with a small 
unbound fraction.125 Only this unbound fraction is responsible for the 
pharmacological action of tacrolimus. Hence, to really understand the 
exposure of pediatric transplant recipients to tacrolimus, it would be 
desirable to measure only the unbound fraction. However, technical 
difficulties and practical challenges (i.e. large sample volumes needed, 
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difficult assay) currently limit the ability to measure the unbound 
fraction. As mentioned, the metabolism of tacrolimus is age dependent. 
However, as shown with sirolimus11 children may metabolize drugs dif-
ferently compared to adults. This has not been studied yet for tacrolimus, 
but would be of interest as the possible different metabolites may be 
active as well and contribute to both effect and toxicity.
Concomitant medication
Several drugs have been reported to either inhibit or induce the activity 
of metabolizing enzymes.126,127 Instead of excluding those patients 
receiving these medications from analysis, concomitant medications 
should be handled as covariates. The combination of the administered 
drugs as a covariate would be interesting as well, as transplant recipients 
generally receive multiple medications at the same time. 
New insights in genetic polymorphisms
Various new insights in genetic polymorphisms and their use in research 
have further improved pharmacogenetic understanding of tacrolimus 
disposition. To date, mainly individual single nucleotide polymorphisms 
(SNPs) have been researched, but more data have become available on the 
use of haplotypes and linked polymorphism. A recent study by Wang et 
al has shown the importance of haplotypes, with CYP3A5 A-T-T-T-G haplo-
type carriers had significantly lower tacrolimus stable dose requirements 
(p = 2.41 x 10-5) compared to other haplotype carriers.128 This emphasizes 
the importance of including haplotypes in pharmacogenetic analyses. 
Genetic variation in the genes encoding the drug metabolizing 
enzymes does not explain all the variability reported in tacrolimus 
disposition in either adults or children. Therefore, other pathways may 
possibly influence tacrolimus disposition such as nuclear receptors 
(peroxisome proliferator-activated receptor-alpha, pregnane X-receptor, 
constitutive androstane receptor),129,130,131,132,133 inflammatory genes 
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(interleukin-18, interleukin-10 and interferon-gamma)123,134 and oth-
er drug transporters (multidrug resistance-associated protein 2).135 
We have not been able to show a relationship with some of these genes 
and renal function.
Donor’s influence
So far, we have only focused on the recipient as the major factor. 
However, the donor may play a role as well. Especially in liver and kidney 
transplantation, the influence of the donor may be more important than 
the recipient’s influence. This has been shown in both adult and pediatric 
patients.136 A similar approach should be taken in kidney and small bowel
transplantation as the donor DNA will determine renal and intestinal 
tacrolimus metabolism, respectively. In these solid organ transplant 
groups, it will be therefore key to include the donor’s DNA or mRNA 
expressions of protein in futures studies. 
Dosing algorithms
While the relationship between CYP3A5 genotype and tacrolimus clearance
has been well established in adults and children, the clinical impact of 
genotype-based dosing on tacrolimus therapy becomes more important. 
To study the potential impact of genotype-based dosing on the out-
come of tacrolimus therapy, prospective studies will be needed. Studies 
in adults, using individualized dosing based on genotype have started, 
showing that patients treated with CYP3A5 genotype-based tacrolimus 
doses had tacrolimus concentrations more often within the target range 
and achieved the target concentrations quicker than those patients with 
standard of care.137
Although the management of tacrolimus dosing requirements improved 
in the adapted group, the renal function at day 14 and 3 months post-
transplantation was comparable between the two groups.137 This finding 
raises the question if optimization of tacrolimus doses is actually the way 
to improve patient outcomes. However, the population studied was at a 
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low risk for acute rejection and hence the dosing algorithm needs to be 
validated in other patient groups where tacrolimus is started at the day of 
transplantation, as this is more commonly done in clinical practise.138 
These results suggest the importance to incorporate clinically relevant 
endpoints in trials evaluating the effect of genotype-based dosing, but 
it also stresses the importance to prospectively study these patients, 
despite the significant costs and efforts needed to conduct such trials. 
The missing variables and tacrolimus pharmacodynamics
Tacrolimus
With an ongoing discussion on the existence of tacrolimus- 
induced nephrotoxicty only the parent compound is taken into 
consideration as the possible cause for renal failure following 
transplantation. However, some authors have suggested that 
the metabolites of tacrolimus may contribute to nephrotoxicity. 
This hypothesis is supported by the renal expression of CYP3A5 and the 
renal clearance of tacrolimus being dependent of CYP3A5 genotype.139 
Nonetheless, the nephrotoxic effects of tacrolimus metabolites have not 
been studied in either adults or children.52
Concomitant medication
Pharmacodynamic interactions have been reported with concomitant 
use of non-steroidal anti-inflammatory drugs (NSAIDs) and aminoglyco-
sides. The concomitant use of these medications facilitates the progres-
sion of chronic changes in the kidney.140,141 Due to these interactions, 
caution has to be taken to gather this information during research so the 
results can be adequately controlled for concomitant medication use. 
We have tried to control for the use by testing their use of concomitant 
medication against renal function (Chapters 7-9), but found 
no significant influence on renal function. However, we did not 
test combinations of medications, duration of the treatment 
and the dose of the concomitant medication. In future research, 
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the frequency and duration of these administered drugs need to be 
monitored and taken into consideration in the statistical analysis. 
New insights in genetic polymorphisms
In a large genome wide association study (GWAS) potential 
pathways for chronic kidney disease were studied. Two SNPs were 
associated with serum creatinine levels: SHROOM3 rs9992101 and RAP2A 
rs15358.142 Shroom-related protein 3 is thought to be involved in epithelial
cell shape regulation143 and the RAP2A gene is thought to influence 
acetylation of NAT8. This is an interesting finding as NAT8 is strongly and 
almost exclusively expressed in the kidney.142 Two SNPs (rs10206899 and 
CEP89 rs4805834) have been associated with eGFR, cystatin C and CKD. 
Rs10206899 was in linkage disequilibrium with RAP2A rs15358. The last 
two SNPs associated with serum creatinine and eGFR were rs3127573 and 
TBX2 rs8068318.142 The TBX2 gene encodes a member of the T-box family of 
transcription factors.144 Unfortunately, the function of TBX2 is not yet known.142 
In contrast, in another GWAS (n=4006) analysis containing 5 EUROSPAN 
studies and two replication cohorts, none of the studied SNPs met the 
multiple testing significance threshold of 1.55 x 10-7.145 The regions 
studied included those that were previously found to be significant. 
Instead, the authors focused on three promising regions for follow-up in 
the two replication cohorts: the collagen type XXII alpha 1(COL22A1) gene 
on chromosome 8, the synaptotagmin-1 (SYT1) gene on chromosome 12 
as well as the gamma-aminobutyric acid receptor subunit tho-2 (GABRR2) 
and ubiquitin-conjugating enzyme E2 J1 (UBE2J1) genes on chromosome 
6.145 We have included their most significant SNPs into our custom assay, 
but we were unable to confirm a possible relationship between these 
SNPs and renal function in pediatric solid organ transplant recipients. 
Nevertheless, our sample size was significantly smaller than these GWAS 
studies and the candidate gene approach of our study may have limited 
our detection power. 
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Donor’s influence
In addition to the differences in protein expression, the age of the 
donor has been reported to influence the graft outcome with kidney from 
older donors showing a higher susceptibility for renal graft failure.146,147 
An alteration of renal perfusion and a higher prevalence of pre-exist-
ing chronic vascular changes are thought to account for this increased 
susceptibility.146,148
To fully understand inter-individual variation in tacrolimus disposition 
and response, a systems biology approach may aid to individualize 
therapy and improve outcome. This approach may include pharmacoki-
netic and pharmacodyamic pathways. Prospective multi-centre trials may 
aid to collect samples large enough to be able to perform multiple testing 
and enable the use of replication cohorts. Next generation sequencing 
may be of help as it can reduce the costs of analysing hundred of 
thousands SNPs at the same time. 
Other renal dysfunction biomarkers
Several new biomarkers have been studied for their potential to reflect 
renal function or renal damage.149,150 The most promising new biomarker 
for renal function is serum cystatin C levels.151,152,153,154,155 Formulas incor-
porating cystatin C show better accuracy in predicting the GFR compared 
to the conventional Schwartz formula used today in pediatric liver and 
kidney transplant recipients.104,156,157 Kidney injury molecule 1 (KIM-1) and 
netrin-1 are not detectable in healthy kidney tissue,158 159 and appear to be 
potential markers for kidney damage.159,160 KIM-1 strongly correlates with 
serum creatinine levels and eGFR in adult renal allograft recipients160,161 
and has been identified as an independent risk factor for graft loss in adult 
renal transplant recipients.161 Netrin-1 was highly expressed in the tubular 
epithelial cells of adult transplanted kidneys, also showing the potential 
as biomarker.159 
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Biomarkers of tacrolimus efficacy
The biomarkers we have discussed so far, dealt only with renal function. 
Yet, in addition to therapeutic drug monitoring, it would be ideal to be 
able to measure the effectiveness of tacrolimus treatment in patients. 
The mechanism of action of tacrolimus evolves around the inactivation of 
T-cells to prevent an immunological response of the host against the new 
graft. Therefore, the product of T-cell activation may be of interest for test-
ing the effectiveness of tacrolimus. In a review by Oellerich et al. greater 
inhibition of interleukin-2 (IL-2), interleukin-4 (IL-4), IFN-γ and TNF-α was 
reported with increased cyclosporine A (CsA) concentrations.162 
Other potential markers, such as the CD30, CD26 molecule or CD4 T-cells, 
have been proposed as a marker regarding acute rejection and renal 
allograft survival.163,164,165 Unfortunately, most studies were done with CsA 
and the findings with CsA need to be replicated with tacrolimus due to 
the different mechanisms of action of both drugs.
At this time, the tacrolimus therapeutic window used by most pediatric 
transplant physicians is taken from adults. Importantly, the PK-PD 
relationship of tacrolimus in children has not been unequivocally shown. 
The developing child may respond differently to similar tacrolimus plasma 
levels than adults, even at different stages of development. This may be 
due to differences in tacrolimus metabolite formation and levels, but also 
differences in immunology and other organ functions (e.g. kidneys). Due 
to these differences, we wonder if the therapeutic range of tacrolimus 
may need to be adjusted for children. Traditionally, to measure tacrolimus 
pharmacodynamics, clinical endpoints such a rejection and adverse 
events have been used. The ideal study would collect data on tacrolimus 
(doses, tacrolimus and metabolite levels in blood and urine), chemistry 
and haematological laboratory results, concomitant medication, patient’s 
characteristics (age, height, weight), genetic variation of the recipient and 
donor and transplant outcomes (rejection, renal failure, hypertension, 
neurotoxicity) to ultimately develop a model for treatment of the 
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individual patient. This would require a large sample size; yet with pop-
ulation PK-PD modelling it is possible to develop a PK-PD model with 
limited patient numbers as well as limited sample numbers. An approach 
found to be very helpful in small children in case of availability of limited 
samples.166 
Determining the variables of importance for the PK-PD model is limited 
without a better understanding of the underlying mechanisms of renal 
failure in tacrolimus treated patients. A better understanding of the 
underlying mechanism may not only improve the PK-PD model, but 
may also identify possible therapy targets. It may be worthwhile to test 
drugs currently used to counteract the effect of other nephrotoxic drugs 
(ie. N-acetylcysteine for ifosfamide) in a tacrolimus-induced renal failure 
rat model. 
Conclusions
In summary, in this thesis, I have shown the importance of CYP3A5 
and other novel polymorphisms (POR*28, CYP3A4*22) on tacrolimus 
disposition in pediatric transplant patients and the significant interplay 
with maturation. The novel approach of combining CYP3A genotypes, 
showed a significant improvement in explaining the variability in 
tacrolimus disposition. A large proportion of pediatric solid organ trans-
plant recipients receiving tacrolimus develop CKD, warranting the need for 
future studies in which risk factors, clinical and genetic, are studied to 
ultimately develop a model for the identification of patient with an 
increased risk of developing renal failure post-transplantation. 
These data provide guidance for future personalized tacrolimus dosing in 
pediatric transplant recipients, with the ultimate goal to improve long-term 
outcome.
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English Summary
The introduction of solid organ transplantation has dramatically increased 
survival rates of both adults and children with end-stage organ failure. 
The additional introduction of immunosuppressive therapy has further 
improved the short term survival yet, the long-term outcomes have barely 
improved. 
Children have long been considered miniature adults. However, over the last 
decades we have come to better understand the developmental changes 
in children and realized that drug therapy needed to be adapted. In 1995, 
tacrolimus was introduced as a new immunosuppressive drug. It has since 
become the drug of choice in pediatric solid organ transplantation even 
though its pharmacokinetic and pharmacodynamic properties have hardly 
been studied in children. 
Part I: Renal failure after solid organ transplantation
Renal failure is a serious complication of tacrolimus treatment in pediatric 
non-renal solid organ transplant recipients. In chapter 2, we reviewed 
the current literature on the prevalence of this complication. We found 
a very wide range in reported prevalences, which we ascribed to the 
heterogeneity in methodology and renal failure definition in the different 
papers. Focusing on mild and severe renal failure at least one year post- 
transplantation, we narrowed the ranges to 0%-39% and 0%-71.4% for 
mild and severe failure, respectively, in liver transplant recipients; and 
22.7%-50% and 6.8%-46%, respectively, in heart transplant recipients. 
These results show that a considerable proportion of pediatric liver and heart 
transplant recipients may experience renal failure post-transplantation. 
 
In chapter 3 we performed a systematic review of the literature to deter-
mine genetic risk factors for tacrolimus-induced nephrotoxicity in both 
adults and children. The limited evidence suggests that genetic variation 
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involved in pharmacokinetic (ABCB1 and CYP3A5) and pharmacodynamic 
(TGF-ß, CYP2C8, ACE, CCR5) pathways of tacrolimus may impact the risk of 
developing tacrolimus-induced nephrotoxicity across different transplant 
organ groups. However, the quality of these studies varied considerably, 
limiting the conclusions that can be drawn. 
Part II: Tacrolimus pharmacokinetics and genetic variability
Tacrolimus is metabolized by the phase I enzymes, CYP3A4 and CYP3A5. 
Its disposition can be affected by genetic variation in these enzymes, as 
has been shown in adults. Yet, data on the impact of these variations on 
tacrolimus disposition in children is scarce. Chapter 4 presents the results 
of our study in pediatric heart transplant recipients, showing that younger 
children as well as CYP3A5-expressers required higher tacrolimus doses to 
reach similar tacrolimus trough concentrations as older children or CYP3A5 
non-expressers. The effects of age and CYP3A5 genotype were cumulative
because CYP3A5-expressers younger than six years of age required 1.5 
times higher tacrolimus doses compared to CYP3A5-expressers older than 
six years of age and 6 times higher tacrolimus doses compared to CYP3A5 
non-expressers older than six years. 
After the recent discovery of the new CYP3A4*22 polymorphism, we 
reanalyzed our initial pediatric heart transplant data to determine if this new 
polymorphism has an additional effect to CYP3A5 on tacrolimus disposition. 
In chapter 5 we show that despite the low allele frequency, CYP3A4*22 
carriers needed 30% less tacrolimus to reach similar target concentrations 
compared to CYP3A4*1/*1 carriers. By combining the CYP3A4 and CYP3A5 
genotypes, we were able to categorize the patients into CYP3A poor, 
intermediate or extensive metabolizers. The combined CYP3A genotypes 
were stronger associated with tacrolimus disposition as poor metaboliz-
ers needed significantly less tacrolimus and had higher concentration/
dose (C/D) ratios compared to intermediate and extensive metabolizers. 
The new polymorphism CYP3A4*22 appears to be the first functional 
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variation in CYP3A4. Combining the CYP3A4 and CYP3A5 genotypes into 
phenotypic categories may further reduce the intra-patient variability in 
tacrolimus disposition in the first 14 days post-transplantation. 
Although very promising, the inter-patient variability cannot be completely 
explained by the CYP3A4 and CYP3A5 genotypes. Variants in the gene 
encoding P450 oxidoreductase (POR), the protein that enables the 
activity of cytochrome P450 (CYP) enzymes, may further explain the 
variability. POR*28 has been associated with increased tacrolimus dosing
requirements in adult kidney transplant recipients, but has not been 
studied in children. In chapter 6, we report for the first time in pediatric 
kidney transplant recipients that the POR*28 allele in CYP3A5-expressers 
explains some of the variability in tacrolimus disposition. CYP3A5-express-
ers carrying at least one POR*28 allele had 18.3% lower tacrolimus trough 
concentrations as well as 20.2% lower tacrolimus C/D ratios compared to 
CYP3A5-expressers with the POR*1/*1 genotype. This effect could not be 
shown in CYP3A5 non-expressers, suggesting a more important role of POR 
in CYP3A5 activity than CYP3A4 in relation to tacrolimus disposition.
Part III: Renal failure after solid organ transplantation
The long-term outcome of pediatric solid organ transplant recipients can 
be further improved by individualization of the current patient manage-
ment. Renal failure post-transplantation is a major complication and know-
ing the risk factors for renal failure may help optimize therapy. In addition 
to clinical factors, genetic variation may also explain renal function decline 
after pediatric solid organ transplantation. We developed a custom assay 
of 96 polymorphisms previously associated with tacrolimus-induced 
nephrotoxicity, tacrolimus disposition and renal function. In chapter 7, 
we show a cumulative incidence of chronic kidney disease of 40% in 199 
pediatric kidney transplant recipients. Renal function remained stable 
throughout the study period, yet a small number of patients developed 
chronic kidney disease already in the first months post-transplantation. 
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Chapter 8 presents the results for pediatric liver transplant recipients 
(n=135). The cumulative incidence of chronic kidney disease was 24% in 
this population. The prevalence of mild renal failure was 5.7% at one year 
post-transplantation and 0% at 5 years post-transplantation. In chapter 9
we show that the cumulative incidence of chronic kidney disease in 
pediatric heart transplant recipients (n=161) was 34.2%. At one year post-
transplantation the prevalence of moderate renal failure was 2.9% and at 5 
years post-transplantation 1.7%. These results suggests that although the 
estimated glomerular filtration rate appears stable in all organ groups, a 
small group of patients experience renal problems early on and throughout 
the follow-up period develop more serious renal failure. 
We also studied the impact of genetic variation on renal function. None of 
the genetic polymorphisms investigated was significantly associated with 
renal function decline in either of the three organ groups.
The use of serum creatinine and the estimated glomerular filtration rate for 
determining renal function has several limitations. One of the new potential 
biomarkers for renal failure is neutrophil gelatinase-associated protein or 
NGAL. Urinary NGAL levels have been associated with acute and chronic 
renal failure in adult transplant recipient, but have rarely been reported 
in pediatric kidney and liver transplant recipients. In chapter 10 we show 
that uNGAL levels in pediatric liver and kidney transplant recipients were 
marginally increased, but seldom as high as previously associated with 
acute kidney injury. Although this was a pilot study, these results suggest 
subclinical renal damage in the majority of the children. 
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Part IV: Discussion and future directions
Chapter 11 discusses the results from the studies presented in this thesis, 
as well as challenges encountered. Furthermore, we present several gaps 
in knowledge as well as recommendations for future research. The main 
conclusions are the following:
• CYP3A4/5 and POR genotypes as well as age explain a considerable 
 proportion of the variability found in tacrolimus disposition in pediatric 
 transplant recipients early after transplantation.
• A significant proportion of pediatric solid organ transplant recipients 
 experience chronic kidney disease in the years following transplantation.
• Chronic kidney disease may already manifest in the first months 
 post-transplantation and in a small proportion of pediatric transplant 
 recipients renal function deteriorates over time. 
• We were not able to identify genetic risk factors for CKD in pediatric 
 transplant recipients.
• Urinary NGAL levels are a potential marker for subclinical renal damage 
 in pediatric liver and kidney transplant recipients. 
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Nederlandse Samenvatting
De introductie van orgaantransplantatie heeft de overlevingskans 
van volwassenen en kinderen met orgaan falen drastisch verbeterd. 
De bijkomende introductie van immuunsuppressiva (afweer onder-
drukkende medicijnen) heeft de overleving op korte termijn verder 
verbeterd, maar dit heeft geen invloed gehad op de overleving op 
langere termijn.
Kinderen zijn lange tijd beschouwd als kleine volwassenen. Echter, in de 
laatste jaren hebben we meer inzicht gekregen in de relatie tussen de 
groei en ontwikkeling van het kind en de manier waarop het lichaam 
met geneesmiddelen omgaat. In 1995 is het afweer-onderdrukkende 
medicijn tacrolimus op de markt gekomen en dit is sindsdien de eerste 
keus bij kinderen die een geheel orgaan ontvangen. De  farmacokinetische 
en farmacodynamische eigenschappen van tacrolimus zijn uitvoerig 
bestudeerd bij volwassenen, maar nauwelijks bij kinderen.
Deel I: Nierfalen na orgaan transplantatie
Nierfalen na een orgaantransplantatie is een ernstige complicatie bij 
kinderen die behandeld worden met tacrolimus. Hoofdstuk 2 geeft een 
overzicht van de huidige literatuur over dit probleem. De gerapporteerde 
prevalenties (de mate waarin het voorkomt) verschillen sterk vanwege 
de verschillende onderzoeksmethodes en de diverse definities van nier-
falen in de artikelen. We hebben de uitkomsten onderverdeeld in mild 
en ernstig nierfalen, en konden toen vaststellen dat bij kinderen na 
lever transplantatie de prevalentie van mild nierfalen varieert van 
0%-39% en de prevalentie van ernstig nierfalen van 0%-71,4%. 
De respectivelijke percentages na hart transplantatie zijn 22,7%-50% en 
6,8%-46%. Hieruit blijkt dat veel kinderen de kans lopen op nierfalen na 
lever- of niertransplantatie. 
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Voor hoofdstuk 3 hebben we systematisch in kaart gebracht welke 
mogelijk erfelijke factoren voor tacrolimus-geïnduceerde nierschade in 
de huidige literatuur wroden beschreven, zowel voor volwassenen als 
kinderen. Er blijkt een vermoedelijke rol te zijn voor variaties in de genen 
die betrokken zijn bij de farmacokinetiek (ABCB1 en CYP3A5) en farmaco-
dynamiek (TGF-β, CYP2C8, ACE, CCR5) van tacrolimus. De kwaliteit van de 
studies was erg variabel, hetgeen het trekken van definitieve conclusies 
bemoeilijkt.
Deel II: De farmacokinetiek van tacrolimus en genetische variatie
Tacrolimus wordt omgezet in de darm, lever en nieren door de geneesmiddel- 
metaboliserende eiwitten CYP3A4 en CYP3A5. Bij volwassenen is aange-
toond dat erfelijke variatie in deze genen deels verklaart hoe dit in zijn 
werk gaat (farmacokinetiek). Wat betreft kinderen is dit nog grotendeels 
een open boek. In hoofdstuk 4 presenteren we de resultaten van onze 
studie naar hart transplantatie en het gebruik van tacrolimus. Het bleek 
dat jongere kinderen en kinderen bij wie CYP3A5 tot expressie komt 
hogere tacrolimus doseringen nodig hebben om dezelfde tacrolimus 
concentraties te bereiken als andere kinderen. Het effect wordt ver-
sterkt als jongere kinderen ook CYP3A5 tot expressie brengen, aangezien 
kinderen jonger dan 6 jaar gemiddeld 1.5 keer hogere doseringen nodig 
hadden dan oudere kinderen, en zelfs zes keer hogere doseringen dan 
oudere kinderen bij wie CYP3A5 niet tot expressie komt.
Na de recente ontdekking van een nieuwe erfelijke variatie in het CYP3A4 
gen: CYP3A4*22, hebben we een nieuw onderzoek gedaan bij dezelfde 
kinderen om te bepalen of dit extra invloed heeft op de farmacokinetiek 
van tacrolimus na harttransplantatie. In hoofdstuk 5 laten we voor de 
eerste keer zien dat kinderen met deze variant 30% minder tacrolimus 
nodig hebben om dezelfde tacrolimus concentraties te bereiken als 
CYP3A4*1/*1 dragers. Door het combineren van de CYP3A4 en CYP3A5 
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genotypes konden we de kinderen classificeren als langzame, gemiddelde 
en snelle omzetters. Het gecombineerde CYP3A genotype bleek sterker
geassocieerd te zijn met de omzetting van tacrolimus: langzame 
omzetters hadden significant lagere tacrolimus doseringen en hogere 
concentratie/dosis (C/D) ratios vergeleken met gemiddelde en snelle 
omzetters. Deze nieuwe variant lijkt de eerste functionele variant in het 
CYP3A4 gen te zijn die tot nu toe gevonden is.  Het doseren van tacrolimus 
op basis van de combinatie van deze twee erfelijke varianten (CYP3A5*3 
en CYP3A4*22) kan de variatie in de tacrolimus spiegels bij kinderen na 
hart-transplantatie helpen verminderen. Alhoewel, niet alle variatie in 
tacrolimus spiegels tussen patiënten kan verklaard worden door alleen 
deze twee erfelijke varianten in de CYP3A genen.
Varianten in het gen coderend voor P450 oxidoreductase (POR), het 
eiwit dat de activiteit van cytochroom P450 enzymen bevordert, kunnen 
mogelijk deze variabiliteit verder verklaren. POR*28 is gecorreleerd met 
hogere tacrolimus doseringen voor volwassen nier transplantatie patiënten, 
maar dit is nog niet eerder onderzocht bij kinderen die een niertrans-
plantatie ondergaan. Wij hebben dat wel gedaan en in hoofdstuk 6, 
kunnen we concluderen dat bij kinderen bij wie CYP3A5 tot expressie 
komt, POR*28 ook een deel van de variabiliteit in het omzetten van 
tacrolimus verklaart. Deze kinderen hadden 18% lagere tacrolimus 
concentraties en 20,2% lagere tacrolimus C/D ratios dan de kinderen met 
het POR*1/*1 genotype. Aangezien dit effect niet werd aangetoond bij de 
kinderen bij wie CYP3A5 niet tot expressie komt, lijkt POR een grotere rol 
te spelen op de activiteit van CYP3A5 dan van CYP3A4.
Deel III: Nierfalen na orgaan transplantatie
Nierfalen na transplantatie is een ernstige complicatie. Als we weten 
welke factoren daarvoor verantwoordelijk zijn, kunnen we wellicht de 
kans daarop verkleinen. Dit zijn niet alleen klinische factoren, maar ook 
genetische factoren. Wij hebben daarom een assay ontwikkeld met 96 
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variaties in genen. Dit zijn variaties die anderen al  eerder hebben geasso-
cieerd met tacrolimus-geïnduceerde nierschade, tacrolimus dispositie en 
nierfalen. Uit hoofdstuk 7 blijkt een cumulatieve incidentie van chronisch 
nierfalen van 40%; en dit betrof 199 kinderen die een niertransplantatie 
hadden ondergaan. Gedurende de gehele studie periode bleef de nier-
functie stabiel. Desalniettemin was bij een klein aantal kinderen ervoer 
chronisch nierfalen al in de eerste maanden na transplantatie zichtbaar. 
In hoofdstuk 8 laten we een cumulatieve incidentie van chronisch 
nierfalen van 24% zien in 135 kinderen die in levertransplantatie hebben 
ondergaan. Één jaar na transplantatie ondervond 5,7% van de levertrans-
plantatie kinderen mild nierfalen en 5 jaar na transplantatie geen van 
de kinderen (0%). Tenslotte, de cumulatieve incidentie in 161 harttrans- 
plantatie kinderen was 34.2% (hoofdstuk 9). De prevalentie van nierfalen 
was 2,9% een jaar na transplantatie en 1,7% 5 jaar na harttransplantatie. 
Deze resultaten voor alle drie de vormen van transplantatie suggereren 
dat ondanks stabiele nierfuncties, een klein aantal nierschade ontwikkelt 
al vroeg na transplantatie en waarbij we ernstiger nierfalen zien op 
langere termijn. 
Wat betreft het assay om de invloed van genetische factoren op nierfalen 
te bepalen: geen van de bestudeerde varianties was geassocieerd met 
een verslechterde nierfunctie, en dit gold voor alle drie vormen van trans-
plantatie.
Iemands nierfunctie wordt vaak bepaald aan de hand van de creatinine 
concentratie in het serum en het schatten van de glomerulaire filtratie 
ratios. Deze methoden hebben diverse beperkingen. Een van de nieuwe 
veelbelovende biomarkers voor nierfalen is neutrofiel gelatinase- 
geassocieerd eiwit (NGAL). Bij volwassen transplantatie patienten 
zijn NGAL levels in de urine zijn geassocieerd met acuut en chronisch 
nierfalen, maar bij kinderen is dit nog weinig onderzocht. In hoofdstuk 
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10 laten we zien dat kinderen na een lever of nier transplantatie licht 
verhoogde NGAL concentraties in de urine hebben, maar zelden in de 
mate die geassocieerd is met acuut nierfalen bij kinderen met andere 
aandoeningen. Deze pilotstudie getuigt van subklinische nierschade bij 
de meeste kinderen vroeg na lever- en nier transplantatie.
Deel IV: Discussie en toekomst perspectieven
In hoofdstuk 11 bespreken we de resultaten van alle studies in dit proef-
schrift. Daarnaast presenteren we enkele kennishiaten en aanbevelingen 
voor de toekomst. De belangrijkste conclusies zijn:
• CYP3A4/5 en POR genotypes evenals de leeftijd verklaren een groot 
 deel van de variabiliteit in tacrolimus dispositie in de eerste twee 
 weken na transplantatie bij kinderen na solide orgaan transplantatie. 
• Een beduidend grote groep kinderen die een nier-, hart- of levertrans- 
 plantatie ondergaan en tacrolimus toegediend krijgen lijden aan 
 chronisch nierfalen in de jaren na transplantatie.
• Chronisch nierfalen treedt vaak al op vanaf 3 maanden na de 
 transplantatie en bij een klein aantal patiënten verslechtert de 
 nierfunctie in de latere jaren.
• Wij hebben geen genetische risico factoren voor chronisch nierfalen 
 kunnen vaststellen bij kinderen die een nier-, hart- of levertrans- 
 plantatie hebben ondergaan en tacrolimus toegediend krijgen. 
• NGAL concentraties in de urine zijn een potentiële marker voor 
 subklinische nierschade in kinderen vroeg na lever- en niertrans- 
 plantatie.
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Toronto, Canada, as part of her medical degree to study the effects of Reiki 
on post-operative pain in women who underwent a Caesarean section. 
After one year, she received her doctorate degree in Medical Science. 
She continued to stay in Toronto and started her PhD project. During 
her stay in Toronto she volunteered at a children’s play, Tails, which was a 
weekly show especially for the sick children admitted to the Hospital for 
Sick Children. In September 2011, she moved back to Rotterdam to finish 
her PhD at the Erasmus MC Sophia Children’s Hospital. She also started 
her clinical rotations for her Medical Training in March 2013. 
In July 2009 she received the Bill Mahon Presentation Award for the 
best trainee presentation at the Canadian Society of Pharmacology and 
Therapeutics Conference in Saskatoon for her systematic review of the 
pharmacogenetics of tacrolimus-induced nephrotoxicity in adults. 
In June 2010 she was invited to present her project on the effect of age 
and genotype on the pharmacokinetics of tacrolimus in the first 14 days 
after transplantation at the Canadian Society of Pharmacology and 
Therapeutics Conference in Toronto as part of the trainee session. 
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Name PhD student:   Violette M.G.J. Gijsen
Erasmus MC department:  Intensive Care and Pediatric Surgery
PhD Period:   October 2008 - May 2013
Promotors:    Prof. Dr. D. Tibboel, Prof. G. Koren
Supervisors:    Dr. SN de Wildt, Dr. RHN van Schaik
Year Workload
(ECTS)
General courses
Research Design and Statistical Analysis 2009 4
Specific courses
Clinical pharmacology 2008 4
Maternal-fetal Pharmacology 2010 2
Presentations
ASCPT: oral (1x), poster (3x) 2012 1.0
ASCPT: poster 2011 0.3
CPNDS: oral 2011 0.4
CSPT: poster 2011 0.3
Pediatric Pharmacogenomics and Personalized Medicine: poster 2011 0.3
CSPT: oral 2010 0.4
ASCPT: poster 2010 0.3
CPNDS: oral 2010 0.4
CSPT: poster 2009 0.3
CPNDS: oral 2009 0.4
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Year Workload
International conferences
ASCPT, National Harbor, MD, USA 2012 1
ASCPT, Dallas, TX, USA 2011 1
CPNDS, Vancouver, Canada 2011 0.5
CSPT, Montreal, Canada 2011 1
Pediatric Pharmacogenomics and Personalized Medicine, Kansas 
City, MO, USA
2011 0.5
CSPT, Toronto, Canada 2010 1
ASCPT, Atlanta, GA, USA 2010 1
CPNDS:, Vancouver, Canada 2010 0.5
CSPT, Saskatoon, Canada 2009 0.5
CPNDS, Vancouver, Canada 2009 0.5
Workshops and Seminars
Career Bootcamp 2012 0.1
Clinical Pharmacology Review 2011 0.1
Other
Various research meetings at The Hospital for Sick Children, Toron-
to, Canada and Erasmus MC Sophia Children’s Hospital, Rotterdam.
2008-2013 5
Teaching activities
Pharmacokinetics and Dosing to first year medical students 2011 0.3
Clinical Pharmacology to first year medical students 2011 0.3
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1. Gijsen VMGJ, van Schaik RHN, Soldin OP, Soldin SJ, Nulman I, Koren G, 
 de Wildt SN. P450 oxidoreductase *28 (POR*28) and tacrolimus 
 disposition in pediatric kidney transplant recipients – a pilot study. 
 Submitted.
2. Gijsen VMGJ, Zwiers AJM, van Schaik RHN, Soldin OP, Soldin SJ, 
 Hesselink DA, Nulman I, Koren G, de Wildt SN. Urinary NGAL levels early 
 after pediatric kidney and liver transplantation: a pilot study. 
 Submitted.
3. Gijsen VMGJ, van Schaik RHN, Elens L, Soldin OP, Soldin SJ, Koren G, 
 de Wildt SN. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) 
 and CYP3A combined genotypes both correlate with tacrolimus 
 disposition in pediatric heart transplant recipients. 
 Accepted in Pharmacogenomics April 2013
4. Gijsen VM, Hesselink DA, Croes K, Koren G, de Wildt SN. Prevalence of 
 renal dysfunction in tacrolimus-treated pediatric transplant recipients: 
 A systematic review. 
 Pediatr Transplant. 2013 Feb 28. 
5. Gijsen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN. 
 Tacrolimus-induced nephrotoxicity and genetic variability: a review. 
 Ann Transplant. 2012 Apr-Jun;17(2):111-21. Review.
6. Vandervaart S, Berger H, Tam C, Goh YI, Gijsen VM, de Wildt SN, 
 Taddio A, Koren G. The effect of distant reiki on pain in women after 
 elective Caesarean section: a double-blinded randomised controlled trial. 
 BMJ Open. 2011 Feb 26;1(1):e000021. 
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 Koren G, de Wildt SN. Acute liver failure after recommended doses of 
 acetaminophen in patients with myopathies. 
 Crit Care Med. 2011 Apr;39(4):678-82. 
10. vanderVaart S, Gijsen VM, de Wildt SN, Koren G. A systematic review of 
 the therapeutic effects of Reiki. 
 J Altern Complement Med. 2009 Nov;15(11):1157-69. 
11. Gijsen VM, de Wildt SN, Ito S. 
 Probability of rash related to gabapentin therapy in a child. 
 Ann Pharmacother. 2009 Feb;43(2):387-9. 
12. Gijsen V, Fulga N, Garcia-Bournissen F, Koren G. Does light drinking 
 during pregnancy improve pregnancy outcome? A critical commentary.
  Can J Clin Pharmacol. 2008 Fall;15(3):e782-6. 
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Dankwoord / Acknowledgement
Eindelijk is het dan zover: het is af! Wat een bijzondere tijd en een bij-
zondere ervaring is het om te mogen promoveren. Het zijn 4 fantastische 
jaren geweest met zoveel nieuwe ervaringen die ik nooit ga vergeten. 
Allereest wil ik graag alle ouders en kinderen bedanken die mee 
hebben gedaan met de studies. De bereidwilligheid om mee te doen om 
het voor toekomstige transplantatie kinderen mogelijk beter te maken 
was ongelooflijk groot. 
Door de ongelooflijke kans om mijn onderzoek in twee landen te mogen 
doen, heb ik ook van de begeleiding van twee promotoren mogen 
genieten. Prof. Dr. D. Tibboel, beste Dick, zes jaar geleden hadden we een 
gesprek over wat ik met mijn keuzeonderzoek zou doen en toen kwam 
jij met het idee om mijn achtergrond van farmacie te combineren met 
geneeskunde en naar Toronto te gaan voor een onderzoek in de klinische 
farmacologie. Hoe ongelooflijk goed die keuze was, heb ik toen niet 
gezien, maar ik kan me niks beters meer voorstellen. Dank je voor alle 
steun van de afgelopen jaren en de kansen die je me hebt geboden. 
Je wijze woorden, die je altijd weet te vinden, zijn van onschatbare waarde. 
Prof. G. Koren, dear Gidi, my time at your department in Toronto was 
incredible. Thank you for giving me the opportunity to be independent 
throughout my research, yet you are always there for me when needed. 
Your work at Tails is admiring and thank you for letting me volunteer at 
the show. It is an experience I’ll never forget and I will always treasure. 
Naast mijn twee promotoren, heb ik ook het geluk om met twee co- 
promotoren te mogen werken; Dr. SN de Wildt en Dr. R. van Schaik. Dr. 
SN de Wildt, lieve Sas, het is alweer bijna 6 jaar geleden dat je me onder 
je vleugels nam en me alle fijne kneepjes van het vak hebt laten zien. 
Wat hebben we in die tijd veel samen mee gemaakt. Er zijn zoveel dingen 
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die ik van jou heb geleerd die ik voor altijd kan gebruiken om mezelf 
verder te ontwikkelen. Ik ben nog steeds onder de indruk van de ho-
eveelheid dingen die in jouw hoofd omgaan. Ik hoop dat we nog lang 
mogen samenwerken. Dr R. van Schaik, beste Ron, ontzettend bedankt 
voor je hulp om de genetische informatie en analytische methodes uit te 
leggen zodat ik het ook begrijp. Je bent altijd op de hoogte van de nieuwste 
ontwikkelingen en dat heeft tot nieuwe leuke projecten geleid. 
Mijn interesse in de farmacogenetica is voor altijd gewekt en ik hoop dan 
ook dat we elkaar nog vaak gaan tegen komen. 
De leden van de kleine commisie, Prof Dr. T. van Gelder, Prof. Dr. A Bogers 
en Prof. Dr. G Kearns wil ik graag hartelijk bedanken voor het beoordelen 
van het manuscript. Prof. Dr. G. Kearns, thank you for wiling to be part of 
my thesis defense. I feel truly honored. 
Prof. J. Danser, Dr. M de Hoog, Dr. M. Dalinghaus en Dr. D. Hesselink wil 
ik hartelijk bedanken voor het plaats nemen in de grote commissie. 
Dr. D. Hesselink, beste Dennis, hartelijk dank voor je goede advies en 
kritische blik. Je inzichten zijn van erg belangrijk geweest en hebben me 
veel geholpen om de kliniek beter te begrijpen. 
Thank you to all the physicians and nurses working at the Transplant 
Centre at Sickkids in Toronto for their help in facilitating this research 
project. In particular, Gomatie, for always being available to help me with 
the logistical processes. Dr. G. ‘t Jong, beste Geert, dank voor je hulp bij 
het ordenen van mijn data. Het was erg leuk om samen met een andere 
Nederlander in Toronto iedereen een beetje Nederland te leren. Dikkertje 
Dap zal altijd verbonden zijn met jou.
In Rotterdam, wil ik graag Kenneth Croes en Joke Dunk bedanken voor 
hun hulp bij het includeren van patienten en verzamelen van de data voor 
het Rotterdam Cohort. Beste Joke, je bent echt van onschatbare waarde 
voor me geweest. 
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Every one at Motherisk has been amazingly friendly and my four years at 
the department really felt like I had my own canadian family. The phrase 
“English with an accent” will forever be linked with all of you. I’d like to 
thank the counselors, Aida, Pina, Angela, Michael, Caroline, Kathy and 
Yvette, it was always fun to have you around. I miss the laughter I heard 
every day. Sammy, I miss talking about your doggie and the crazy things 
he did. Moumita, my Canadian sister, you are such an amazing person and 
thank you for being there for me. Ingrid, Patricia, Lisa, Sandy, Sabina, you 
were there when I first started and thank you for showing me the ropes. 
Jeremy, Nathalie, Jessica, Aniket, Amanda, Deborah, Seth and Judith, 
you were all there during my last year and what a year it has been. 
We had so much fun and I really try to stay away from sporcle, which will be 
connected with you all forever. Carolyn and Jacqueline, we are so close 
in birthdays and have had a lot of fun every day we worked together. 
Tatyana, without you my lab work would be lost. You are a true angel, 
Dear Bhushan, you taught me such much about everything I can think of. 
You have shown be the importance of knowing all the techniques used 
in the lab and you have taught me how to think critically when it comes 
to laboratory results. Your knowledge about toxicology is endless and I 
could listen to you talk all day. 
To all my friends in Toronto, I miss you all! Rory & Haley, David, Mike & 
Efrat, Inge, Noor & Charlotte, thank you for the Friday afternoons, the 
dinners, the babysitting and all the fun we have had. I’m glad we are still 
in touch and I hope we will stay friends. Dear friends at Tails; the two years 
we volunteered together were amazing, Every Thursday was a party in 
itself. You are all amazing and have shown me so many great views on life. 
I miss you all and I’ll never forget the fun we had. 
Adrienne, my Canadian Mother. I still can’t believe how you have been 
able to pick me up every time I sat down in your office and cried. I don’t 
know how to thank you, because words are not enough for what you 
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have done for me. You are so kind and so sweet and I hope we will work 
together some day soon. Tom, you are the first who has been able to 
teach me anything about statistics and even showed me it can be fun. 
You and Adrienne have been amazing and I hope we will meet up again 
soon either in the Netherlands or in Canada. 
Mijn collega promovendi/onderzoekers Marlous, Anneke, Joke, Carlijn, 
Ilse, Gerbrich, Alexandra, Mirjam, Erik, Bram, Sanne, Marie-Chantal, 
Ibrahim, Anniek en Nienke, dank jullie wel voor een geweldige tijd in 
Rotterdam. Lieve Anneke, Joke, Marlous en Carlijn, de westzeedijkers, 
dank jullie wel voor een ontzettend leuke tijd samen op de kamer. 
Joke en Marlous, het waren een paar stressvolle weken met z’n drieën, 
maar we staan er dan nu wel allemaal. Mirjam en Alexandra dank jullie dat 
jullie me mee sleepte naar de fitness. Het was erg gezellig om samen met 
jullie te sporten. Lieve Iba, mijn buddie in de farmacologie, dank je dat je 
me altijd aan het lachen maakte en het dagje dierentuin moeten we snel 
maar weer eens overdoen.  
Jeroen, dank je wel voor je continue steun tijdens mijn promotie en in 
onze tijd samen in Toronto. Je bent vaak een rots in mijn chaotische 
denkpatronen geweest en een ongelooflijke steun voor mij. Het was een 
geweldige tijd. 
Lieve Eef, super bedankt dat je de lay-out van dit boekje hebt gedaan. 
Ik kon niemand beter bedenken dan mijn beste vriendin om dit samen 
mee te maken. Ondanks dat het voor ons allebei een nieuwe weg inslaan 
was, heb ik het erg leuk gevonden om dit samen met je doen. Samen met 
Bart hebben jullie mij aardig wat weekenden entertained om ervoor te 
zorgen dat dit mooie boekje op tijd af kwam. Super bedankt beide voor 
jullie steun, liefde en het feit dat jullie altijd voor me klaar staan. 
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Lieve Niek, neeffie, dank je dat je altijd aanneemt als ik je bel en er door-
heen zit en langs wilt komen als ik je nodig heb. We hebben het altijd 
gezellig samen en je bent een goede rots in de branding. Op naar de 
volgende borrel, honkbal wedstrijd, jazzfestival of welke aangelegenheid 
dan ook om samen op stap te gaan.
Lieve pap en mam, zonder jullie was ik hier zeker niet en zonder jullie 
was ik niet de persoon die ik nu ben. Dank jullie wel dat jullie me altijd 
stimuleerde in wat ik graag wilde doen en me ook uitdaagt om meer 
te doen dan ik soms voor ogen hou zodat ik meer eruit kan halen. 
Jullie onvoorwaardelijke steun betekent heel veel voor me. 
Dank jullie wel!
Mijn paranimfen, George en Lot, lieve broer en zus, jullie zijn geweldig. 
Ik kan me geen betere paranimfen voorstellen. Ondanks dat alles voor 
ons allemaal nieuw was, hebben jullie altijd naast me gestaan gedurende 
mijn gehele promotie. En natuurlijk al lang daarvoor en nog lang daarna. 
Ik hou heel veel van jullie!
Violette
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